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General introduction and outline of this thesis
The skin is the largest and most visible organ of the human body, and therefore relatively 
easy to examine in comparison to other organs. Hence, dermatological diagnoses 
are primarily based on the preliminary patient history and visual assessment of the 
involved skin.1 The latter includes distinguishment between distribution patterns, 
colors and morphologic appearance of skin lesions.2 In certain circumstances, a skin 
biopsy is necessary to secure the exact diagnosis. Although skin tissue is easily 
available for histologic examination, sampling error and complications (e.g. bleeding, 
infection and scar formation) do occur.3 
 Dermoscopy is a non-invasive method that allows evaluation of skin lesions by 
a tenfold magnification of the clinical macroscopic view.4 Dermoscopy has been 
implemented in clinical dermatology by means of standardized pattern algorithms, 
mainly applied in the field of melanocytic lesions and non-melanocytic proliferations.5, 6 
This technique can form a bridge between clinical assessment and histopathological 
examination. 
 Despite its advantages in daily clinical practice, dermoscopic images are two- 
dimensional and contain information of the uppermost skin layers only. Other non- 
invasive techniques have been developed to improve quality of these in vivo images 
and thereby avoiding the need for a skin biopsy.
 In vivo reflectance confocal microscopy (RCM) is the link between dermoscopy 
and histopathology, because it provides horizontal (en face) images and in vivo 
information with a microscopic resolution high enough to view cellular detail.7 
 Despite the aforementioned advantages of RCM, dermatologists have been slow 
to adopt advanced technologic diagnostic aids, primarily because of the relative ease 
of macroscopic skin examination and accessibility to a diagnostic biopsy.8, 9 However, 
RCM is a promising non-invasive technique providing real-time information of the skin. 
 
History of Reflectance Confocal Microscopy 
The principle of confocal scanning microscopy was invented in 1955 and patented in 
1957 by Marvin Minsky.10, 11 After Minsky’s patent expired, practical laser scanning 
confocal microscope designs were translated into working instruments by, amongst 
others, the Dutch physicist G. Fred Brakenhoff. It was Brakenhoff who was responsible 
for establishing the term ‘confocal’, which means ‘same or common focus’, derived 
from conjugated focal planes.11, 12 The first commercial instruments were introduced 
in 1987.12 The enormous size of these early models made them infeasible for clinical 
practice. However, during the nineties the devices were improved into a size useful 
for bedside examination.13 Most frequently used RCM devices to date are the are 
the VivaScope 1500 and VivaScope 3000 (Lucid Inc. Rochester, New York, USA). 
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 The probe generates images of 500µm x 500µm field of view in a horizontal 
manner, the confocal image (Figure 3A). In addition, the objective lens moves 
vertically to capture images in depth (VivaStack) while maintaining the same field of 
view (Figure 3B). This VivaStack has an automatic section depth of 4,5µm,  but can 
adopt to other preferable depths. The separate horizontal confocal images can be 
assembled into a large mosaic image of 8mm x 8mm. This mosaic is known as a 
VivaBlock (Figure 3C). More than visualizing skin morphology by static images, this 
technique is able to capture dynamic processes (e.g. blood flow, migration of 
leucocytes) by videos ( 15-25 frames per second). 
 The large RCM probe is not suited for concave body areas (e.g. nose, ear, 
peri-orbital regions), because placement of the metal ring on these concave body 
areas is not possible. For these anatomical localizations the handheld (VivaScope 
Technical aspects of Reflectance Confocal Microscopy 
The reflectance confocal microscope consists of a laser, beam splitter, lens system, 
pinhole aperture and a detector (Figure 1). The laser beam illuminates inside the skin, 
which is followed by the reflection of light from the focal point back towards the 
objective lens. The lens focuses the light onto a small pinhole-sized aperture in front 
of the detector. The detector is responsible for signal transduction to a computer. 
Light from the focal region is detected and out of focus light will be eliminated. The 
point source of light, the illuminated skin tissue and the pinhole aperture lie in 
conjugated focal planes.7 RCM enables horizontal plane, en face, visualization of a 
skin lesion with a resolution at cellular level (0.5-1.0µm in the lateral, and 4-5µm in 
the axial dimensions). The VivaScope 1500 uses laser light with a near infrared 
wavelength of 830nm. Importantly, this laser light does not cause skin damage. RCM 
allows to visualize to a depth of 200-300µm, which corresponds to the papillary 
dermis. The depth varies between different anatomical skin sites.14 RCM obtains 
horizontal images, parallel to the skin. The field of view is 500μm x 500μm and the 
generated image is an approximately 30 fold magnification.15, 16 Images are obtained 
in grayscale, because of the differences in reflectivity by endogenous chromophores.17 
Structures with a white appearance have components with an higher refractive index 
compared with the surrounding structures.18 A black image means no reflection at 
all.19 Melanin is the strongest endogenous contrast agent. Other skin structures as 
keratin, collagen and inflammatory cells strongly reflect RCM light and have a bright 
appearance in RCM images.16, 18
Practical aspects of Reflectance Confocal Microscopy
Prior to imaging a patient needs to be placed in a comfortable position. Locations 
with hyperkeratosis or hairs lead to suboptimal imaging and therefore need to be 
avoided.  Before applying the ring on the skin lesion, the large RCM probe (VivaScope 
1500) should be positioned above the lesion to find out the best imaging position. 
After proper positioning, a drop of water is applied to the skin connecting the plastic 
disposable window within the metal ring to the skin lesion (Figure 2B, 2C). The ring is 
hold by a double adhesive tape, attached to metal ring (Figure 2D). A digital 
5-megapixels macro camera (VivaCam) is coupled to the RCM (Figure 2E). Prior to 
RCM imaging, the VivaCam captures a dermoscopic image with a 10mm x 10mm field 
of view and serves as a navigation map during RCM imaging.21 In addition, this 
dermoscopic image is used for the correlation between the macroscopic lesion and 
the RCM images. After using the VivaCam, a drop of ultrasound gel is applied on top 
of the plastic window (Figure 2F). Water and ultrasound gel have refractive indices 
comparable to the epidermis, which allows the laser beam to image through the 
epidermis into the dermis.21 Thereafter, the metal ring is magnetically attached to the 
large RCM probe. 
Figure 1  Schematic diagram of the principle of reflectance confocal microscopy 
(adapted from Rossetti et.al).20
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equivocal pigmented lesions.29, 30, 35, 38-45 Furthermore, non-melanoma skin cancer, 
including basal cell carcinoma (BCC), actinic keratosis and squamous cell carcinoma, 
can be diagnosed by RCM.32, 34, 36, 37, 46, 47 Different BCC subtypes can be differentiated 
with RCM imaging.48, 49 The diagnostic value of RCM has also been studied in 
inflammatory skin diseases26, 27, 33, 50-53 and pigmented disorders.28, 31, 54, 55 
 In addition to diagnostic purposes, RCM can serve as a monitoring device for 
evaluation of dynamic processes such as in inflammatory skin diseases.56, 57 Moreover, 
treatment responses can be monitored, such as the effect of biologicals in psoriasis, 
the effect of imiquimod in lentigo maligna and the response of photodynamic 
treatment (PDT) in BCC.58-60 RCM can also be used to increase the accuracy of skin 
biopsies, by identifying disease representative localizations, thereby decreasing the 
likelihood of sampling error.61, 62 Another application for RCM is in vivo examination of 
tumor margins before surgical excision.63-65
 
Normal skin 
The normal skin can be divided into separate skin layers, based on the unique 
appearance of keratinocytes in each of the layers as imaged by RCM.7 The most 
superficial layer is known as the  stratum corneum (SC). The SC consists of anucleated 
and polygonal shaped keratinocytes. The SC appears as a highly refractive bright 
surface, due to the dense content of surrounded by low refractive black skin folds 
(Figure 4A). The stratum granulosum (SG) is the first layer with vital keratinocytes. 
These cells are also polygonally shaped (Figure 4B). The next layer is the stratum 
spinosum (SS). The keratinocytes in this layer are smaller compared to the cells in the 
SG (Figure 4C). However, the shape of the keratinocytes is similar to the more 
3000) can be used. This device has a smaller probe, which makes it easier to use on 
concave surfaces, but generates no standardized images and has a small view of 1mm 
x 1mm.22 
 Overall, the imaging procedure will take 5-10 minutes, depending on lesion size, 
difficulties in interpretation of images and experience of the confocalist. 
RCM applications
In vivo RCM has been applied in both fundamental research23-25 and in clinical 
dermatology.26-37 In clinical dermatology, a wide spectrum of skin diseases have been 
imaged by RCM for diagnostic purposes. Early diagnosis of skin cancer represents an 
important field for RCM imaging. RCM can be used as an additional diagnostic tool 
for characterization of skin lesions that are difficult to assess by physical examination 
and dermoscopy. Many studies examined the applicability of RCM for melanoma and 
Figure 2  Reflectance Confocal Microscope (RCM). A: VivaScope 1500; B, C and D: 
Attachment of metal ring to the skin with double adhesive window and drop of water; 
E: VivaCam captures dermoscopic image; F: Adding ultrasound gel on the window; 
G-H: Magnetically attachment of large RCM probe to metal ring. Probe attachment is 
possible in different directions, always in correlation to VivaCam image (both labeled 
with direction mark).
Figure 3  Reflectance Confocal Microscopy (RCM) images. A: Confocal image: represents a 
basic image of 500µm x 500µm; B: VivaStack: captures vertical images with 500µm x 
500µm field of view; C: VivaBlock: represents a mosaic of 8x8 confocal images (4mm 
x 4mm).
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superficial layers. The SG and SS are easily recognized on RCM images due to the 
characteristic honeycombed pattern. This pattern represents the dark nuclei and 
white thin keratin-containing cytoplasm with regular spacing between the 
keratinocytes (Fig 4B and 4C).7, 16 The deepest epidermal layer, known as the basal 
layer, is characterized by small keratinocytes and reveals a cobblestone pattern by 
melanin caps. These caps form bright disks on top of the nuclei. The dermo-epider-
mal junction (DEJ) appears as upward finger-like projections into the epidermis, 
which are the dermal papillae (DP).66 A horizontal section trough the papillae reveals 
dark round to oval areas (Figure 4D), centered by dermal vascular loops. These DP are 
surrounded by a bright rim, consisting of pigmented basal cells and melanocytes.16, 66 
The papillary dermis and superficial reticular dermis contain a network of fibers and 
bundles (Figure 4E). Collagen appears as bright elongated fibrillar structures without 
cellular components and no nuclei. It is distributed side by side throughout the 
dermis into a reticular network.66 Superficial blood vessels can be observed as coiled 
or ringed structures. Real time imaging allows to capture individual blood cells, which 
rapidly move through the blood vessels.66 The blood cells appear as a mixture of 
weakly refractile and brightly refractile cells. Leukocytes can be differentiated from 
erythrocytes by the difference in diameter, respectively 6-30 µm and 6-9µm.67
 Superficial segments of the skin appendages such as hair follicles, hair shafts, 
sweat ducts and sebaceous glands can be identified by RCM as well. The infundibular 
part of the hair follicle appears as an ostium with central refractile keratin debris, 
often containing a hair shaft and a central lumen.  Hair shafts appears as a cylindrical 
or tubular long acellular structure with uniform refractivity surface and less refractile 
in the central core.66 Eccrine sweat ducts have a bright appearance of oval to round 
centrally hollow structures that spiral through the epidermis and dermis.7, 66 Apocrine 
ducts are straight structures, resembling a follicle without a hair shaft. Normally, 
apocrine ducts cannot be seen because they usually insert into the follicular 
infundibulum above the insertion point of the sebaceous duct.66 Sebaceous glands, 
which are mainly located in the face appear as highly refractile morular appearance. 
This morula appearance is caused by the presence of lipid droplets. Each sebocyte 
contains a central, round, dark nucleus, surrounded by a well-defined rim of bright 
multi-lobular cytoplasm.7, 66 
 RCM images show a large variation in the appearance of different skin structures. 
This is also true for normal skin. Differences are caused by intra-individual variation, 
for example different anatomical locations. Inter-individual variation in skin type, age 
and sun exposure also occurs.7, 66 
 Overall, RCM is a useful tool to visualize different normal skin structures. 
Figure 4  Three-dimensional model of normal skin layers. A-E: Reflectance Confocal 
Microscopic (RCM) characteristics of each skin layer. A: The stratum corneum (SC) is 
recognizable by the bright surface and absence of nuclei, separated by dark skin 
folds. The visible circle is the reflection of the attached metal ring. B: The stratum 
granulosum (SG) and C: stratum spinosum (SS) are recognizable by the visible nuclei 
in a honeycombed pattern. D: The dermo-epidermal junction (DEJ) is characterized 
by round dark dermal papillae. E. The dermis (De) appears as dark with a loosened 
reflective fiber network
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subtypes have specific clinical and histopathological characteristics.74 Currently, 
histo pathologic examination of a biopsy is the gold standard for the diagnosis of 
BCC and its subtype. There are many histopathological classifications. Some major 
subtypes, based on their growth pattern, can be differentiated: superficial BCC 
(sBCC), nodular BCC (nBCC), micronodular BCC (mnBCC) and infiltrating BCC (iBCC).74 
A combination of subtypes with different aggressiveness can form a mixed-type 
BCC.75 A sBCC is characterized by proliferation of atypical basaloid cells, adjacent to 
the basal layer or just beneath the epidermis. At dermal level a band-like lymphoid 
infiltrate may be present.74 nBCCs are characterized  by large rounded nodules of 
basaloid cells with peripheral palisading. These are present in the papillary or 
reticular dermis. The mnBCC nests are smaller and diffusely spread than those in 
nBCCs. They extend into the deeper dermis accompanied by stromal proliferation.74 
Characterization of the iBCC is based on irregular size and shape of the tumor nests, 
poor circumscription and sometimes invasion into the subcutis.74  
 Choice of treatment depends, amongst others, on the subtype BCC. In most 
cases, surgical excision is first choice of treatment. Surgical excision may not be 
preferred in patients with comorbidities or at cosmetic areas. Non-invasive therapies, 
such as PDT, can therefore be considered for low aggressive BCCs (e.g. sBCC and thin 
nBCCs).76, 77 The photodynamic reaction depends on the presence of sufficient 
quantities of photosensitizer, activating light and oxygen. 5-Aminolevulinic acid (ALA) 
and methyl-aminolevulinate (MAL) are endogenously converted by the heme 
biosynthetic pathway to protoporphyrin IX (PpIX). PpIX is more concentrated in target 
lesions than in healthy skin. This is possibly related to alterations in surface 
permeability in tumor porphyrin metabolism.78 Illumination of the lesion results in 
reactive oxygen release and subsequent apoptosis and necrosis.78 
 The increasing incidence of BCCs and the ongoing development of new 
non-invasive therapies also leads to the development of non-invasive diagnostic 
methods. As a result, RCM is an interesting tool in the BCC workflow.79 Previous 
research showed the ability of RCM to diagnose BCCs and determining different 
subtypes.48, 49 Characteristic RCM features of BCC are elongation nuclei along same 
axis, inflammatory cells, increased vascularization, keratinocyte atypia, tumor nests 
surrounded by a cleft and peripheral palisading.30, 32, 34, 49, 80 The RCM used as a 
diagnostic tool for BCCs showed a sensitivity of 0.97 (95% CI 0.90-0.99) and specificity 
of 0.93 (95% CI 0.88-0.96).79 Apart from diagnostic ability, RCM can be used for 
treatment monitoring (e.g. response after PDT).81 
Melanoma
Cutaneous melanoma is one of the most aggressive types of skin cancer with a high 
mortality rate. It represents 4% of skin cancers and is responsible for 80% of skin 
cancer deaths.82, 83 Early diagnosis is essential for improving the survival of patients 
Psoriasis
Psoriasis is a chronic immune-mediated inflammatory skin disease which affects 
0.7-2.9% of the general population in Europe.68, 69 Chronic plaque psoriasis is the most 
common variant and clinically characterized by well-demarcated erythemato-
squamous plaques (Figure 5A), mainly located at extensional body sites. Other body 
surface areas can also be affected.70, 71 Psoriatic plaques can have active, expanding 
edges and may relapse in time.70, 71 The diagnosis is mainly based on clinical findings. 
However, sometimes it is difficult to differentiate psoriasis from other erythemato-
squamous skin diseases and additional histopathology is conducted. A fully developed 
clinical psoriatic plaque shows hyperkeratosis, alternating with orthokeratosis and 
parakeratosis. Subjacent no granular layer or a diminished layer can be present. 
There are elongated epidermal rete ridges and elongation of intervening DP 
containing dilated and tortuous  capillaries. Further, thinning of the epidermis above 
the DP can be seen. This is known as suprapapillary plate thinning.72 Microabscesses 
are formed by the migration of neutrophils from the papillary capillaries. The 
neutrophils migrate via thinned suprapapillary plates, which is described as squirting 
papillae. These cells aggregate within the stratum spinosum to form Kogoj abscess. 
Aggregation within the stratum corneum,  typically located above the DP, are known 
as Munro microabscess. A sparse superficial dermal perivascular lymphocytic 
inflammatory infiltrate with occasional neutrophils is also present.72 However, a 
histo pathology-based diagnosis can be misleading, because modest and sparse 
changes in the early phase of the disease.26 In addition to these changes, an invasive 
skin biopsy is not capable of monitoring a skin entity over time.73 RCM could therefore 
be an additional tool, supplemental to histopathology. This technique identifies the 
most representative localization for a biopsy or even may avoid a biopsy by providing 
in vivo information with a strong correlation to histopathology.26, 52, 53 Most remarkable 
RCM features for plaque psoriasis are hyperkeratosis, parakeratosis, reduced or 
absent granular layer, inflammatory cells and microabscesses, papillomatosis, and 
dilated blood vessels.26, 52, 53 Previous research showed a sensitivity and specificity of 
respectively 89.15% and 95.41% for the RCM diagnosis psoriasis.51 An advantage of 
RCM is the non-invasive assessment of dynamic phases of the plaque.57 However, 
hyperkeratotic  layers could limit the laser penetration depth onto the lesion. Well 
designed methodological studies for the differential diagnoses of psoriasis are 
lacking. 
Basal cell carcinoma
BCC is one of the most common types of non-melanoma skin cancer. In general, BCCs 
are clinically recognizable by a pearly pink or skin colored papules and nodules with 
teleangiectasia (Figure 5B). These tumors can also be erythematous with a rolled 
border, accompanied by bleeding, scaling or crusting. Different BCC histopathological 
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 RCM can be seen as an additional step in the diagnostic melanoma workflow. 
The advantages of both dermoscopy and histopathology are used by creation of 
horizontal images with cellular resolution. There has been a great interest in RCM in 
melanoma for two main reasons. First, melanoma has a high mortality rate. Secondly, 
it is relatively easy to image melanocytic lesions by RCM because of the strong 
contrast, due to the high refractive index, comparing to other structures. 
Characteristic RCM features of melanoma are epidermal disarray, pagetoid cells in 
epidermis, non-edged DP, cerebriform nests and marked cytological atypia.30, 38 
Algorithms have been developed for diagnosis of melanoma by the RCM.30, 43 Within 
these algorithms melanocytic lesions are first distinguished from non-melanocytic 
lesions. Subsequently, they will be subdivided into either melanoma  or nevi. Further, 
a meta-analysis showed a sensitivity of 93.3% and specificity of 75.9% for the RCM 
diagnosis of melanoma.90 Purpose of this technique in pigmented lesions is accurate 
diagnosis and thereby limiting number of excisions.91, 92  
Implementation
There is a growing interest in RCM for skin imaging. A search in Pubmed (terms: in 
vivo reflectance confocal microscopy AND dermatology, restricted from 1995-2000) 
revealed 11 publications in 2000. The number has grown to more than 230 
publications, with the highest increasing rate between 2013 and 2015 (increase of 
49%) (Figure 6). Despite this rapid increase, the implementation process of RCM in 
clinical dermatology is still ongoing. RCM can be considered as an complementary 
tool to conventional histopathology, leading to further synergy between 
histopathology and RCM. Correct diagnosis requires training and experience and 
therefore varies between observers.  In order to  implement non-invasive techniques 
such as RCM, the development of practical algorithms and clinical protocols is 
needed. Also, cost-effectiveness of this application has to be assessed. 
with melanoma. The diagnostic workflow of detecting melanoma is currently based 
on clinical assessment, dermoscopy and diagnostic excision. A cornerstone in the 
clinical assessment of melanoma is the ABCD(E) algorithm; Asymmetry, Border 
irregularity, Color variation, Diameter (>6 mm) and Evolution/Elevation.84 Lesions 
do not have to fulfill all ABCD(E) criteria, the more criteria, the higher suspicion of 
melanoma. Having at least two criteria showed a sensitivity and specificity of 89.30% 
and 65.30%. The use of three criteria let to a higher number of misdiagnosed 
melanomas by a sensitivity of 65.50% and specificity of 80.0%.85 The accuracy of 
the ABCD(E) algorithm depends on the level of experience of the clinician.84 
Dermatologists can detect melanoma by clinical examination only in 65-80%.86 
 The diagnostic accuracy further increased with the use of dermoscopy. Several 
algorithms have been developed for dermoscopy.5, 87 The ABCD-rule for dermoscopy 
is commonly used in clinical practice in order to distinguish benign and malignant 
melanocytic lesions.87 This rule is based on four criteria: Asymmetry (on 0, 1 or 2 
perpendicular axes), Border (abrupt disruption of pigment at peripheral areas in 0-8 
segments), Color (up to 6 colors: white, red, light brown, dark brown, blue-gray and 
black) and Different dermoscopic structures (network, structureless areas, branched 
streaks, dots and globules).5, 87 Each criteria has its own scoring system . The sum of 
these scores results in one final score, the total dermoscopy score. This score 
indicates suspicion of a melanoma.5 Detection of melanoma with the use of 
dermoscopy has a sensitivity and specificity of 91% and 86%, respectively.88 
If suspicious for melanoma,  a diagnostic excision of the lesion will be performed. 
Despite having excision material for histological assessment, accurate diagnosis of a 
melanoma remains a challenge for the histopathologist.89 There are different 
histologic subtypes of melanoma. The most common histologic subtype is the 
superficial spreading melanoma (SSM) (Figure 5C). This tumor is characterized by the 
lateral spreading of malignant melanocytes within the epidermis and architectural 
changes in the epidermis such as poor circumscribed melanocytes, single melanocytes 
predominating over nests of melanocytes, disorganized distribution of melanocytes, 
pagetoid spread (presence of melanocytes above the basal layer) and non-cohesive 
nests of melanocytes.89 Lack of maturation of melanocytes, mitotic activity, 
asymmetrical inflammatory infiltrate and focal fibrosis with neovascularization can 
occur in the dermis.89 Another common subtype of melanoma is the nodular 
melanoma (NM).  Many characteristics of this tumor are similar to those of SSM. In 
contrast, NM are sharply circumscribed and extend into the dermal layer.  The 
extensions consist of large dermal nests and sheets of cytological atypical 
melanocytes.89 Dermal melanocytes are enlarged with prominent eosinophilic 
nucleoli with lack of maturation and high mitotic activity. In the epidermis, 
melanocytes with abundant cytoplasm, vesicular nuclei and prominent nuclei can be 
found.89 
Figure 5  Clinical images. A: Psoriatic plaques; B: (micro)Nodular basal cell carcinoma; 
C: Superficial spreading melanoma.
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lesions, we focus on distinguishment between nBCC and intradermal nevi by in vivo 
RCM (chapter 3.2). 
 The international confocal field originally started with melanoma research, 
because melanin has the highest reflective index in skin tissue and is therefore most 
easily detectable by RCM. Many diagnostic melanoma studies were performed by 
international confocal groups. We aim to conduct a systematic review of most 
described RCM features for melanoma and its clinical simulators (chapter 4.1). This 
systematic review serves as a new RCM focus of our center. 
 The results of the aforementioned chapters are summarized and discussed in 
chapter 5.
Aims and outline of the thesis
This thesis describes studies towards implementation of in vivo RCM in clinical 
dermatology. For implementation of RCM in clinical dermatology it is essential to 
acquire knowledge concerning the possibilities of RCM in different skin entities. 
We aim to explore the use of RCM in inflammatory skin diseases, based on the 
classification scheme of Dermatology2 (Figure 7), by systematically reviewing all 
available literature concerning this subject (chapter 2.1). We also focus on the role of 
RCM in diagnosis of stable and unstable psoriatic plaques (chapter 2.2). Insights in 
the differentiation of stable and unstable plaques by RCM provide information about 
the phase of a psoriatic plaque. In future, this information might be used to adjust 
treatment strategies. Finally, we aim to conduct an implementation strategy. This 
strategy describes the approach of our center towards the application of RCM in 
psoriasis. The strategy may serve as general implementation model for RCM in other 
dermatological entities (chapter 2.3).  
   Less aggressive BCCs, such as sBCCs, can be treated by non-invasive PDT. The 
response rate of PDT depends on, amongst others, the correct diagnosed subtype 
BCC. In chapter 3.1 we determine whether a treatment failure or recurrence after 
PDT is based on underdiagnosis of histological examination, so a more aggressive 
subtype than sBCC that is missed on punch biopsy. The number of mixed-type BCCs 
underdiagnosed by initial biopsy may lead to the use of additional non-invasive 
diagnostics such as RCM. BCCs can clinically mimic benign lesions. A nBCC and intra- 
dermal nevus demonstrate similarities in clinical appearance. However, a different 
treatment approach is needed. In order to reduce number of excisions of benign 
Figure 6  Number of RCM publications from 1995 until November 2015.
Figure 7  Classification scheme for dermatologic disorders (from Dermatology2).
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Abstract  
In vivo examination of the skin by reflectance confocal microscopy (RCM) has been 
performed for about 20 years, leading to a broad spectrum of imaged infectious 
and inflammatory skin diseases (ISD) with many described RCM features. We 
systematically reviewed all available literature concerning ISD evaluated by RCM. 
Furthermore, we assessed the accuracy of the features and defined recommen-
dations for future studies after indicating the limitations in the current published 
literature. Pubmed, EMBASE, Cochrane Library and Web of science databases were 
searched for literature. All studies on RCM and ISD were reviewed and quality assessment 
was determined by using the Strengthening the Reporting of Observational studies in 
Epidemiology (STROBE) checklist. Literature search revealed 77 eligible studies for 
inclusion. Different RCM features in a broad spectrum of ISD have been described. 
Further, RCM has been used for monitoring treatment and evolution of ISD, as well as 
diagnostic purposes. 
 This systematic review provides an overview of the broad spectrum of ISD imaged 
by RCM. Although RCM seems to be a promising monitoring and diagnostic tool for 
ISD, studies with appropriate methodological quality are necessary to create adequate 
guidelines and protocols for further implementation of RCM in clinical practice. 
Introduction
In 1957, Marvin Minsky described the principles of confocal microscopy.1 About three 
decades later, confocal scanning technologies were further developed, resulting in a 
device suitable for in vivo imaging of the human skin.2 As a consequence, systems 
were introduced for clinical practice. Currently, the most applied commercially 
available reflectance confocal microscope in clinical practice, utilizes a near infrared 
laser (830 nm) for imaging the skin until a depth of 200-300 µm and obtains horizontal 
(en face) images with a resolution comparable to light microscopy.3 
 Melanoma and non-melanoma skin cancer have been studied extensively by 
RCM.4-6  Furthermore, inflammatory skin diseases (ISD) have been studied by RCM, 
however, less frequent. 7-9 Currently, in case the clinical diagnosis of an inflammatory 
lesion is difficult, histopathological examination of a biopsy is the gold standard for 
further investigation. This may result in scar formation or other local inflammatory 
reactions. Other disadvantages of a biopsy are the possibility of a sampling error and 
the inability to follow dynamic processes over time. RCM may overcome these 
drawbacks.10-12 Moreover, the majority of features related to ISD reside within the 
epidermis or upper dermis, in which RCM has a good resolution.13 Therefore, RCM 
seems to be an appropriate application for ISD.   
 Multiple review articles on general principles and applications of RCM have been 
published.3, 13, 14 However, these reviews lacked a systematic approach and did not focus 
on ISD. A systematic review can elucidate the entire field of ISD assessed by RCM.
The current literature was reviewed for the following purposes:
1. To present an overview of the ISD which can be evaluated by RCM. 
2. To assess diagnostic- and monitoring RCM features and their accuracy in ISD.
3. Provide recommendations for future use of RCM in ISD and describing the limitations 
in current published studies.  
 
Methods
 
A systematic literature search was performed in four electronic databases: Pubmed, 
EMBASE, The Cochrane Library and Web of Science. The search was based on 
confocal microscopy and all synonyms. ISD included a broad spectrum of diagnosis, 
requiring a systematical approach based on the classification scheme of inflammatory 
dermatologic disorders by Dermatology.15 We included publications with the 
Vivascope systems, because this is currently the most applied system in clinical 
practice. Studies on oral- and genital ISD, genodermatoses, pigmentary- and vascular 
diseases were excluded. An exception was made for cutaneous T-cell lymphomas, 
since  this neoplasm can mimic eczematous and papulosquamous dermatoses.16 
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Furthermore, some bullous diseases with both genetic- and bullous origin were 
included. 
 The searches were restricted to publications on humans, English, German and 
Dutch language. All published studies until 14 march 2014 were included. Full details 
on the search strategy are available in supplement 1. After the initial search, titles and 
when necessary abstract and/or material and methods were screened (LH). After this 
selection, two reviewers (LH and MP) screened titles and abstracts by a checklist 
specifying in- and exclusion criteria. Thereafter, two reviewers (LH and MP) critically 
assessed the full texts for their eligibility. Differences in assessment between the two 
reviewers were discussed with a third investigator (PvE). Case reports and case series 
had to fulfill three criteria for inclusion: the use of RCM, an ISD and RCM features 
should be described.  Abstracts  with unavailable full texts, reviews about different 
non-invasive imaging techniques and other skin diseases than ISD according to 
Dermatology15 were excluded. To ensure all relevant studies were included, the reference 
lists of all included articles were checked for relevant articles not identified by the 
initial search.
 Study characteristics included type of ISD, study design, number of participants, 
type of RCM system, number and location of the scanned lesions, aim of the study, 
RCM features and their accuracy and reference test to RCM images.  
 Methodological quality of the included studies was assessed by the STrengthening 
the Reporting of OBservational studies in Epidemiology (STROBE) criteria.17  This scale 
was modified to assess the quality for case reports and case series by exclusion of the 
items ‘variables’ and ‘study size’, (Supplement 2). Category A was defined as fulfilling 
more than 80% of the STROBE criteria, B as 50-80%  and C  when less than 50% of the 
criteria were achieved. 
 
Results
A total of 10,049 articles were identified after the literature search (Figure 1). 
Subsequently, 6,885 articles were assessed for further screening, because 3,164 
publications were duplicates. The first screening resulted in inclusion of 562 articles 
on in vivo RCM examination of the skin. This screening had an overlap of 92% between the 
two reviewers and 148 abstracts were eligible for full text screening. Unfortunately, 
in 15 publications full texts were not available and 57 articles did not met the inclusion 
criteria. The full text screening by the two reviewers showed an overlap of 96%. The 
additional check of the reference lists of the included studies resulted in inclusion of 
one extra publication.  
 Finally, 77 publications were included for this systematic review (Figure 1, 
Supplement 3): papulosquamous and eczematous diseases (n=30), cutaneous T-cell 
lymphoma (n=6), (autoimmune) bullous diseases (n=8), adnexal diseases (n=5), 
autoimmune connective tissue diseases (n=4) and infectious skin diseases (n=35). 
Four studies were included in several categories, because multiple inflammatory 
diagnoses were described (table 3)8, 9, 18, 19. RCM features and their descriptions were 
summarized by diagnosis (Table 1 (online) and 2, Supplement  4).
 As the total number of the published RCM and skin related studies (n=562) was 
compared to the number of RCM and ISD related studies (n=77), we noted an increase 
at the end of 2010 (Graph 1). Most of the included studies were case reports (n=27) 
and case series (n=14), the remaining studies were cohort studies (n=9), case-control 
studies (n=20) and cross-sectional studies (n=7). The methodological quality 
assessment showed that 56% (43/77) studies were classified in category B and the 
remaining 44% (34/77) were classified in category C. The majority of the studies lack 
descriptions of the setting, potential sources of bias, explanation on the study size, 
quantitative variables and their statistical analysis. Consistent with the low 
methodological quality,  6 out of the 77 studies determined the sensitivity and 
specificity of different RCM diagnosis or features (Table 1 (online)). 
Figure 1  Flow chart: selection process of included studies.
Citations from databases
n=10,049  
Titles (abstracts / methods)
n= 6,885 
RCM and skin
n= 562 
Included studies 
n= 77 
Full text screening  RCM and inﬂammatory skin disorders 
n=133 
Web of Science: n=4,124  Cochrane: n=161 EMBASE: n=2,716 Pubmed: n= 3,048 
Studies by reference lists n=1 Exclusion n= 57 
No full text available n=15 
Exclusion n = 414 
Exclusion n = 6,323 
Duplicates n = 3,164 
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The main part of the included studies were categorized to the papulosquamous and 
eczematous diagnoses; psoriasis8, 9, 11, 18, 20-30, pityriasis rubra pilaris31, lichen planus32 
and lichen nitidus33, radiation-34, allergic contact dermatitis and irritant contact 
dermatitis8, 35-44. The cutaneous T-cell lymphoma (mycosis fungoides, parapsoriasis en 
petite plaque, lymphomatoid papulosis, sézary Syndrome)8, 45-49 and bullous diseases 
(pemphigus foliaceus, pemphigus vulgaris, bullous pemphigoid, Hailey-Hailey, Darier-
White)9, 18, 50-55 have been examined as well by RCM. Other imaged diseases were 
alopecia56-60 and auto-immune connective tissue diseases like lupus8, 61, systemic62- 
and lichen sclerosus.63 Moreover, various infectious skin diseases were studied by 
RCM; parasitic (demodex folliculitis, larva migrans, leishmaniasis, scabies and 
pyemotes ventricosus) 19, 64-78, bacterial (secondary syphilis and bacterial surinfection)9, 
79, fungal (tinea and onychomycosis)19, 80-86, viral (varicella, herpes, human papilloma 
virus, molluscum contagiosum)9, 87-91 . Because of the extensive spectrum of imaged 
ISD, the skin disorders with RCM diagnosis and/or feature accuracy determinations 
will be discussed in detail.
 
Psoriasis
Fifteen studies revealed RCM features for diagnostic and monitoring  applications in 
psoriasis (Table 1 (online)).8, 9, 11, 18, 20-30  Most observed features were parakeratosis, 
thinning or absence of the stratum granulosum (SG) , Munro’s microabscesses, 
infiltrating cells in the epidermis, non-edged dermal papillae (DP), papillomatosis and 
tortuous, twisted and dilated blood vessels (BV) in DP (Table 1 (online),Supplement 
4). Although a high correlation between these features and histologic findings was 
reported, the non-blinded interpretation of the RCM features and the histopatholog-
ical parameters could have biased the results.23 Moreover, the majority of the 
research were case-control studies or case-reports (Table 1 (online),Supplement 5) 
requiring a careful interpretation. Koller et al. showed a sensitivity and specificity of, 
respectively, 89.13% and 95.41% to diagnose psoriasis with RCM.8 Frequently 
mentioned limitations for examining psoriasis with RCM were the limited penetration 
depth, hyperkeratosis and the elongation of the interpapillary epithelium.21-24 
Pityriasis rubra pilaris (PRP), an important differential diagnosis of psoriasis, has been 
described by one letter.31 In PRP, a lack of neutrophils , maintenance of the SG, and 
irregular shaped and sized DP at the DEJ were observed.31 Zhong et al. showed a high 
sensitivity (90.0%) and specificity (96.4%) for Munro’s microabscesses.26 (Pseudo)
Pautrier’s microabscesses may resemble Munro’s microabscesses, however cells in 
Pautrier’s microabscesses were less refractile and smaller.26  
 Several studies showed the monitoring capacity of RCM to examine therapeutic 
effect or the natural course of psoriasis.11, 24, 25, 27, 28, 30, however there were several 
limitations regarding to the monitoring of psoriasis by RCM. All the studies, except by 
Basaran et al.30 were not-blinded, hyperkeratotic lesions could not be evaluated and 
there was no consensus about the criteria reported by the different studies. Overall, 
RCM can be considered as a diagnostic and monitoring tool for evaluation of different 
therapies, the dynamics- and subclinical changes of psoriasis.  
Allergic and irritant contact dermatitis 
RCM imaging of allergic- and irritant contact dermatitis (ACD and ICD) has been 
described in 11 studies (table 3).8, 35-44 . Common features for ACD and ICD were 
summarized in Table 1 (online) and Supplement 4.37, 39, 41 The most described features 
for both types of contact dermatitis (CD) were epidermal spongiosis and -necrosis 
and perivascular infiltrates. Presence of vesicle formation, spongiosis and exocytosis 
were more specific for ACD . ICD was mainly characterized by SC disruption, individual 
corneocytes, spongiosis, parakeratosis, necrosis and increased epidermal thickness. 
RCM had the ability to differentiate ACD from ICD, to follow the dynamic inflammatory 
processes in CD and to show typical features of CD in a subclinical lesion. 37-39 SC 
disruption, parakeratosis and spongiosis interfered with the ability of RCM to visualize 
the deeper dermis CD lesions.37  These conclusions were mainly based on case-control 
and cohort studies of moderate methodological quality (Table 1 (online),Supplement 
5).  Three studies determined the accuracy of the RCM features for CD. Koller et al. 
showed a sensitivity of 83.3% and specificity of 92.3% for the general diagnosis of 
CD.8 Astner et al. showed in two studies a widened sensitivity (51.9%-96.3%) and a 
high specificity (95.8%-100%) for ACD. Logistic regression analysis demonstrated that 
spongiosis at the stratum spinosum (SS) was the best predictor for ACD. 38, 41 
Interestingly, no studies examined the monitoring capacity of RCM in the therapeutic 
responses in allergic dermatitis.  
Cutaneous T-cell lymphoma
Six studies with moderate methodological quality (Table 1 (online),Supplement 5)8, 
45-49, described features for different cutaneous T-cell lymphomas which can mimic 
eczematous and papulosquamous dermatoses. General features for mycosis 
fungoides (MF), Sézary syndrome (SEZ), parapsoriasis en plaque (PARA) and lymphoid 
papulosis (LYP) were: spongiosis, blurred intercellular demarcations, epidermal 
disarray, epidermal-, junctional- and dermal atypical lymphocytes, hyporefractile DP, 
BV dilatation, dendritic cells (DC), vesicle-like structures, fibrosis, elongation of 
keratinocyte nuclei (Table 1 (online),Supplement 4). Specified features for LYP were 
parakeratosis, Pautrier abscesses-like structures in epidermis, mild disarray at the 
DEJ and dermal sclerosis.48 Furthermore, features for each stage of MF were 
described (Table 1 (online),Supplement 4).45, 49 MF can be diagnosed with a sensitivity 
and specificity of, respectively, 63.33% and 92.89%.8 In addition, the highest 
sensitivity and specificity was found for spongiosis, blurred intercellular demarcations 
and disruption of the epidermal architecture (Table 1 (online)). Selected parameters 
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showed a high inter-observer reproducibility, except for vesicle-like structures and 
hole-like perforations.47 Low sensitivity values were clarified by common RCM 
features in different diagnosis.8 For example, MF and lichenoid dermatitis showed 
hyporefractility of the basal layer surrounding the DP and vesicular structures as seen in 
MF, were sometimes difficult to differentiate from vesicles filled with inflammatory 
cells in ACD.45
Discoid lupus erythematosus
Chronic discoid lupus erythematosus (CDLE) and subacute cutaneous lupus 
erythematosus (SCLE) were described by a case-series and case-control study (Table 1 
(online), Supplement 5).8, 61 Koller et al. showed a sensitivity and specificity of, 
respectively, 62.96% and 94.53%, to diagnose CDLE and SCLE.8  Characteristic features 
were parakeratosis, spongiosis, epidermal disarray with necrotic keratinocytes, 
epidermal-, perivascular-, and adnexal inflammatory infiltrate. Furthermore, interface 
dermatitis, Langerhans cells, dilated BV, abnormal collagen bundles, dilated- and 
hyperkeratotic adnexal infundibula have been described (Table 1 (online), Supplement 5). 
CDLE showed some common features as in other ISD, like the disturbed appearance 
of the papillary rings as in MF and the interface dermatitis and peri-adnexal infiltration 
in lichen planus.32, 45, 47 Spongiosis and necrotic keratinocytes were detected more 
frequently with RCM than in histopathology. The ‘en face’ orientation of the RCM 
images and the transversal plane in conventional histopathology can be a possible 
explanation.61
   
Onychomycosis
Another application of RCM is imaging of the nail plate to diagnose onychomycosis. 
This has been described by a case report and two case-controlled studies (Table 2 
(online), Supplement 4,5).80, 82, 84 Sattler et al. showed  just below the surface of the 
nail plate a network of branched hyphae, characterized by lengthy structures or 
spore-like aggregates with a high reflection and the typical shape of hyphae.82 
Rothmund et al. showed the sensitivity (79,5%), specificity (81%) and positive 
predictive value (88,6%) for RCM to diagnose onychomycosis. RCM was superior to 
potassium hydroxide (KOH) preparation, culture and OCT.84 
Discussion
 
Confocal microscopy is an applied technique in both clinical practice and laboratorial 
setting, explaining  the enormous amount of publications found after the literature 
search. 
 We included publications with the clinically used Vivascope systems, although 
an exception was made for relevant studies accomplished with a 1064nm laser 20, 21, 35, 
55, 64, 80, the system that was used before the Vivascope systems were introduced.2 
At the end of the 2010, the number of published RCM studies increased rapidly 
(Figure 2). This exponential increase could be clarified by the expanded knowledge of 
the RCM users, the benefits of a non-invasive device or by the fact that more 
dermatological practices all over the world have been using the RCM technique.
 So far, there is a lack of well performed methodological studies which assess 
the ability and accuracy of RCM in distinguishing different inflammatory cells. This 
can be considered as one of the main limitations of RCM as a diagnostic tool in the 
field of ISD.    
 No validated tool was available for assessing all different included study designs. 
We considered to apply the Quality Assessment of Diagnostic Accuracy Studies 
(QUADAS)-2 tool92, but the focus of the included studies was both observational and 
descriptive. Therefore it was not adequate to assess the diagnostic capacity of RCM 
by the QUADAS-2 method. Since the majority of the included studies were pilot- or 
preliminary studies, a modified STROBE was applied to compare all different included 
Figure 2  Total number of reflectance confocal microscopy (RCM) publications from 
1995 until 2013 and number of publications of infectious and inflammatory skin 
diseases imaged by RCM (dotted line).
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study designs. Overall, 43% of the included studies were classified to the lowest 
category (C) and none of the studies fulfilled the criteria for the highest category. This 
indicates the low methodological quality of the present available studies. However, 
as discussed in the Oxford Centre for Evidenced Based Medicine, there is a growing 
recognition that lower levels of evidence, for example observational studies, case 
reports and case series can have an impressive effect and may sometimes provide 
stronger evidence than higher level studies.93, 94
 Only six out of 76 included studies determined sensitivity and specificity. 
Unfortunately, the number is too small to compare results and interpret conclusions 
about different applications of RCM in ISD. Moreover, in a laborious technique like 
RCM, extensive training is necessary prior to adequate use. The experience of the 
observer is of utmost importance to reliably establish the sensitivity and specificity. 
Therefore, the inter-observer variability is an important factor to evaluate.47 
RCM has been shown to be valuable in monitoring treatment and the (natural) course 
of ISD. Still, it remains unclear if and in which proportion RCM can substitute a biopsy 
in case of clinically unclear diagnosis in ISD. Therefore, there is a need for comparative 
studies of RCM features of the most common ISD, like psoriasis, eczema, lupus and 
lichen planus.
 Overall, in the field of ISD, we recommend the use of uniform RCM terms, correlated 
to histopathology examined by blinded experienced investigators. Furthermore, studies 
with large sample size of different ISD are needed, to assess the accuracy of the 
differential diagnosis.
 In conclusion, this systematic review provides an overview of the broad spectrum 
of ISD imaged by RCM. RCM seems to be a promising tool for monitoring and 
diagnosing inflammatory lesions. However, studies with good methodological quality 
are necessary to create adequate guidelines and protocols for further implementation 
of RCM in clinical practice. 
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Supplement 1  Search strategy
Search Topic Search terms  March -14th, 2014
Pubmed (MEDLINE)  
Search terms March -14th, 2014
EMBASE 
Search terms  March -14th, 2014
Cochrane Library
Search terms  March -14th, 2014
Web of Science
Search A: 
RCM
Mesh terms: 
#1  Microscopy, Confocal
In free text (title or abstract):  
#2  confocal microscop*  
#3  confocal laser scanning microscop*  
#4  confocal imag* 
#5  (reflect* AND confocal)
#6  CLSM
#7  confocal scanning microscope
#8  laser microscop* 
#9 (#2 OR #3 ..OR #7 OR #8)
#10 (#1 OR #9) 
Citations: 61.468
Emtree terms: 
#1  confocal microscopy
#2  confocal laser microscopy
#3  confocal laser scanning microscope
#4  confocal microscope
#5 (#1 OR #2 OR #3 OR #4)
In free text (In title or abstract):  
#6  confocal microscop*  
#7  confocal laser scanning microscop*  
#8  confocal imag* 
#9  (reflect* AND confocal)
#10 CLSM
#11 confocal scanning microscope
#12 laser microscop* 
#13 (#6 OR #7..OR #11 OR #12) 
  Citations: 63.470
Mesh terms: 
#1 Microscopy, Confocal
In free text(In title or abstract):  
#2  confocal microscop*  
#3  confocal laser scanning microscop*  
#4  confocal imag* 
#5  (reflect* AND confocal)
#6  CLSM
#7  confocal scanning microscope
#8  laser microscop* 
#9 (#2 OR #3 ..OR #7 OR #8)
#10 (#1 OR #9) 
                                        
                                            
Citations:584
In free text (Topic)
#1 confocal microscop*  
#2  confocal laser scanning microscop*  
#3  confocal imag* 
#4  (reflect* AND confocal)
#5  CLSM
#6  confocal scanning microscope
#7  laser microscop* 
#8 (#1 OR #2..#6 OR #7)
Citations: 93.384
Search B:   
Inflammatory 
skin diseases
Mesh term: 
#1  Skin and Connective Tissue Diseases 
In free text (title or abstract):  
#2  Skin
#3  Cutaneous
#4  Dermatoses
#5  (Inflammatory AND skin)
#6  Papulosquamous
#7  Psoriasis
#8  Pityriasis
#9  Lichen*
#10  Eczema*
#11  Dermatisis
#12  Urticaria
#13  Erythema*
#14  Scleroderma
#15  Morphea
#16  Lupus
#17  Vesiculobullous
#18  Bullous
#19  Pemphig*
#20  Bullosa
#21  (Infectious  AND skin)
#22  (Viral AND skin)
#23  Herpes
Emtree term:
#1 Exp skin disease
 
In free text (title or abstract): 
#2  Skin
#3  Cutaneous
#4  Dermatoses
#5  (Inflammatory AND skin)
#6  Papulosquamous
#7  Psoriasis
#8  Pityriasis
#9  Lichen*
#10  Eczema*
#11  Dermatisis
#12  Urticaria
#13  Erythema*
#14  Scleroderma
#15  Morphea
#16  Lupus
#17  Vesiculobullous
#18  Bullous
#19  Pemphig*
#20  Bullosa
#21  (Infectious  AND skin)
#22  (Viral AND skin)
#23  Herpes
Mesh term: 
#1  Skin and Connective Tissue Diseases 
In free text (title or abstract):  
#2  Skin
#3  Cutaneous
#4  Dermatoses
#5  (Inflammatory AND skin)
#6  Papulosquamous
#7  Psoriasis
#8  Pityriasis
#9  Lichen*
#10  Eczema*
#11  Dermatisis
#12  Urticaria
#13  Erythema*
#14  Scleroderma
#15  Morphea
#16  Lupus
#17  Vesiculobullous
#18  Bullous
#19  Pemphig*
#20  Bullosa
#21  (Infectious  AND skin)
#22  (Viral AND skin)
#23  Herpes
In free text (Topic)
#1  Skin
#2  Cutaneous
#3  Dermatoses
#4  (Inflammatory AND skin)
#5  Papulosquamous
#6  Psoriasis
#7  Pityriasis
#8  Lichen*
#9  Eczema*
#10  Dermatisis
#11  Urticaria
#12  Erythema*
#13  Scleroderma
#14  Morphea
#15  Lupus
#16  Vesiculobullous
#17  Bullous
#18  Pemphig*
#19  Bullosa
#20  (Infectious  AND skin)
#21  (Viral AND skin)
#22  Herpes
#23  Molluscum contagiosum
#24  (Bacterial AND skin)
#25  Staphylococ* 
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Supplement 1  Continued
Search Topic Search terms  March -14th, 2014
Pubmed (MEDLINE)  
Search terms March -14th, 2014
EMBASE 
Search terms  March -14th, 2014
Cochrane Library
Search terms  March -14th, 2014
Web of Science
Search B:   
Inflammatory 
skin diseases
#24  Molluscum contagiosum
#25  (Bacterial AND skin)
#26  Staphylococ*
#27  impetigo
#28  Dermatomycoses
#29  Tinea
#30  (Infestations AND skin)
#31  Mite
#32  Larva
#33  Leishmaniasis
#34  Scabies
#35  Rosacea
#36  Acne
#37  Mycosis fungoides
#38 (#2 OR #3 …OR #36 OR #37)
#39 (#1 OR #38)
Citations: 1.464.800
#24  Molluscum contagiosum
#25  (Bacterial AND skin)
#26  Staphylococ*
#27  impetigo
#28  Dermatomycoses
#29  Tinea
#30  (Infestations AND skin)
#31  Mite
#32  Larva
#33  Leishmaniasis
#34  Scabies
#35  Rosacea
#36  Acne
#37  Mycosis fungoides
#38 (#2 OR #3 …OR #36 OR #37)
#39 (#1 OR #38)
Citations: 1.679.350
#24  Molluscum contagiosum
#25  (Bacterial AND skin)
#26  Staphylococ*
#27  impetigo
#28  Dermatomycoses
#29  Tinea
#30  (Infestations AND skin)
#31  Mite
#32  Larva
#33  Leishmaniasis
#34  Scabies
#35  Rosacea
#36  Acne
#37  Mycosis fungoides
#38 (#2 OR #3 …OR #36 OR #37)
#39 (#1 OR #38)                                    
                                    
Citations:153.124
#26  impetigo
#27  Dermatomycoses
#28  Tinea
#29  (Infestations AND skin)
#30  Mite
#31  Larva
#32  Leishmaniasis
#33  Scabies
#34  Rosacea
#35  Acne
#36 Mycosis fungoides
#37 (#1 OR #2 ..OR #35 OR #36)
                               
Citations: 938.390
Crossed  
searches:
Search A AND Search B 
Limits: English, German, Dutch, humans
  Citations: 3048
Search A AND Search B 
Limits: English, German, Dutch, humans  
Citations:2716 
Search A AND Search B 
No limits
                                                                                  
Citations: 161
Search A AND Search B
Limits: English, German, Dutch, humans 
Citations: 4124
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Supplement 3  Category and number of included studies
Papulosquamous and eczematous diseases n=30
Psoriasis 
PRP
Lichen planus and Lichen nitidus 
ACD / ICD
Radiation dermatitis
n=15 
n=1
n=2 
n=11* 
n=1
Cutaneous T-cell lymphoma n=6*
MF, PARA, LYP, SEZ n=6
(Autoimmune) bullous diseases n=8*
PF, PV, BP
Hailey-Hailey 
Darier-White 
n=5 
n=2 
n=1
Adnexal diseases n=5
Alopecia n=5
Auto-immune connective tissue diseases n=4
Lupus: CDLE / SCLE
Systemic Sclerosis Ssc
Lichen sclerosis (extragenital)
n=2 
n=1
n=1
Infections and infestations n=32
Parasitic: 
  Demodex folliculitis, Cutaneous Leishmaniasis, Larva migrans, Scabies, 
Pyemotes ventricosus
Bacterial
 Secondary syphillis, Bacterial surinfection 
Fungal: 
 Onychomycosis, Tinea corpus,-manus,-pedis 
Viral:
 Varicella, Herpes, Verruca, Molluscum Contagiosum
n= 16*
n=2* 
 
n=8 
 
n=6*
*Studies included in multiple diagnostic categories
ACD: allergic contact dermatitis, BP: bullous pemphigoid, CDLE: chronic discoid lupus erythematosus, 
ICD: irritant contact dermatitis, LYP: lymphomatoid papulosis, MF: mycoses fungoides, PARA: para -
psoriasis en plaque , PF: pemphigus foliaceus, PV: pemphigus vulgaris, PRP: pityriasis rubra pilaris, SEZ: 
Sézary syndrome, SCLE: subacute cutaneous lupus erythematosus, Ssc: systemic sclerosis
Supplement 5  STROBE Scores and categories 
Author, year Study design STROBE 
Score*
STROBE 
category
Papulosquamous and eczematous 
diseases: psoriasis
Gonzalez, 1998 Letter 30.5 C
Gonzalez, 1999 Case-control 57.4 B
Koller*, 2009 Case-control 58.9 B
Ardigo, 2009 Case- control 56.1 B
Wolberink, 2011 Case-control 59.3 B
Koehler*, 2011 Case report 59.5 B
Archid, 2012 Case-control 61.8 B
Wolberink, 2012 Case-control 51.8 B
Zhong, 2012 Letter: with case-control study 36.2 C
Ardigo, 2013 Cohort 58.3 B
Debarieux*, 2013 Case- series 59.8 B
Hui, 2013 Letter: with cross-sectional study 40.6 C
Moscarella, 2013 Case report 32.5 C
Başaran, 2014 Cohort 58.4 B
Wolberink, 2014 Case series 54.4 B
Papulosquamous and eczematous 
diseases: Pityriasis rubra pilaris
Pietroleonardo, 2013 Letter: with case report 34.5 C
Papulosquamous and eczematous 
diseases: Lichen planus and lichen 
nitidus
Liu H.,2011 Case report 26.0 C
Moscarella, 2012 Case series 67.4 B
Papulosquamous and eczematous 
diseases Allergic Contact Dermatitis / 
Irritant Contact Dermatitis
Gonzalez, 1999 Case-control 41.1 C
Hicks, 2003 Cohort study 52.5 B
Swindells, 2004 Cohort study 61.9 B
Astner, 2005 Case-control 60.9 B
Astner, 2005 Cohort 56.7 B
Astner, 2006 Cohort 52.7 B
Astner, 2006 Cohort 65.6 B
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Supplement 5  Continued 
Author, year Study design STROBE 
Score*
STROBE 
category
Koller*, 2009 Case-control 58.9 B
Sakanashi, 2010 Case-control 54.4 B
Ardigo, 2012 Cross-sectional 38.1 C
Benjamin, 2012 Cohort 46.4 C
Papulosquamous and eczematous 
diseases: Radiation dermatitis
Vano-Galvan, 2013 Case series 69.0 B
Cutaneous T-cell lymphoma:  
Mycoses Fungoides, Parapsoriasis 
en plaque, Lymphomatoid papulosis, 
Sézary Syndrome
Agero, 2007 Case series 62.0 B
Koller*, 2009 Case-control 58.9 B
Liu, Z.H. 2011 Case report 29.4 C
Lange-Asschefeldt, 2012 Case-control 68.2 B
Ardigo, 2013 Case series 52.2 B
Li, 2013 Cross-sectional 38.8 C
(Autoimmune) bullous diseases: 
Pemphigus Foliaceus, Pemphigus 
Vulgaris, Bullous Pemphigoid, Hailey-
Hailey, Darier-White 
Angelo-va-Fischer, 2009 Case report 55.3 B
Koehler*, 2011 Case report 59.5 B
Kurzeja, 2012 Case-control 50.3 B
Levi, 2012 Case series 39.5 C
Ardigo,2014 Case series 65.7 B
Debarieux*, 2013 Case series 59.8 B
Kurzeja, 2014 Case series 54.8 B
Gonzalez, 1999 Case report 48.0 C
Adnexal diseases: Alopecia
Rudnicka, 2008 Case-control 38.9 C
Slowińska, 2010 Case report 47.2 C
Agozzino, 2011 Case series 70.5 B
Ardigo, 2011 Letter: with case series 29.5 C
Ardigo, 2011 Cross sectional 39.3 C
Supplement 5  Continued 
Author, year Study design STROBE 
Score*
STROBE 
category
Auto-immune connective tissue 
diseases: Lichen Sclerosus 
(extragenital), Discoid Lupus 
Erythematosus and Systemic Sclerosis
Kreuter, 2002 Case report 35.5 C
Ardigo,2007 Case series 67.4 B
Koller*, 2009 Case- control 58.9 B
Sauermann, 2002 Case-control 53.0 B
Parasitic:  folliculitis/demodex, 
cutaneous larva migrans, cutaneous 
leishmaniasis, scabies, pyemotes 
ventricosus
Gonzalez, 1999 Case report 49.7 B
Longo, 2005 Case report 32.0 C
Ahlgrimm-Siess, 2008 Case report 52.7 B
Slutsky*, 2011 Case report 21.0 C
Purdy, 2011 Case report 42.7 C
Slutsky*, 2011 Case report 21.0 C
Levi, 2011 Letter: with case report 35.4 C
Levi, 2012 Letter: with case report 44.8 C
Longo, 2012 Letter 43.8 C
Sattler, 2012 Case-control 52.3 B
Cinotti, 2013 Case report 61.7 B
Del Giudice, 2013 Cohort 47.1 C
Sattler, 2013 Letter 36.5 C
Veasy, 2013 Letter: case report 47.0 C
Harmelin, 2013 Letter: case-control 45.5 C
Turgut Erdemir, 2014 Case-control 56.7 B
Alarcon, 2014 Case report 63.2 B
Infections and infestations: Bacterial
Venturini, 2009 Case series 65.5 B
Debarieux*, 2013 Case report 59.8 B
Infections and infestations: Fungal
Hongcharu, 2000 Case report 39.5 C
Markus, 2001 Case report 50.5 B
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Abstract
Background: Distinguishing between stable and unstable plaque psoriasis is of 
importance to obtain information of the course of psoriasis and to chose therapeutic 
strategies. Currently, patients report, clinical assessment and histopathology provide 
limited information. No previous studies examined the ability of in vivo reflectance 
confocal microscopy (RCM) to non-invasively examine stable and unstable psoriasis. 
Objective: To assess the ability to differentiate between stable and unstable psoriasis 
by RCM. 
Methods: Twelve stable- and fourteen unstable psoriatic plaques from thirteen 
patients with chronic plaque psoriasis were imaged by RCM.  Differences between 
center and margin were examined. Regression analyses were performed.  
Results: Unstable plaques showed a higher number of inflammatory cells within (epi)
dermis , including Munro and Kogoj microabscesses (all p <0.01), a larger diameter of 
dermal papillae (p=0.03), a higher capillary flow (p<0.01) with more tortuous 
capillaries (p=0.04). No differences were seen between center and margin, except 
the higher number of edged dermal papillae at the margin in stable plaques (p=0.01). 
Numbers of epidermal inflammatory cells were predictive for unstable plaques 
(p=0.02). Areas with a high number of epidermal  inflammatory cells may be 
considered to be a RCM defined hot spot. 
Conclusion: Stable and unstable chronic plaque psoriasis can be differentiated by 
RCM.
Introduction
Psoriasis is a chronic immune-mediated inflammatory skin disease with genetic- and 
environmental predisposing factors.1 Chronic plaque psoriasis is the most common 
variant and therefore considered as the prototype psoriasis.2, 3 However, psoriatic 
lesions are clinically and histopathologically heterogeneous.4 Moreover, the 
progression, severity and treatment response among patients differ.5 This relapsing 
disease occurs in a variety of dynamic forms, as inactive, non spreading stable 
plaques or as unstable spreading psoriasis. Unstable psoriasis may result in increased 
disease activity with novel and/or progress of pre-existing lesions.6 According to the 
dynamic phases, the hallmarks of psoriasis as hyperkeratosis, epidermal thickening, 
Munro microabscesses, prominent blood vessels and dermal neutrophil- and T-cell 
infiltrates, may vary in number and intensity.7 
 A bimodal immune activation has been proposed with an autoinflammatory and 
an adaptive immunity phase2, which is in alignment with the hypothesis of hot- and 
cold spots within a fully developed psoriatic plaque.8 Hot spots are described as 
acute active foci and characterized by, amongst others, accumulation of polymor-
phonuclear neutrophils (PMN). Previous studies described that hot spots are mainly 
located at the margin of a plaque and more therapy resistant than the surrounding 
chronic inflammatory area. This chronic is described as cold spots.4, 8 
 Distinguishing stable from unstable plaque psoriasis is of importance to obtain 
information about the course of the disease and for therapeutic strategies. Currently, 
patients report, clinical assessment and histopathology provide only limited information. 
 The imaging technique Reflectance Confocal Microscopy (RCM) offers the 
opportunity to non-invasively study skin. The correlation between RCM features and 
histopathology in plaque psoriasis have been studied extensively.9-11 However, to the 
best of our knowledge, this is the first study that aims to non-invasively differentiate 
between stable and unstable chronic plaque psoriasis by in vivo RCM. In addition, we 
studied possible differences in activity in the center and at the margin of psoriatic 
plaques, according to the centrifugal expansion hypothesis.12 Furthermore, we studied 
the possibility to characterize a RCM defined hot spot. Differentiation between stable 
and unstable psoriatic plaques by RCM, may provide new insights in the pathophysio-
logical mechanism in the psoriatic plaque and variability in treatment response. 
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Methods
Patients
In this explorative study thirteen Caucasian patients (Fitzpatrick skin type I-II) with 
previously clinically diagnosed chronic plaque psoriasis, were recruited from the 
department of Dermatology of the Radboud University Medical Center, Nijmegen, 
The Netherlands. All patients gave written informed consent prior to inclusion. 
Furthermore, the study was approved by the local medical ethics committee and 
conducted according to the Declaration of Helsinki principles.
 Based on patients report and clinical examination, six patients (five males, one 
female, age between 40-71 years) with two stable plaques (defined as non-growing 
plaques for at least one year) were included. The onset of their psoriasis varied 
between 10 and 50 years. None of the patients used systemic treatment. Furthermore, 
a washout period for topical treatment (n= 1 betamethasone diproprionate/calcipotriol, 
n=1 betamethasone diproprionate and calcitriol, n= 1 clobetasol propionate and 
calcitriol, n=3 none topical treatment) of one week was requisited. One week prior to 
imaging, keratolytic ointments (salicylic petrolatum 10%) were applied on the two 
selected stable plaques. 
 Seven patients (four males, three females, age between 27-59 years) reported 
unstable psoriatic plaques (defined as new or extending of pre-existing plaques 
within a few weeks), no signs of pustular psoriasis were observed. However, during 
physical examination, one of these patients appeared to have none of the typical 
clinical characteristics of unstable plaques. With initial RCM investigation also none 
of the expected features of an unstable plaque were found, and this patient was 
therefore excluded prior to the analysis. The duration of the psoriasis of the patients 
included varied between 1 and 40 years. In addition, the unstable phases varied from 
1-8 months.  Four patients used only topical corticosteroids or vitamin-D derivates 
during this phase. One patient developed an exacerbation despite UVB therapy (9 
days prior to inclusion). One patient developed an unstable phase after discontinua-
tion of fumarates (3 weeks prior to inclusion), and one patient after discontinuation 
of infliximab (3 months prior to inclusion). There was an urgency to treat these 
unstable psoriatic patients. Therefore, a minimum washout period of one week for 
topical therapy was not possible, and therefore varied from 4 days to 1 week. Two of 
the most expanding and exacerbated lesions were selected for RCM imaging. 
Thereafter, the precise RCM location within the lesions was determined by patients 
report for the most expanding part of the lesion. In addition to patients report, 
clinical examination determined the most erythematous part and dermoscopy 
selected the most visible dermal papillae (DP) representing the most active location. 
 
Clinical examination
The clinical severity of the plaques was assessed by the SUM score at the moment of 
RCM imaging. Clinical pictures of the lesions were taken with a digital camera (Nikon 
D 200, Nikon,Tokyo, Japan)  and afterwards classified as stable or unstable by three 
blinded dermatologists (Figure 1). Subsequently, the correlation between the patients 
report, clinical examination and RCM were compared. This method was adapted 
because of the possible difficulties in distinguishing stable and unstable psoriasis in 
clinical practice. 
Figure 1  Clinical images of the psoriatic lesions. A-Z: Clinical images of psoriatic lesions 
were assessed into stable or unstable by three dermatologists.
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RCM imaging
The VivaScope 1500 (Lucid Inc, Rochester, New York, USA) was used to image the 
selected plaques. The RCM technique has been described in detail before.13  Prior to 
the imaging, dermoscopic pictures were obtained with a Vivacam Macro Camera 
(Lucid Inc., Rochester, N.Y., USA). According to the margin zone model, which suggests 
more activity at the margin as compared to the center of the lesion 8, 12, two different 
locations within the center and two locations at the inner margin of each plaque 
were imaged.
 A RCM protocol for psoriasis was applied and 13 well-known RCM features for 
psoriasis were quantified (Table 1). The protocol consisted of a horizontal mapping at 
the stratum corneum (SC), stratum granulosum (SG), stratum spinosum (SS) and 
dermoepidermal junction (DEJ). Thereafter, two vertical stacks were taken from the 
SC up to the deeper dermis. Furthermore, movies were made at the DEJ to examine 
the capillary blood flow. 
 RCM images were analyzed by ImageJ (ImageJ version  1.46). 
Statistical analyses
The characteristics (mean of 4 imaged foci within plaque) of stable and unstable 
plaque psoriasis were examined in 6 patients with stable psoriasis (12 plaques) and 
6 patients with unstable psoriasis (12 plaques). Stable plaques were defined as 
non-growing or non-expanding plaques for at least one year and unstable plaques 
were defined as new, acute arisen plaques and/or extending of pre-existing plaques 
within one year. 
 Initially, the analyses were performed, both, on plaque level and on patient level 
(mean of two plaques per patient).  However, we found nearly identical results using 
these approaches and, here, only the results based on the plaque level are presented. 
The t-test, was used to test differences between two groups for statistical significance, 
in case of continuous variables, the test of Mann Whitney  in case of ordinal variables 
and the Fisher exact test in case of 2X2 tables.
 The difference between the center (mean of two measurements in center) and 
the margin (mean of two measurements at margin) of the plaque were tested by the 
Wilcoxon signed rank test. 
Multivariable logistic regression analyses with selection procedures was used to 
study possible independent RCM features that discriminate plaque with unstable 
psoriasis from stable psoriasis. Statistical analyses were performed using IBM 
statistical package for social sciences (SPSS) Statistics 20.0 for Windows (SPSS Inc., 
Chicago, IL).
Table 1  Scored RCM Features 
Feature Description Measurement
Thickness SC From the top of SC up till the top of 
the first cells with nuclei
Mean of two vertical stacks 
(µm)
Presence 
Parakeratosis
White nuclei with dark surrounding at 
level of SC  
Percentage parakeratosis at 
SC (Vivablock) (%)
Presence SG Islands of SG cells with strikingly 
bright cytoplasm surrounding a dark 
nucleus
SG (Vivablock)
(Partly present  or absent) 
Nr. of epidermal 
inflammatory cells
Round-oval shaped / round-polygonal 
refractive small cells  
Nr. inflammatory cells at SS 
(Vivablock)
(Nr. /cm2)
Nr. of Munro 
abscesses
Large, polyform, very bright cells 
aggregating at the level of the SC
Nr. abscesses at SC 
(Vivablock) 
(Nr. /cm2)
Nr. of Kogoj 
abscesses
Aggregation of bright cells surrounded 
by a dark acellular area at SS*
Nr. abscesses at SS 
(Vivablock)
(Nr. /cm2)
Thickness SPP Between top of SC and level of first 
distinct DP were visible 
Mean of two vertical stacks 
(µm)
Nr. of DP DP at DEJ Nr. of DP at DEJ (Vivablock)
(Nr. /cm2)
Edged DP Bright cellular ring surrounding DP 
at DEJ
Percentage of edged DP at 
DEJ (Vivablock) (%)
Diameter DP The inside diameter of DP Mean of 10% of total nr. of 
DP at DEJ (Vivablock) (µm)
Capillary flow Capillaries within DP at DEJ Mean of 5 video’s
( Low flow or high flow)
Section of capillaries Capillaries within DP at DEJ Mean of 5 video’s
(Tortuous or less-tortuous) 
Nr. dermal 
inflammatory cells
Within DP at DEJ Nr. of inflammatory cells 
(Vivablock) (Nr. /cm2)
DP: dermal papillae, Nr: number, SC: stratum corneum, SG: stratum granulosum, SS: stratum spinosum, 
SPP: suprapapillary plate.
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Results
 
Clinical examination
The SUM scores differed between the stable and unstable group (Table 2). The three 
dermatologists showed in 12 plaques a total agreement (46%) in scoring the plaques 
into stable or unstable. Furthermore, a total agreement between dermatologists and 
RCM, and between patients report and dermatologists was found in 9 plaques (35%) 
(Table 3, Figure 2). 
Table 2  SUM scores
Stable Unstable
Patient 1 2 3 4 5 6 1 2 3 4 5 6 7
SUM plaque 1 3 5 3 4 3 4 7 7 6 4 5 5 4
SUM plaque 2 3 5 4 4 5 5 7 7 6 5 4 5 4
Mean SUM 3 5 3.5 4 4 4.5 7 7 6 4.5 4.5 5 4
Total Mean SUM 4 5.43
SUM score: a plaque severity score based on a cumulative score for erythema, induration and scaling 
of the psoriatic plaque. Each of the three symptoms is classified by the scale 0, none; 1, mild (light red, 
slightly elevated, fine scaling); 2, moderate (red, moderate elevation, fine to rough scaling); 3, severe 
(dark red, marked elevation, rough thick scaling)and 4, very severe (very dark red, very marked 
elevation, very rough, very thick scaling). Scores vary between 0-12.
Table 3  Characterization of the plaque into stable or unstable 
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A Stable Unstable Unstable Unstable Stable 3 0 0
B Stable Stable Stable Stable Stable 3 3 3
C Stable Stable Stable Stable Stable 3 3 3
D Stable Unstable Unstable Stable Stable 2 1 1
E Stable Stable Stable Stable Stable 3 3 3
F Stable Stable Unstable Stable Stable 2 2 2
G Stable Unstable Unstable Stable Stable 2 1 1
H Stable Stable Stable Stable Stable 3 3 3
I Stable Stable Stable Stable Stable 3 3 3
J Stable Unstable Unstable Stable Stable 2 1 1
K Stable Stable Stable Stable Stable 3 3 3
L Stable Stable Unstable Stable Stable 2 2 2
M Unstable Unstable Unstable Unstable Unstable 3 3 3
N Unstable Unstable Unstable Unstable Unstable 3 3 3
O Unstable Stable Unstable Stable Unstable 2 1 1
P Unstable Stable Stable Stable Unstable 3 0 0
Q Unstable Stable Unstable Stable Unstable 2 1 1
R Unstable Unstable Stable Stable Unstable 2 1 1
S Unstable Unstable Unstable Unstable Unstable 3 3 3
T Unstable Unstable Stable Stable Unstable 2 1 1
U Unstable Stable Unstable Unstable Unstable 2 2 2
V Unstable Stable Stable Stable Unstable 3 0 0
W Unstable Stable Unstable Stable Unstable 2 1 1
X Unstable Unstable Stable Stable Unstable 2 1 1
Y*** Unstable Unstable Stable Stable Stable 2 2 1
 Z*** Unstable Unstable Stable Stable Stable 2 2 1
PR: patients report, MD: medical doctor, RCM: Reflectance Confocal Microscopy. *Figure 1 provides 
the clinical images, ** Figure 2 provides graph, *** Excluded from statistical analysis; the PR and RCM 
did not agree with respect to the characteristics of unstable
Figure 2  Clinical agreement. The percentage of agreement (0= no agreement, 1= one 
time agreement, 2= two times agreement, 3= total agreement) to categorize stable 
or unstable between the three MD’s (left panel), between the three MD’s and RCM 
(middle panel) and with the PR (right panel). Note that in 46% (12/26) all three MD’s 
mutually agreed (left panel), in 35% (9/26) the three observers were in total 
agreement with RCM (middle panel), and that in 35% (9/26) the three dermatologists 
were in total agreement with patients report.
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RCM imaging
Significant differences of RCM features were seen between stable- and unstable 
plaques (Table 4, Figure 3). The number of epidermal inflammatory cells and Munro 
– and Kogoj abscesses were significantly higher in unstable plaques compared to 
stable plaques (Mann-Whitney test; all p-value <0.01) (Figure 4). Moreover, the 
diameter of DP, capillary flow and tortuous section of the capillaries within DP, and 
the number of dermal inflammatory cells were also significantly higher in unstable 
plaques (Mann-Whitney test; p=0.03, Fisher exact test; p<0.01, p=0.04 and t-test; 
p<0.01, respectively). The  remaining  RCM features showed no significant difference 
between the groups (Table 4). 
 The number of inflammatory cells in the epidermis appeared to be the most 
significant predictive parameter for an unstable plaque (p=0.02), whereas the 
number of dermal inflammatory cells was a close alternative (p=0.03). Furthermore, 
we found that none of the other RCM features were independent predictors for 
unstable psoriasis next to either feature mentioned above (logistic regression 
analysis with selection procedures).
 Based on the duration of the unstable phase, two subgroups arose within the 
unstable group: the chronic progressive group (n=3, unstable since 5-8 months) and 
the acute exacerbated group (n=3, unstable since 1-3 months). Subgroup analyses 
showed more epidermal inflammatory cells in the acute exacerbated plaques 
(Mann-Whitney test; p=0.01). Furthermore, a higher number of Munro- and Kogoj 
abscesses (Mann-Whitney test; p<0.01 en p=0.05), less edged DP (Mann-Whitney 
test; p=0.05), and more dermal inflammatory cells (Mann-Whitney test; p=0.02) 
were seen (Table 4, Figure 3). 
 No significant differences between center and margin were seen in the stable or 
the unstable group, except for the number of edged DP in stable plaques. The paired 
analysis at plaque level showed a higher number of edged DP (median: 48 DP/cm2) 
at the margin in comparison to the center (median: 0 DP/cm2) (Wilcoxon signed rank 
test; p=0.01).
Table 4  RCM features of the stable- and unstable psoriasis plaques (including chronic 
progressive and acute exacerbated psoriasis plaques) 
RCM feature Stable plaques 
(n=12)
Unstable plaques 
(n=12)
p-value
Thickness SC (µm) 21 (15 – 69) 25 (16-69) 0.47
Presence Parakeratosis (%) 23 (4-40) 24 (2-42) 0.57
Presence SG 
  
Partly present
Absent
12
0 
(100%)
(0%)
10 
2 
(83%) 
(17%)
0.48
Epidermal inflammatory cells (Nr. /cm2) 97 (0-1172) 2152 (425-10985) <0.01
Munro’s (Nr. /cm2) 2 (0-8) 10 (2-55) <0.01
Kogoj’s (Nr. /cm2) 0 (0-16) 12 (3-135) <0.01
Height of the SPP (µm) 71 (51-156) 77 (59-124) 0.69
Nr. of DP (Nr. /cm2) 1812 (766-3031) 1996 (1406-2914) 0.29
Diameter DP (µm) 67 (59-79) 79 (59-147) 0.03
Edged DP (%) 24 (0-58) 0 (0-91) 0.99
Dermal inflammatory cells (Nr. /cm2) 660 (0-2925) 4713 (686-9594) <0.01
Capillary flow
  
Low 
High
8
4 
(67%) 
(33%)
0  
12 
(0%)
(100%)
<0.01
Section capillaries
  
Less tortuous
Tortuous
5
7
(42%) 
(58%)
0 
12
(0%) 
(100%)
0.04
Subgroups unstable plaques Chronic progressive 
(n=6)
Acute exacerbated 
(n=6)
Epidermal inflammatory cells (Nr. /cm2) 1076 (425-4010) 4458 (1336-10985) 0.01
Munro’s (Nr. /cm2) 6 (2-10) 16 (11-55) <0.01
Kogoj’s (Nr. /cm2) 9 (3-66) 64 (10-135) 0.05
Edged DP (%) 58 (0-91) 0 (0-13) 0.05
Dermal inflammatory cells (Nr. /cm2) 1021 (686-5812) 5782 (4146-9594) 0.02
SC: stratum corneum, SG: stratum granulosum, SSP: suprapapillary plate, DP: dermal papillae
Stable and unstable groups were provided by six patients, each providing two psoriatic plaques. 
Chronic progressive plaques were provided by three patients, each providing two psoriatic plaques 
(unstable since 5-8 months). Acute exacerbated plaques were provided by three patient, each 
providing two psoriatic plaques (unstable since 1-3 months). The results are displayed as median 
(range) or n(%).
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Discussion 
 
The present study showed that non-invasive differentiation between stable and unstable 
plaque psoriasis can be achieved with RCM. Unstable plaques revealed a significantly 
higher number of inflammatory cells within the (epi)dermis, including Munro and Kogoj 
microabscesses, a larger diameter of DP, a higher capillary flow with more tortuous 
capillaries. 
 SUM scores showed no substantial difference between the stable and unstable 
plaques. Furthermore, the clinical assessment by the experienced dermatologists showed 
moderate consensus. However, erythema and induration were difficult to assess, 
because of the assessment by photographs. 
 Comparison of the SC thickness by RCM was not possible, since the lack of the 
use of keratolytics in the unstable plaques.  The increased dermal vasculature within 
the psoriatic lesions corresponds with RCM literature, whereas dermal vasculature 
has been described as a predictor in the course of remissions and exacerbations and 
the severity of psoriasis.14 The subgroup analyses in the unstable psoriatic patients 
showed a higher number of (epi)dermal inflammatory cells (including Munro- and 
Kogoj abscesses) and edged DP in the acute exacerbated group, which can be clarified 
by the duration of the unstable phase in the acute exacerbated patients (<3 months) 
in comparison with the chronic progressive patients (5-8 months) Despite the small 
Figure 3  Psoriasis. A-C: Dermoscopic pictures by VivaCam®: stable (A), unstable (B: chronic 
progressive, C: acute exacerbated) plaque. D-F: RCM images at stratum spinosum: 
two bright round refractive small inflammatory cells (D), some inflammatory cells (E), 
many inflammatory cells, but individual cells are discernible and not yet merged 
together to form an abscess (F). G-J: RCM images at DEJ: non-edged dermal papillae 
(DP) with some round high refractive inflammatory cells (G), enlarged DP and increase 
number of inflammatory cells within the DP (H), enlarged DP and clearly an increased 
number of inflammatory cells within the DP (I). 
Figure 4  Abscesses within unstable plaque. A: Munro abscess: large, polyform, very 
bright cells aggregating at the level of the stratum corneum, on the left side 
parakeratosis (asterisk). B: Kogoj abscess: aggregation of bright cells surrounded by 
stratum spinosum. 
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sample size, the differences between these two groups were significant and can be 
useful in non-invasively examining the degree of activity within unstable psoriasis, 
which may have consequences for the therapeutic strategy. 
 No differences were found between center and margin in the stable group nor in 
the unstable group, except the higher number of edged DP at the margin in stable 
plaques. In stable plaque type psoriasis there is presumably a mechanism active 
keeping the lesion from expanding and therefore actively showing features of normal 
skin being edged DP, as edged DP are a feature of normal healthy skin.13  This is in 
contrast to non-edged DP in psoriasis , which seems to be the result of the inhibitory 
effect of TNF-alfa on melanogenesis.10, 15 The absence of a difference between center 
and margin is in contrast with the margin zone model that describes more activity at 
the margin than within the center of a plaque. Our RCM results confirms previous 
findings which showed no significant histopathological changes 16 (amongst others 
inflammation and proliferation)12 between center and margin. On the contrary, in the 
same study Mommers et al. supported the margin zone model, since they found a 
higher percentage of differentiated cells at the margin. 12 Moreover, Keijsers et al. 
found a trend towards a higher number of T-cell markers at the margin.17 Based on 
our RCM findings we can question the margin zone model as previously postulated, 
however a pitfall in the present study might be that the most active foci could have 
been missed by the clinical determination of the imaged foci. It would be reasonable 
to have an impression of the total psoriatic plaque, before imaging specific spots. 
 Because of the hypothesis that in lesional skin of unstable psoriasis are more 
hot spots, we studied the independent contribution of different RCM features to 
discriminate unstable psoriasis from stable psoriasis. Higher numbers of epidermal 
inflammatory cells was the most predictive feature for unstable plaques. Thus we 
may consider this feature to be a RCM measure for defining hot spots. Though, we 
have to realize that the number of inflammatory cells within a psoriatic plaque are in 
a cyclic pattern from dermis up to epidermis to finally form microabscesses.18 As 
showed in previous studies, distinction between T-lymphocytes and PMN’s is not 
possible yet.18-20  Future RCM technique development will hopefully lead to further 
differentiation between leukocytes. Furthermore, in future studies, it would be 
interesting to follow-up (hotspots within) psoriatic plaques with RCM after initiating 
(systemic) therapy. 
 This is the first study that examined the possibility to distinguish stable from 
unstable plaque psoriasis by RCM. A high number of epidermal inflammatory cells 
proved to be the most important predictive variable for unstable psoriasis. Therefore, 
areas with a high number of epidermal inflammatory cells can be considered as a 
RCM defined hot spot. Non-invasive assessment of the course of psoriatic plaques 
and valuable information for therapeutic strategies can be obtained by the use of 
RCM in clinical practice.
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Abstract
Background: Reflectance Confocal Microscopy (RCM) is gradually implemented in 
dermatology. Strategies for further implementation and practical ‘hands on’ guidelines 
are lacking.
Objective:  The primary outcome was to conduct a general strategy for further 
implementation of RCM. The secondary outcome was the diagnosis of psoriasis and 
differentiation of stable from unstable psoriatic plaques by means of the ‘hands on’ 
protocol, derived from the strategy.
Methods: We used a four phase model; an exploring phase, a systematic literature 
search, a clinical approach and, finally, an integration phase to develop a clinical 
guideline for RCM in psoriasis. Receiver operating characteristic curve statistics was 
applied to define the accuracy for the diagnosis of unstable psoriasis.
Results: A general strategy for further implementation of RCM and practical approach 
was developed to examine psoriasis by RCM and to distinguish stable from unstable 
psoriasis. Unstable psoriasis was diagnosed by epidermal inflammatory cell counts 
with a sensitivity and specificity of 91.7% and 98.3%, respectively and with an accuracy 
of 0.92 (area under the curve). Additionally, a monitoring model was proposed.
Conclusion: This is the first study that shows a method for implementation of RCM in 
dermatology. The strategy and hands on protocol for psoriasis may serve as a model 
for other dermatological entities and additionally may lead to specialized ready to 
use RCM protocols for clinical dermatological practice.
Introduction 
Dermatologists have been working on the implementation of Reflectance Confocal 
Microscopy (RCM) in dermatology since 1995.1 Within two decades, the non-invasive 
imaging device has become smaller, more flexible and patient friendly and therefore 
applicable in clinical practice.2 RCM has been used for diagnosis and therapy 
monitoring of different dermatological entities (e.g. melanomas, non-melanoma skin 
cancer and inflammatory skin diseases3-5), however the transition from research to 
clinical practice is still ongoing. Although significant progress has been made, a 
strategy for further implementation of RCM for different clinical diagnosis is lacking. 
Psoriasis is a chronic relapsing inflammatory skin disease.6 Although the diagnosis 
psoriasis often is made clinically, there can be difficult cases. Mainly in psoriasis 
expertise centers, patients do not present a clear history of the disease and visual 
clinical assessment can be difficult. Currently, to diagnose these difficult cases, histo-
pathological examination of a biopsy is the gold standard. For some years, non- 
invasive RCM is available for in vivo detection of psoriatic morphological characteristics 
such as parakeratosis, diminished or absent stratum granulosum (SG), (epi)dermal 
inflammatory cells, Munro- and Kogoj microabscesses, papillomatosis and increased 
vascularization. The correlation between histopathology and RCM imaging has been 
studied extensively in this inflammatory disease.7-10 In addition, some studies 
therapeutic follow up studies of psoriasis have been published.11-14
 As previous studies have shown, RCM can be used in research settings for 
selected investigative clinical studies in psoriatic patients.9, 10 In addition, it can serve 
as a clinical tool for dermatologists, especially in psoriasis expertise centers. It can 
provide non-invasive diagnostic and monitoring information of patients with a persistent 
psoriasis. Moreover, the correct diagnosis of psoriasis is important to prevent 
treatment delay and for applying adequate therapeutic strategies. In future, it may 
provide new insights in the pathophysiology of non-responders, because non-invasive 
information at cell morphological level and dynamic plaque changes can be 
monitored.9 Moreover, there is less patient discomfort compared to a biopsy.
 The implementation of RCM in clinical practice is, amongst others, influenced by 
the quality and number of RCM studies in literature, RCM training courses provided 
by RCM experts and meetings of the international confocal working group.15 From our 
experience with psoriasis, we developed a method for implementation of RCM in 
dermatology, focused on psoriasis. 
 Currently, available literature describing the transition of RCM from research 
tool to clinical device is limited. Many moderate methodological studies, such as case 
reports, have been describing RCM features, but not enhance further implementation. 
Therefore a strategy is needed and to the best of our knowledge no strategies has 
been published before. 
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The primary outcome of this study was to conduct a general strategy for further 
implementation of RCM. The secondary outcome was to diagnose psoriasis and 
differentiate stable and unstable psoriatic plaques by means of a protocol. General 
psoriatic features and information for differentiation between stable and unstable 
psoriatic lesions, which may influence therapeutic strategies, were gained. 
Furthermore, a follow up model was proposed. The final protocol itself provided 
practical instructions to guide confocalists to image psoriatic skin.
Methods
 
The development of a RCM protocol for chronic plaque psoriasis has been accomplished 
according to a four-phase model.
Phase 1: Basic RCM aspects of psoriasis
Within the first phase, basic aspects of RCM were studied and experience was gained 
about the cellular psoriatic RCM features in correlation to histopathology10. 
Thereafter, studies were performed to extend the knowledge and experience with 
RCM in chronic plaque psoriasis.9, 14 
 
Phase 2: Literature review of psoriatic skin imaged by RCM 
We systematically reviewed all RCM studies on psoriasis until February 2014.5 This 
resulted in 15 studies which revealed RCM features for diagnostic and monitoring 
purposes in psoriasis. An extended search until August 2015 showed five additional 
publications.16-20 After reviewing all publications, an overview of general psoriatic 
RCM features was provided for diagnostic and monitoring purposes (Table 1). Four 
therapeutic follow up studies monitored different therapeutics; phototherapy 
(ultraviolet-B (UVB) and psoraleen ultraviolet-A (PUVA)), topical non-steroidal an-
ti-inflammatory drugs (NSAID’s), topical corticosteroids, Methotrexate, Acitretin 
and/or Calcipotriol and Adalimumab by RCM.11-14 RCM features showed a good 
correlation with clinical improvement and improvement of Psoriasis Area Severity 
Index (PASI) scores.13 In addition, RCM was able to show subclinical psoriatic features 
(orthokeratosis with abnormal compact aspect14, high number of dermal papillae (DP), 
vascularization in DP13 and drastic reduction of inflammation12). In non responders to 
UVB large clustered tortuous capillaries were shown.14 Based on this literature11-14 
a therapeutic follow up scheme was proposed (Table 2). 
Table 1  General chronic plaque psoriatic features 
Skin 
layer
Psoriatic feature Description Measurement 
SC Hyperkeratosis Increased thickness of SC 
 ‘Thickened’ when >20 µm  
on the face or 40 µm on  
other location11
Mean of two vertical 
stacks (µm) measured 
from the top of SC up to 
the top of the first cells 
with nuclei (honeycomb)
Presence 
parakeratosis 
(Figure 1)
Highly refractile nucleus 
surrounded by dark cytoplasm, 
no individual cellular outlines 
distinguished at level of SC10
Parakeratosis present or 
absent (Vivablock at SC) 
Presence  Munro 
abscesses (Figure 1)
Focal, round-polygonal, very 
bright cell clusters in epidermis 
at SC9, 13
Presence or absence of  
abscesses (Vivablock at SC)
SG Diminished or  
absent SG
Flattened honeycomb pattern  
and smaller cell size. Relatively 
bright (compared to surrounding 
and overlying SC)10 
Partly present  or absent 
(Vivablock at SG)
SG-SS Presence of 
inflammatory 
epidermis (Figure 1)
Small, round-oval / round-
polygonal refractive cells13, 14 
Presence or absence 
of inflammatory cells 
(Vivablock at SS) 
SS Presence Kogoj 
abscesses (Figure 1)
Aggregations of bright cells 
surrounded by a dark a-cellular 
area at SS9
Presence or absence of  
abscesses (Vivablock  
at SS) 
SC-DEJ Thinning SPP Thickness between top of SC  
and level of first distinct DP13
Mean of two vertical 
stacks (µm) measured 
from the top of SC up to 
the first visible DP
DEJ Increased number  
of DP (Figure 2)
Increased number of round to 
oval areas at DEJ10
Nr. of DP (Vivablock at DEJ)
Presence of  
edged DP
Bright demarcating ring 
surrounding dark DP at DEJ10, 13, 14 
Presence or absence of 
edged DP (Vivablock at DEJ) 
Increased diameter 
DP (Figure 2)
The inside diameter of DP
DP ‘enlarged’: maximum diameter 
>80 µm, associated with dilated 
vessels filling the DP7
Mean of diameter  
(10% of total nr. DP) 
(Vivablock at DEJ) (µm)
Capillary flow Quick movement of prominent 
highly refractive round to oval 
inflammatory cells and medium 
refractive blood cells in a dark 
capillary lumen10 
Mean of flow in 2 video’s 
of the capillary flow  
within DP at DEJ.
Section capillaries Tortuous and dilated capillaries 
within DP at DEJ8, 21
Mean of 2 video’s of the 
section of the capillaries 
within the DP at DEJ
Dermis Presence dermal 
inflammatory cells 
(Figure 2)
Round- to polygonal mildly 
refractive cells around the dilated 
vessels in papillary dermis7
Measured within DP at DEJ
Presence or absence  
of inflammatory cells  
at papillary dermis 
(Vivablock at DEJ)
DEJ: dermo-epidermal junction, DP: dermal papillae, SC: stratum corneum, SG: stratum granulosum, 
SPP: suprapapillary plate, SS: stratum spinosum
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Phase 3: RCM in clinical practice: differentiation stable from  
unstable psoriasis
After literature research and gaining RCM experience, RCM was applied to 
differentiate stable from unstable plaque psoriasis.22 Distinction between those may 
have clinical consequences for therapeutic strategies. Based on patients report and 
clinical examination, six patients with two stable plaques (defined as non-growing 
plaques for at least one year) were included. Seven patients reported unstable 
psoriatic plaques (defined as new - or extending of pre-existing plaques within a few 
weeks) were also included. However, during physical examination, one of these 
patients appeared to have none of the typical clinical characteristics of unstable 
plaques (predominant erythema, limited scaling (by itching) and rapidly progressing 
lesions23). With initial RCM investigation also none of the expected features of an 
unstable plaque were found. Therefore, this patient was excluded prior to the 
analysis. Two different locations within the center and two locations at the inner 
margin of each plaque were imaged, according to the margin zone model. This model 
suggest more activity at the margin in comparison to the center of the lesion.24, 25 
Significant differences were seen between stable and unstable plaques. Unstable 
plaques showed a higher number of inflammatory cells within (epi)dermis , including 
Munro and Kogoj microabscesses (all p <0.01), a larger diameter of dermal papillae 
(p=0.03), a higher capillary flow (p<0.01) with more tortuous capillaries (p=0.04). 
Epidermal inflammatory cells were most predictive for unstable psoriatic plaques.22
Phase 4: Integration phase 
Integration of the previous three phases resulted in the development of a ‘hands on’ 
protocol for RCM in chronic plaque psoriasis for diagnostic clinical purposes. Practical 
aspects,  as well as literature based features are discussed. 
Reflectance Confocal Microscopy imaging
Prior to imaging, a dermoscopic picture of the lesion was captured by the VivaCam® 
(Lucid Inc, Rochester, New York, USA). Thereafter, the VivaScope 1500 (Lucid Inc, 
Rochester, New York, USA) was used to image the selected plaques. The RCM technique, 
which uses a near infrared laser to capture in vivo images of the skin with a resolution 
comparable to light microscopy, has been described before.26 
Statistical methods
Counts of epidermal inflammatory cells within stable and unstable psoriatic plaques 
were adapted from previous study. Statistical analysis included six patients with six 
stable plaques and six patients with six unstable plaques.22 In addition, a  receiver-op-
erating characteristic (ROC) curve was used to study the best threshold of the number 
of epidermal inflammatory cells to predict unstable psoriatic plaques with the highest 
accuracy. Statistical analysis was performed using IBM SPSS Statistics 20.0 for 
Windows (SPSS Inc., Chicago, IL).
Results
We developed a four phase strategy and practical protocol for the examination of 
chronic plaque psoriasis by RCM. The protocol is described in detail in the Supplement. 
The protocol consisted of six practical steps prior to RCM image analysis. The first 
two steps were the selection of the psoriatic lesion and the selection of the locations 
within the psoriatic lesion. Previous study showed no substantial difference between 
center and margin within a psoriatic plaque22 (according to the margin zone model25). 
Therefore this was not adapted to determine the location in the lesion within the 
Table 2  Therapeutic follow up scheme
Time point Features
Baseline at time of diagnosis General psoriatic features (Table 1)
At the end of 
treatment period 
depends on different 
therapies with different  
time course
Decreased thickness SC and total epidermis
Decreased parakeratosis
Decreased number of epidermal 
inflammatory cells (including decreased 
number of Munro and Kogoj abscesses)
Decreased thickness SPP 
Decreased diameter DP
Increased number edged DP
Decreased number of dermal inflammatory 
cells
Decreased capillary blood flow
At time of clinical 
clearance
depends on different 
therapies with different  
time course
Orthokeratosis with an abnormal compact 
aspect
Reduction parakeratosis
Acanthosis
Regular honeycomb SG and SS
Reduction (epi)dermal inflammatory cells
High number of rimmed DP
Low capillary blood flow, with less dilated 
vessels inside DP
DP continuous aspect
DP: dermal papillae, SC: stratum corneum, SG: stratum granulosum, SPP: suprapapillary plate,  
SS: stratum spinosum
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protocol. Thereafter, the metal ring with disposable plastic window was attached to 
the lesional skin and a dermoscopic picture (by VivaCam®) was captured to use as a 
navigation map during imaging. Subsequently, the RCM probe was attached parallel 
to the metal ring and the imaging protocol was applied. In analogy with the 
conventional histopathology of a biopsy, one representative lesion was imaged. 
Horizontal VivaBlocks (4mm x 4mm) from different skin layers, two vertical VivaStacks 
from the upper stratum corneum (SC) down to the dermis were captured and the 
capillary flow and leukocyte trafficking within the DP was captured by a movie. All these 
steps were performed within 10 minutes and provided information from an area of 
16mm2 (4mm x 4mm) within the psoriatic plaque. 
 With respect to the image analysis, the following combination of features in 
different skin layers were analyzed to confirm the RCM diagnosis psoriasis: hyper- 
keratosis, parakeratosis, diminished or absent SG, epidermal inflammatory cells, 
Munro and Kogoj abscesses, height of suprapapillary plate (SPP), papillomatosis, 
edged DP, high capillary flow with tortuous blood vessels and dermal inflammatory 
cells (Table 1, Figure 1,2). 
 Using the protocol wherein subsets of the various features were combined, the 
necessary information was obtained. Sometimes, a single VivaBlock and VivaStack 
provided enough information to diagnose psoriasis. In general, two locations within 
a lesion were imaged to increase the chance to find the specific psoriatic features. 
With adequate confocal experience, one lesion may provide sufficient information to 
obtain the diagnosis. In case of doubt, a second lesion should be imaged. Previous 
study showed the ability of RCM to differentiate stable from unstable psoriasis.22 The 
number of epidermal inflammatory cells was the best predictor for unstable psoriasis 
and was imaged easily, because these cells was located in the upper part of the skin. 
Unstable plaques were defined by patients report and clinical examination. The margin 
zone model was examined and the discriminating factor, inflammatory cells, was not 
related to center or margin.
Figure 1  Epidermis in psoriatic skin. A-D: Reflectance Confocal Microscopic (RCM) images. 
A: parakeratosis, B: Stratum corneum reveals Munro microabscess and parakeratosis 
(asterisk), C: Stratum spinosum shows Kogoj microabscesses, D: Stratum spinosum 
reveals several separate inflammatory cells (white arrows).
Figure 2  Dermis in psoriatic skin. A-B: Reflectance Confocal Microscopic (RCM) images. 
A: Papillomatosis; multiple enlarged dermal papillae with inflammatory cells and 
tortuous blood vessels. B. Detailed image of dermal papillae with inflammatory cells 
and tortuous blood vessels.
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 The ROC curve (Figure 3), based on these previous data22, showed with a 
threshold of 96 inflammatory cells at the level of the epidermis in one VivaBlock 
(16mm2) the highest sensitivity and specificity for detecting unstable psoriasis. For an 
efficient approach 10 images (500µm x 500µm) were used to count the number of 
inflammatory cells at the level of the stratum spinosum (SS). When more than 15 
inflammatory cells in 10 images of 500µm x 500µm were seen, unstable psoriasis 
was diagnosed with a sensitivity of 91.7%, a specificity of 98.3% and an accuracy of 
0.92 (area under the curve). 
Discussion
This is the first study that provides a strategy for further implementation of RCM in 
dermatology by developing a ‘hands on’ imaging protocol focused on chronic plaque 
psoriasis. Until now, clinical RCM imaging protocols were solely described in the method 
section of studies. Furthermore, the RCM handbook published in 2012 provided principles 
of RCM imaging.2 RCM can be implemented in the clinical workflow of psoriasis, initially 
in psoriasis expertise centers and at dermatology departments where RCM is already 
available. In psoriasis expertise centers more cases will be available which may be 
difficult to diagnose or which do not respond to standard treatment modalities. RCM 
may provide in vivo information non-invasively and thereby can gain new insights of 
the dynamics of the psoriatic plaque. By this, the best treatment strategy can be applied 
and treatment delay can be prevented.  As described within the current protocol, the 
Vivacam® was used to capture dermoscopic pictures which serve as a navigation map 
during imaging. In addition, the VivaCam® can be used as a dermoscopic device. 
Dermoscopy may be of additional value, because it shows the number of blood vessels 
within DP in psoriatic skin.27 A slight disadvantage of this approach is the fact that the 
image quality of the VivaCam® depends on the light settings and that the metal ring 
needs be attached separately to the skin for each area of interest. 
 As shown previously, there was a good correlation between the histopathologic 
hallmarks of psoriasis and the RCM features.7, 8, 10 Hyperkeratosis, parakeratosis, 
diminished or absent SG, epidermal inflammatory cells, Munro and Kogoj abscesses, 
height of SPP, papillomatosis, edged DP, high capillary flow with tortuous blood 
vessels and dermal inflammatory cells could be imaged quite easily when the imaging 
conditions are optimal. Difficulties arose in hyperkeratotic and hairy lesions and 
when patients were in an uncomfortable situated position, which caused movement 
artifacts. The distinction between stable and unstable plaques has primarily been 
assessed by the number of epidermal inflammatory cells. Until now, no other non- 
invasive techniques are able to determine this inflammatory infiltrate. Unfortunately, 
distinction between T-lymphocytes and polymorphonuclear cells (PMN) by RCM 
is not possible yet.9, 28, 29 We are aware of the laborious way to count inflammatory 
cells to distinguish between stable and unstable psoriasis. Future RCM technique 
development may lead to automatic counting of the inflammatory cells and further 
differentiation between leukocytes. Furthermore, we are aware of the limited 
numbers of patients and conclusions of the statistical analyses. Future studies with 
higher number of patients are needed for further validation of these results. 
 Reflecting on the primary outcome (conduct a general strategy for further 
implementation of RCM) and secondary outcome (by means of a protocol, to 
diagnose psoriasis and differentiate stable from unstable psoriatic plaques), some 
recommendations can be given and issues should be overweight. 
Figure 3  Receiver operating characteristic (ROC) curve for the diagnosis of unstable 
psoriatic plaques. ROC was performed for the number of epidermal inflammatory 
cells (n=12 plaques; n=6 patients with unstable psoriasis). Area under the curve (AUC) 
for unstable psoriasis by epidermal inflammatory cells is 0.92 with p<0.05.
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 First of all, confocal training is needed for the practical imaging and interpretation 
of the images. As with other new diagnostic techniques, it is known that RCM has a 
steep learning curve for adequate application and interpretation of the images. 
Plenary RCM courses, individual training courses at a RCM dermatological center and 
self study (e-learning) of RCM literature is recommended. Secondly, the protocol as 
described in this paper, has been applied in psoriatic patients in a tertiary psoriasis 
center, with severe (sometimes) therapy resistant psoriasis. This may interfere with 
the ease to obtain psoriatic RCM features. 
 Trained confocalists may obtain the in vivo diagnosis psoriasis within 10 minutes 
by applying the designed RCM protocol as described here. Moreover, the phase of 
the plaque can be differentiated within this short time frame. Applying RCM with a 
proper strategy will positively influence the learning curve of RCM and it will lead to 
a shorter time intensiveness of doing RCM imaging. In any case RCM remains an 
additional tool, supplementary to the clinical expertise view of the dermatologist.
 As with every new technology and corresponding guidelines, development and 
adaptations are necessary in time. A well established decision-tree-model for the 
differential diagnoses of psoriasis, like atopic dermatitis and mycoses fungoides, 
would be a very valuable additional supplement to this protocol. The additional value 
of RCM compared to clinical visual assessment is the ability to gain subclinical 
treatment effects.12 The proposed therapeutic follow up scheme, may serve as a 
general model for monitoring purposes in different therapies. A baseline measurement 
is required before any therapeutic effect can be measured. Adaptation of the scheme 
needs to be accomplished after specific therapeutic follow up studies and follow up 
after clinical clearance of psoriatic lesions. This may provide new insights in pathogenesis 
and different treatment responses. 
 Finishing therapy more early than in routine practice may be an interesting subject 
to examine by RCM. In addition, it would be interesting to study the effect on remission 
duration after prolonged use of therapeutics. This might even lead to a higher cost 
effectiveness. After conducting monitoring studies, the clinical relevance of RCM in 
psoriasis will become more clear. This may result in the transition from research device 
to clinical tool. Future studies are necessary to assess the cost effectiveness of RCM 30 
for conducting diagnosis or adjust the treatment strategy.  The cost factor is relative to 
the number of diseases in which RCM can be successfully applied, which means 
application of RCM in a broader spectrum of dermatological entities is desired. 
 This study is the first study that conducted a strategy and a ’hands on’ RCM 
protocol for further implementation of RCM in dermatology. This strategy may be 
serve as a general model for the development of RCM protocols for other 
dermatological entities. Development of strategies and ‘hands on’ RCM protocols 
facilitate transparency amongst confocalists and thereby more knowledge for further 
implementation of RCM in dermatology.
Supplement: User guide for the application of RCM  
in chronic plaque psoriasis
Step 1: Selection of the psoriatic lesion
1. When multiple psoriasis suspicious lesions are present within a patient, preferably 
select a lesion at a flat body site. Hyperkeratotic lesions and hairs need to be 
avoided. In addition, body sites with wide breath excursions may influence the 
image quality. Further, the patient needs to be positioned in a comfortable 
position during imaging. 
2. When the phase of the psoriatic lesion is of interest (stable or unstable), select the 
most extending lesion based on patient’s report and clinical examination (most 
erythematous part). 
3. When possible, apply keratolytics on the selected lesion(s) one week prior to 
imaging, this improves the penetration depth of the laser in hyperkeratotic 
plaques. 
4. Clean the entire lesion with a cotton and alcohol to remove remnant scales to ease 
further selection of the location within the lesion.
  
Step 2: Selection of the location within the psoriatic lesion
1. Select two different locations within the lesion (regardless center or margin)
 •   Avoid crusts and/or hyperkeratotic foci, this causes a limited penetration depth 
of the laser.
 •   Determine by clinical examination the most erythematous part of the lesion
 •   Determine the location with the highest number of dermal papillae by dermoscopy 
(dermatoscope or VivaCam®). This may represent an active part of the lesion 
(see figure).
Dermoscopic picture of stable (A) and unstable (B,C) psoriatic plaques. The red dots represent dilated 
tortuous blood vessels within the dermal papillae.
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2. When the phase of the lesion is of interest (stable or unstable), select the most 
extending part of the lesion based on patient’s report, clinical and dermoscopic 
examination.
Step 3: Attachment of the metal ring with plastic disposable window  
to the lesional skin
1. Decide in which direction the RCM probe needs to be positioned to image the 
lesion; the microscopic probe needs to be attached perpendicular to the skin. 
2. If possible, attach the ring in a horizontal position and attach the RCM probe 
perpendicular to the skin. It is possible to attach the ring in a vertical position with 
the microscopic probe perpendicular, however this might lead to more artifacts. 
3. The area of interest needs to be positioned in the center of the ring (check this by 
the dermoscopic picture made by the VivaCam® (Step 4). Each side of the lesion can be 
marked with a different skin marker. This may be helpful for the accurate correlation 
between the dermoscopic picture and the clinical appearance of the lesion.  
4. Remove the adhesive tape and apply a drop of water on the selected site within 
the selected lesion. Avoid airdrops under the plastic window, this causes artifacts. 
Step 4: Dermoscopic picture by VivaCam® 
1. The dermoscopic picture captured by VivaCam® appears at the right side of the 
computer screen and will function as a navigation map during imaging.
2. For the accurate correspondence between dermoscopic picture and the RCM images, 
make sure the direction mark of the VivaCam® correlates to the RCM probe. 
Step 5: Attachment of the RCM probe (VivaScope® 1500)  
to the metal ring
1. Add a drop of ultrasound gel to the plastic window within the metal ring.
2. Connect the RCM probe magnetically to the metal ring (a ‘click’ may be heard).
3. For the correct correspondence between dermoscopic picture and the RCM 
images, make sure the direction mark of the VivaCam® correlates to the RCM probe. 
Step 6: Imaging protocol chronic plaque psoriasis
1. Mark the reference (z-depth = 0) at the level of the stratum corneum.
2. Capture a VivaBlock (4mmx4mm) at the level of the
 a.  Stratum Corneum (SC)
 b.  Stratum Granulosum (SG) (if present) 
 c.  Stratum Spinosum (SS)
 d.  Dermoepidermal junction (DEJ)
 NB: Hyperkeratosis, acanthosis, parakeratosis will decrease the laser penetration 
depth. As a result the image quality of the dermis is impaired in psoriatic skin.
3. Capture two VivaStacks from the upper SC until the DEJ with steps of 5 µm. 
 a.  One VivaStack in the center of the attached window.
 b.  One Vivastack in an area of interest (based on a previously obtained VivaBlock).
4. Image the capillary flow and leukocytes trafficking within the dermal papillae (DP) 
in one location.
Information of 16mm2 (4mm x 4mm) area within the psoriatic plaque will be provided 
within 10 minutes. 
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Abstract
 
Background: The treatment response of methyl aminolevulinate photodynamic 
therapy (MAL-PDT) in superficial basal cell carcinoma (sBCC) depends, amongst others, 
on the accuracy of subtype determination by biopsy, since more aggressive subtypes 
not respond well to MAL-PDT.
Objective: The objective of this study is to determine whether a treatment failure 
(defined as partial or no response after PDT) or recurrence (presence of tumor tissue 
detected in follow-up after previous tumor clearance) is based on underdiagnosis of 
histological examination. 
Methods: Retrospective analysis of 257 patients with 503 histopathological confirmed 
sBCC treated with MAL-PDT. 
Results: The number of treatment failures underdiagnosed by primary biopsy was 
69.2%. The recurrences showed a mixed-type tumor in 48.6% comparing primary 
biopsy, repeated biopsy and excision specimen. 40.5% of recurrences missed the 
most aggressive part of the tumor by primary biopsy.
Conclusion: The treatment failures and recurrences showed a substantial percentage 
of mixed-type tumors and therefore underdiagnosis by primary biopsy. The number 
of treatment failures and recurrences after PDT may be decreased by more extensive 
histopathological examination (e.g. deeper step-sections) or by prior non-invasive 
diagnostics (e.g. reflectance confocal microscopy).
Keywords: PDT, sBCC, mixed-type tumors, treatment failure, recurrence, non-invasive
Introduction
Basal cell carcinoma (BCC) is the most common type of skin cancer in the Caucasian 
population.1 
 There are many histopathological classifications. Some major subtypes, based 
on their growth pattern, can be differentiated: superficial BCC (sBCC), nodular BCC (nBCC), 
micronodular BCC (mnBCC) and infiltrating BCC (iBCC).2 A combination of subtypes 
with different aggressiveness can form a mixed-type BCC.3 The choice of therapy is, 
amongst others, determined by histopathologic subtype.
 In the last decades a shift to the superficial histological subtype has been seen.4 
Photodynamic therapy (PDT) is one of the recommended non-invasive therapies 
according to international clinical guidelines for sBCC.5 The photodynamic reaction 
depends on the presence of sufficient quantities of photosensitizer, activating light 
and oxygen. Photosensitizers 5-Aminolevulinic acid  (ALA) or its methylated ester 
methyl-aminolevulinate (MAL) are endogenously converted by the heme biosynthetic 
pathway to protoporphyrin IX (PpIX). PpIX is concentrated in the tumor and 
illumination of the lesion results in reactive oxygen release and subsequent apoptosis 
and necrosis.5 The one-year treatment response of MAL-PDT for primary sBCC varies 
between 72.8-84.0%.6-8 The response rate of PDT depends on, amongst others, the 
correct diagnosed subtype BCC. More aggressive BCCs, such as iBCCs and mnBCCs, 
are undertreated with PDT. In case of undertreatment, a repeated biopsy and 
subsequent therapy is needed. Overall, this leads to more patient discomfort and 
higher costs. 
 Currently, histopathologic examination of a biopsy is the gold standard for the 
diagnosis of BCC and its subtype. Accuracy for BCC subtype by punch biopsy 
compared to the subsequent excision specimen in primary BCCs varies between 
60.9-80.7%9-11 and is 67.1% in recurrent BCCs.12 Most aggressive growth patterns of 
primary BCCs are diagnosed correctly by a punch biopsy in 84.4-89.0%.10, 11 However, 
43.0-74.0% of all primary BCCs consist of more than one histological subtype.3, 10 
Accuracy of a mixed-type BCC by punch biopsy is 37.0%.11 
 Many PDT studies focus on the response rate of PDT. However, there is a lack of 
studies that examine the number of mixed-type tumors within the non-responders. 
The objective of this study was to determine whether a treatment failure or 
recurrence was based on underdiagnosis of histological examination, so a more 
aggressive subtype than sBCC was missed on punch biopsy. This study reveals 
information on the composition of tumors not responding to MAL-PDT. Finally, it may 
provide insight in the current used diagnostics and the potential need for additional 
diagnostics. 
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Patients and design
Patients with a histopathological confirmed sBCC treated with MAL-PDT, in the period 
from January 2010 to January 2015, in the Dermatology Department of the Radboud 
University Medical Center (Radboudumc) were retrospectively analyzed. Exclusion 
criteria were: patients without a histopathological confirmed sBCC, patients with 
basal cell naevus syndrome (BCNS), patients with BAP1 (BRCA1-Associated Protein 1) 
mutation, transplant recipients, patient with other lesions than sBCC (nBCC, actinic 
keratosis (AK), Morbus Bowen) treated with PDT and patients with absence of 
follow-up after treatment.
 For all patients age, gender, total number of included sBCCs and the number of 
previous BCCs (at time of the first included sBCC) were recorded. For all included 
tumors the following data were assessed: location, size (lenticular and papular lesions 
were considered as <10mm, plaques as >10mm), primary or recurrent tumor type 
with eventual previous therapy and type of pretreatment. Both primary and recurrent 
BCCs were included as a representation of a daily clinical practice setting. In addition, 
histopathological diagnosis of primary biopsies, repeated biopsies, excision specimens 
and follow-up time (until 1-7-2015) were determined. 
MAL-PDT treatment
All included patients were treated according to regular PDT protocol.13 Before 
treatment, each tumor was pretreated with a hydrocolloid dressing (Duoderm®) or 
salicylic acid for one week. Based on clinical assessment, tumors were previously 
debulked or prepared with curettage.  Methylaminolaevulinate (Metvix® 160 mg/g, 
Galderma) 1 mm thick was applied on the tumor with a surrounding area of 10 mm of 
the healthy skin and covered with adhesive, occlusive dressing (Tegaderm®, 3 M 
Health Care Ltd, Bracknell, United Kingdom) for three hours. After three hours, the 
dressings were removed and cream cleaned-off with saline before illumination with a 
red light (630 nm, light dose 37 J/cm2) using the Aktilite CL 128 lamp (Q-Med-a 
Galderma division). One week after this first treatment, the procedure was repeated. 
The procedure was performed by a nurse specialized in PDT treatment. The first 
response was measured three months after PDT. Thereafter, the examinations were 
outlined according to insight of usual daily clinical practice.
Outcomes 
The outcome of this study was to determine whether a treatment failure or 
recurrence was based on underdiagnosis of histological examination. Treatment 
failure was defined as partial or no response after PDT. Recurrence was defined as 
the presence of tumor tissue detected in follow-up after previous tumor clearance. 
Follow-up time was calculated from date of treatment to date of treatment failure, 
recurrence or last follow-up. 
 Histopathological examination was done by certified pathologists at the 
Radboudumc. The determination of the BCC subtype was according to the Dutch 
guidelines of BCC.14 sBCCs were defined as nests of basaloid cells located in the 
superficial epidermis, often in a multifocal pattern.14 Treatment failures and recurrences 
that showed a sBCC and subsequently were excised, were re-examined by a specialized 
dermatopathologists to confirm the absence of a more aggressive component. 
 
Statistical analysis 
Patient and tumor characteristics were presented as mean and standard deviations 
or median and range in case of continuous variables, and as number and percentage 
in case of categorical variables. 
 Statistical analysis were performed using IBM SPSS Statistics 20.0 for Windows 
(SPSS Inc., Chicago, IL).
Results
Patient characteristics
We examined 397 patient charts and included 257 patients (126 males and 131 
females) with 503 sBCCs treated with MAL-PDT. The mean age was 61.4 years (SD 
±12.9). The majority of included patients had a history of BCCs and included one BCC 
in this study (Table 1). 
Tumor characteristics 
The majority of sBCCs were located on the trunk (60.2%). More than 50% of the 
tumors was smaller than 10mm. Most included BCCs were primary BCCs (96.2%). The 
recurrent BCCs were previously treated with either cryotherapy (n=6), PDT (n=3) or 
imiquimod (n=9) and one tumor was previously excised. The majority of the lesions 
(85.5%) was pretreated by hydrocolloid dressing, the remaining lesions by salicylic 
acid (Table 1).
Follow-up
Follow-up was available for all included tumors. The median follow-up time was 2 years 
(range 40 days-5 years).  
Treatment failures
Treatment failures were mainly diagnosed at the first clinical assessment after PDT. 
The median time for the first clinical assessment after PDT was 92 days (range 27-281 
days). During this first assessment, 50 lesions (9.9%) were clinically suspicious for a 
treatment failure. 19 (3.8%) suspicious lesions were biopsied, resulting in confirmation 
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of 15 treatment failures and four lesions with scar tissue. The remaining 31 clinical 
suspected lesions were followed up over time. 15 Lesions showed clearance over 
time and six lesions were repeatedly biopsied and showed scar tissue (n=1), nBCC 
(n=1) and sBCC (n=3). After next clinical examination seven lesions were directly 
excised, two were directly treated by cryotherapy, one lesion was directly treated by 
PDT, and two were directly treated with imiquimod. 
 Finally, after all clinical examinations and repeated biopsies, 6.0% showed a 
clinical treatment failure and 5.4% was histopathologically confirmed (Table 2). The 
median time till treatment failure was 127 days (55-281). Additional therapy of the 
treatment failures is shown in Table 2. 
 Histological examination of the primary biopsy, repeated biopsy and excision 
specimen resulted in the overall diagnosis of four sBCCs  (30.8%) and nine mixed-type 
BCCs  (69.2%) (Table 3, Supplement 1). In 69.2% of the treatment failures the primary 
biopsies missed the most aggressive component of the BCC (Table 3). Two treatment 
failures were recurrent BCCs at time of inclusion. One lesion was previously treated 
by cryotherapy, another by PDT.
Table 1  Baseline Characteristics
 
n (%) / mean ±SD
Patient characteristics 257 (100)
Gender 
   Male      
   Female  
126
131 
(49.0)
(51.0)
Age (years) 61.4 ±12.9
Number of previous BCC 
   0 
   1-5 
   5-10
   >10
83
100
24
50
(32.3)
(38.9)
(9.3)
(19.5)
Number of BCC 
1
2
3
4
5
6
7
8
9
10
153
45
25
12
10
3
5
3
0
1
(59.5)
(17.5)
(9.7)
(4.7)
(3.9)
(1.2)
(1.9)
(1.2)
(0.0)
(0.4)
Tumor characteristics 503 (100)
Location 
   Head
   Neck
   Upper extremities
   Trunk
   Lower extremities
25 
10 
71
303
94
(5.0)
(2.0)
(14.1)
(60.2)
(18.7)
Size 
   <10 mm
   >10mm
285
218
(56.7)
(43.3)
Primary or recurrence
   Primary 
   Recurrence
484
19
(96.2)
(3.8)
Previous treatment 
   Cryotherapy
   PDT
   Imiquimod
   Excision
6 
3 
9 
1 
(31.6)
(15.8)
(47.4)
(5.3)
Pretreatment 
Hydrocolloid dressing*    
Salicylic acid 
430
73
 (85.5)
(14.5)
sBCC: Superficial basal cell carcinoma, PDT: Photodynamic therapy
*2 lesions were debulked and 14 lesions were treated with curettage prior to hydrocolloïd dressing
Table 2  Treatment failures and recurrences
N
Treatment fail-
ures n (%)
 
N
Recurrences
n  (%)
Clinical treatment failures / recurrences  503 30 (6.0) 503 46 (9.2)
Confirmed by histopathology 503 27 (5.4) 503 45 (9.0)
Confirmed by histopathology
   Biopsy   
   No biopsy1 
   Excision
   No excision 
   Biopsy and excision4
27
20
7
20
7
13
(74.1)
(25.9)
(74.1)
(25.9)2
(48.2)
45
45
0
37
8
37
(100)
(0)
(82.2) 
(17.8)3
(82.2)
Additional treatment 
   Cryotherapy
   Imiquimod
   PDT
   Radical biopsy
   Excision
30
2
2
5
1
20
(6.7)
(6.7)
(16.7)
(3.3)
(66.7)
46
0
3
5
1 
37
(0.0)
(6.5)
(10.9)
(2.2)
(80.4)
1n=7 lesions were directly excised, 2n=7 lesions were directly treated (n=1 cryotherapy, n=5 PDT, n=1 
radical biopsy), 3n=8 lesions were directly treated (n=2 imiquimod, n=5 PDT, n=1 radical biopsy), 
4Supplement 1, PDT: photodynamic therapy
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Recurrences
9.1% showed a clinical recurrence; subsequently 9.0% was confirmed by histo-
pathology (Table 2).  The median time till recurrence was 436 days (151-1542 days). 
Subsequent therapy for the recurrences is shown in Table 2. 
 Histological examination resulted in the overall diagnosis of 19 sBCCs (51.4%) 
and 18 mixed-type tumors (48.6%) (Table 4, Supplement 1). When comparing the 
primary biopsies to the overall diagnosis of recurrences 40.5% missed the most 
aggressive part of the tumor (Table 4). Two recurrences were already recurrent BCCs 
at inclusion. One lesion was previously treated by PDT , and one by imiquimod. 
Table 3  Treatment failures
n=13 Repeated biopsy n (%)
Primary biopsy sBCC nBCC s/nBCC Total
sBCC 10 (76.9) 1 (7.7) 2 (15.4) 13 (100)
Most aggressive subtype 
missed 3 (23.1)
n=13 Excision specimen n (%)
Primary biopsy sBCC nBCC s/nBCC s/iBCC Total
sBCC 5 (38.5) 1 (7.7) 6 (46.2) 1 (7.7) 13 (100)
Most aggressive subtype 
missed 8 (61.6)
n=13 Excision specimen n (%)
Second biopsy sBCC nBCC s/nBCC s/iBCC Total
sBCC 4 (30.8) 1 (7.7) 4 (30.8) 1 (7.7) 10 (76.9)
nBCC 1 (7.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (7.7)
s/nBCC 0 (0.0) 0 (0.0) 2 (15.4) 0 (0.0) 2 (15.4)
Total 5 (38.5) 1 (7.7) 6 (46.2) 1 (7.7) 13 (100)
Most aggressive subtype 
missed 6 (46.2)
n=13 Overall diagnosis* n (%)
Primary biopsy sBCC s/nBCC s/iBCC Total
sBCC 4 (30.8) 8 (61.6) 1 (7.7) 13 (100)
Most aggressive subtype 
missed 9 (69.2)
*Overall diagnosis based on primary biopsy, repeated biopsy and excision specimen
sBCC: superficial basal cell carcinoma, s/nBCC: superficial/nodular basal cell carcinoma, s/iBCC: superficial/ 
infiltrative basal cell carcinoma
Table 4  Recurrences
n=37 Repeated biopsy n (%)
Primary biopsy sBCC nBCC s/nBCC mn/iBCC AK Total
sBCC 34 (75.6) 7 (15.6) 2 (4.4) 1 (2.2) 1 (2.2) 37 (100)
Most aggressive 
subtype missed 10 (22.2)
n=37 Excision specimen n (%)
Primary biopsy sBCC nBCC s/nBCC s/iBCC AK Total
sBCC 24 (64.9) 2 (5.4) 5 (13.5) 2 (5.4) 4 (10.8) 37 (100)
Most aggressive 
subtype missed 9 (24.3)
n=37 Excision specimen n (%)
Second biopsy sBCC nBCC s/nBCC s/iBCC AK Total
sBCC 19 (51.4) 1 (2.7) 1(2.7) 2 (5.4) 3 (8.1) 26 (70.3)
nBCC 4 (10.8) 0 (0.0) 2 (5.4) 0 (0.0) 1(2.7) 7 (18.9)
s/nBCC 0 (0.0) 1(2.7) 1(2.7) 0 (0.0) 0 (0.0) 2  (5.4)
mn/iBCC 1(2.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.7)
AK 0 (0.0) 0 (0.0) 1(2.7) 0 (0.0) 0 (0.0) 1 (2.7)
Total 24 (64.7) 2 (5.4) 5 (13.5) 2 (5.4) 4 (10.8) 37 (100)
Most aggressive 
subtype missed 5 (13.5)
n=37 Overall diagnosis* n (%)
Primary biopsy sBCC s/nBCC s/iBCC s/mn/
iBCC
s/nBC-
C+AK
sBCC+AK Total
sBCC 19 
(51.4)
10 
(27.0)
2 (5.4) 1 (2.7) 2 (5.4) 3 (8.1) 37 (100)
Most aggressive 
subtype missed 15 (40.5)
*Overall diagnosis based on initial biopsy, additional biopsy and excision specimen
sBCC: superficial basal cell carcinoma, s/nBCC: superficial/nodular basal cell carcinoma, s/iBCC: superficial/ 
infiltrative basal cell carcinoma, s/mn/iBCC: superficial/micronodular/infiltrative basal cell carcinoma, 
AK: actinic keratosis
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Discussion
The number of treatment failures underdiagnosed by primary biopsy was 69.2%. 
In these tumors a more aggressive subtype than sBCC was shown that was missed on 
punch biopsy. The recurrences showed a mixed-type tumor in 48.6%. The number of 
mixed-type BCCs might be underestimated in this study, because not all treatment 
failures and recurrences were excised. In addition, only lesions with both an repeated 
biopsy and subsequent excision specimen were included in the analysis. BCCs that 
did respond well to PDT might also have been mixed tumors. However, these tumors 
were not histopathologically examined after treatment success. Fiechter et al. 
showed that 62.5% of the recurrent facial BCCs after PDT revealed a relapse by a 
more aggressive histological pattern.15 In contrast to Fiechter et al., we used the 
definitions treatment failure and recurrence as two separate entities.  A recurrent 
BCC may be transformed to a more aggressive subtype, compared to the original 
biopsy diagnosis.16 Therefore, it can be questioned if a more aggressive subtype 
already was present at time of primary biopsy or the growth pattern was changed in 
time. Therefore we believe that the analyzed treatment failures indicate the most 
robust numbers of underdiagnosis.
 Though, there were no significant differences seen in patient and tumor charac-
teristics between the patients that showed a clinical treatment failure or that showed 
a clinical recurrence (Supplement 2).  Another difference in comparison to Fiechter et 
al. was the inclusion of facial sBCCs and nBCCs. It has been known that lesions located 
in the face, and the deeper component of nBCCs, may respond less to PDT. Other 
studies concerning the discordance between the primary biopsy and subsequent 
excision specimen in primary BCCs without PDT treatment showed a discordance of 
27.7-31.0% 11, 17and 32.9% in recurrent BCCs.12
 Our results showed that in 69.2% of the primary biopsies in the treatment 
failures and 40.5% in the recurrences missed most aggressive component of the 
tumor. The highest discrepancy of two separate histology specimens in the treatment 
failures and recurrences was seen between the primary biopsy and the subsequent 
excision specimen, respectively 61.6% and 24.3%. AKs in the recurrences were 
interpreted as repeated diagnosis instead of underdiagnosis. Fiechter et al. revealed 
that in 50% of the tumors the histological aggressive part was missed by biopsy 
alone. In other studies concerning the correlation between primary biopsies and 
subsequent excision specimens without PDT therapy showed that in 11% of the 
primary and 19% of the recurrent BCCs the most aggressive component of the BCC 
was missed by the primary biopsy.11, 12 The difference can be explained by the 
inclusion of solely low aggressive sBCCs in our cohort. 
 Limitations of this study were the retrospective study design in a single center, 
unavailable excision specimens for all treatment failures and recurrences and the 
 histopathological diagnosis may be influenced by the variation in different patho -
logists. These were consequences of the clinical practice situation.
 The increasing incidence of BCC will require new diagnosing and therapeutic 
management strategies. Increasing the likelihood of correct subtyping BCC will 
improve treatment decision-making. As a consequence of the previous results, the 
reliability of the primary biopsy is questionable. Moreover the general believe of PDT 
response may be underestimated by the underdiagnosis of treated BCCs. In future 
studies it is valuable to examine primary biopsies, repeated biopsies and subsequent 
excision specimens after failure or recurrence in all available non-invasive therapies 
for sBCC. A more extensive histopathological examination, with deeper step-sections 
of a biopsy in case of diagnosis of sBCC, could confirm the absence of a more aggressive 
component. Further, non-invasive techniques, such as reflectance confocal microscopy 
(RCM), might be helpful for the diagnosis of sBCCs prior to non-invasive treatment. 
RCM studies already showed the ability of RCM to distinguish different BCC 
subtypes.18, 19 Further, Venturini et al. showed the capability of RCM to detect subclinical 
BCC recurrences.20 In future, non-invasive techniques may be used additionally to 
biopsies for an accurate tumor diagnosis prior to PDT. This might lead to higher 
cost-effectiveness, because repeated biopsies and subsequent treatment may be 
prevented.
 In conclusion, these results revealed underdiagnosis of BCCs in treatment failures 
and recurrences by the current histopathologic approach. The number of treatment 
failures and recurrences after PDT may be decreased by more extensive histopatho-
logical examination (e.g. deeper step-sections) or by prior non-invasive diagnostics. 
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Supplement 1  
Primary 
biopsy
Repeated 
biopsy
Excision 
specimen
Overall 
diagnosis* 
Treatment failure (n=13) sBCC nBCC sBCC s/nBCC
sBCC sBCC nBCC s/nBCC
sBCC sBCC s/iBCC s/iBCC
sBCC sBCC s/nBCC s/nBCC
sBCC sBCC s/nBCC s/nBCC
sBCC sBCC s/nBCC s/nBCC
sBCC sBCC sBCC sBCC
sBCC s/nBCC s/nBCC s/nBCC
sBCC sBCC s/nBCC s/nBCC
sBCC s/nBCC s/nBCC s/nBCC
sBCC sBCC sBCC sBCC
sBCC sBCC sBCC sBCC
sBCC sBCC sBCC sBCC
Recurrences (n=37) sBCC sBCC AK sBCC+AK
sBCC nBCC sBCC s/nBCC
sBCC sBCC sBCC sBCC
sBCC sBCC sBCC sBCC
sBCC sBCC sBCC sBCC
sBCC nBCC sBCC s/nBCC
sBCC nBCC sBCC s/nBCC
sBCC sBCC sBCC sBCC
sBCC nBCC sBCC s/nBCC
sBCC nBCC s/nBCC s/nBCC
sBCC sBCC sBCC sBCC
sBCC sBCC AK sBCC+AK
sBCC sBCC sBCC sBCC
sBCC nBCC AK s/nBCC+AK
sBCC sBCC sBCC sBCC
sBCC sBCC nBCC s/nBCC
sBCC sBCC sBCC sBCC
sBCC sBCC sBCC sBCC
sBCC sBCC sBCC sBCC
Supplement 1  Continued
Primary 
biopsy
Repeated 
biopsy
Excision 
specimen
Overall 
diagnosis* 
Recurrences (n=37) sBCC mn/iBCC sBCC s/mn/iBCC
sBCC sBCC s/nBCC s/nBCC
sBCC sBCC s/iBCC s/iBCC
sBCC sBCC sBCC sBCC
sBCC sBCC AK sBCC+AK
sBCC sBCC sBCC sBCC
sBCC sBCC sBCC sBCC
sBCC sBCC sBCC sBCC
sBCC AK s/nBCC s/nBCC+AK
sBCC sBCC s/iBCC s/iBCC
sBCC sBCC sBCC sBCC
sBCC sBCC sBCC sBCC
sBCC nBCC s/nBCC s/nBCC
sBCC sBCC sBCC sBCC
sBCC s/nBCC s/nBCC s/nBCC
sBCC sBCC sBCC sBCC
sBCC s/nBCC nBCC s/nBCC
sBCC sBCC sBCC sBCC
*Based on primary biopsy, repeated biopsy and excision specimen
sBCC: superficial basal cell carcinoma, s/nBCC: superficial/nodular basal cell carcinoma, s/iBCC: superficial/ 
infiltrative basal cell carcinoma, s/mn/iBCC: superficial/micronodular/infiltrative basal cell carcinoma, 
AK: actinic keratosis
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Supplement 2
N
30
Treatment failures 
n (%) / median [range]
N
46
Recurrences 
n (%) / median 
[range]
p-value
Gender 
   Male      
   Female  
17
13
(56.7)
(43.3)
25 
21
(54.3)
(45.7) 0.84
Age (years) 56 [31-81] 53 [34-79] 0.58 
Location 
   Head
   Neck
   Upper extremities
   Trunk
   Lower extremities
1
0
3
19
7
(3.3)
(0)
(10)
(63.3)
(23.3)
1
1
6
30
8
(2.2)
(2.2)
(13.3)
(65.0)
(17.4) 0.94
Size 
   <10 mm
   >10mm
10
20
(33.3)
(66.7)
22
24
(47.8)
(52.2) 0.21
Primary or recurrence
   Primary 
   Recurrence
28
2
(93.3)
(6.7)
44
2
(95.7)
(4.3) 0.66
Previous treatment*
   Yes
   No
2
28
(6.7)
(93.3)
2
44
(4.3)
(95.7) 0.66
Pretreatment 
   Hydrocolloid dressing 
   Salicylic acid
23
7
(76.7)
(23.3)
39
7
(84.8)
(15.2) 0.37
Number of included 
sBCCs per patient 
2 [1-8] 2 [1-7] 0.66
Number of previous BCC
   0 
   1-5 
   5-10
   >10
9
13
0
8
(30)
(43.3)
(0)
(26.7)
14
18
2
12
(30.4)
(39.1)
(4.3)
(26.1) 0.86
*One of the treatment failure lesions was previously  treated with cryotherapy and one lesion with 
PDT. One of the recurrences was previously treated with cryotherapy and one lesion with PDT.
p-values were calculated by Chi2 test, if 1 cell have expected count less than 5, than Fisher’s exact test 
was used. For numeric variables the Mann-Whitney test was used.
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Abstract 
Background: Clinical differentiation between a nodular basal cell carcinoma (nBCC) 
and a benign intradermal nevus can be difficult. Even with additional dermoscopic 
evaluation, a correct diagnosis may be difficult. Currently, histopathological examination 
of a biopsy is the gold standard to differentiate between these lesions. However, 
this is an invasive technique and sampling errors can occur. In vivo Reflectance 
Confocal Microscopy (RCM) is a non-invasive technique to evaluate a skin lesion at a 
microscopic level. RCM features of nodular basal cell carcinomas and intradermal nevi 
have been described in research setting. However, the use of RCM for prospective 
differentiation between difficult to diagnose nodules into nBCCs and intradermal 
nevi in clinical practice has not been demonstrated yet.
Objective: In this study we aim to address a common clinical scenario; to differentiate 
clinically and dermoscopically difficult to distinguish nodules, into nBCCs and intradermal 
nevi by RCM.
Material and Methods: 6 patients with clinically and dermoscopically difficult to 
distinguish nodular skin lesions were evaluated by RCM in order to differentiate 
prospectively between nBCCs and intradermal nevi. In 5 out of 6 cases, a 3mm punch 
biopsy was obtained to confirm the RCM diagnosis.
Results: Observed RCM features that allowed differentiation between nBCC and 
intradermal nevi were the DEJ patterns, the appearance of the nests and the degree 
of vascularisation.
Conclusions: This case series study demonstrates the value of non-invasive in vivo 
RCM in routine patient care, with respect to the prospective diagnosis of clinically 
difficult to distinguish nBCCs and intradermal nevi. Subsequently, biopsies of benign 
lesions in cosmetic areas could be avoided.
Introduction
Clinically, it can be challenging to distinguish between nodular basal cell carcinomas 
(nBCCs) and intradermal nevi.1 A nBCC appears as a shiny, pearly, sometimes erythematous 
nodule with telangiectasias. These clinical features can mimic intradermal nevi. 
Correct differentiation between these two kinds of lesions is necessary, because they 
require a different treatment approach.2 In case of a nBCC, a biopsy and excision of the 
lesion is required, while these procedures are unnecessary in benign intradermal 
nevi. Dermoscopy is an additional tool, which may help to differentiate between 
these equivocal nodular lesions. Besides the well-known specific features for BCCs and 
intradermal nevi, they may share some dermoscopic characteristics.2, 3 In addition, in 
many nodular lesions no specific dermoscopic features may be seen4, often because 
of the elevated shape of these lesions. This clinical and dermoscopic limitations may 
often result in obtaining a biopsy to determine the correct diagnosis.
 In vivo Reflectance Confocal Microscopy (RCM) is a useful non-invasive technique 
to evaluate a lesion at a microscopic level in a horizontal plane, without obtaining a 
biopsy.5 RCM features and terminology for nodular lesions like BCCs and nevi have 
been described.6-10 However, the use of RCM for prospective differentiation between 
difficult to diagnose nodules into nBCCs and intradermal nevi in clinical practice has 
not been demonstrated yet. Therefore, in this study we aim to address a common 
clinical scenario; to differentiate between clinically and dermoscopically difficult to 
distinguish nBCCs and intradermal nevi, with the additional use of non-invasive RCM. 
Material and methods
Patients 
Six patients with nodular lesions, clinically and dermoscopically suspect for nBCC and 
intradermal nevi were included. They were referred from the outpatient Department 
of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands. 
The lesions were located in the face or at the chest of the patients. 
Images
Prior to RCM imaging, clinical pictures of the lesions were taken with a digital camera 
(Nikon D 200, Nikon,Tokyo, Japan) and dermoscopic pictures were obtained with a 
Vivacam Macro Camera (Lucid Inc., Rochester, N.Y., USA) (Figure 1).
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RCM evaluation
The commercially available VivaScope 1500 system (Lucid Inc., Rochester, N.Y., 
USA)  was used to obtain the RCM images. The RCM system has been extensively 
described elsewhere.5 The imaging was performed according to a standardized 
protocol. All different levels of the skin (stratum corneum, stratum granulosum, 
stratum spinosum, dermal-epidermal junction and papillary dermis) were imaged 
by a horizontal mapping of 4mm x 4mm (Vivablock). When indicated, Vivastacks 
(vertical mapping with steps of 4,5µm) were made from the stratum corneum until the 
papillary dermis. At the dermal-epidermal junction (DEJ) and dermis, vascularisation 
was captured in several movies. Two RCM users evaluated the lesions and made an 
in vivo diagnosis based on the obtained confocal features.
Histopathological evaluation
After the RCM evaluation, a 3-mm biopsy (under local anesthesia of 1% xylocaine/
adrenaline) was obtained in 5 out of 6 lesions and evaluated by a dermatopathologist. 
The skin samples were processed by a standard protocol.11 Eventually the sections 
were hematoxylin-eosin (HE) stained for assessment of histopathological character-
istics. The RCM diagnoses were compared to the histopathological diagnosis of the 
dermatopathologist.
Results
Case 1. A 61-year-old woman, frequently sun exposed, was referred to our outpatient 
clinic. During the last two years a slow growing lesion on the right nasolabial fold had 
developed. Clinically, a well-demarcated, lenticular, pinkish nodule with telangiectasia 
was seen (Fig. 1a). Dermoscopy revealed telangiectasia (Fig. 1b). Based on clinical and 
dermoscopic examination, it was not possible to differentiate between a nBCC or 
intradermal nevus. RCM imaging showed architectural disarray of the epidermis and 
a nonspecific architecture of the DEJ. Round to oval nests of basaloid cells, varying 
in size, were observed at the dermal level (Table 1). Within these nests, peripheral 
palisading and branch-like structures were present. The nests were surrounded by a 
cleft, fibrosis and blood vessels with enlarged diameter. These RCM findings suggested 
a nBCC with micronodular component (Fig. 2a). Histopathology demonstrated large 
nests of basaloid cells with peripheral palisading and surrounding cleft, corresponding 
to a nBCC. Re-evaluation of the biopsy specimen revealed also small basaloid nests, 
as observed with RCM, indicating a mixed type BCC with a nodular and micronodular 
component (Fig. 2b). The lesion was surgically excised.
Case 2 A 48-year-old woman known with nevoid basal cell carcinoma syndrome 
(NBCCS), also known as Gorlin-Goltz syndrome12, visited our department. During 
this visit, multiple lesions suspicious for nBCCs or intradermal nevi were found. 
We only describe a prominent lesion on the left nasolabial fold, which appeared 
as a skin-coloured nodule with telangiectasias (Fig. 1c). Dermoscopy showed small 
telangiectasia, but could not discriminate between an intradermal nevus or nBCC (Fig. 
1d). RCM imaging of the epidermis revealed mild keratinocyte atypia and spongiosis 
(Table 1). At dermal level, one large round nest of tightly packed basaloid cells was 
observed (Fig. 2c). Within this nest, enlarged blood vessels were seen in real time. 
Further, dermal solar elastosis and fibrosis were noted. The large nest visualized 
by RCM corresponded to the large nest of basaloid cells with peripheral palisading 
seen in conventional histopathology (Fig. 2d). Based on these findings, the lesion was 
diagnosed as a nBCC and was surgically excised. 
Figure 1  Clinical and dermoscopic images (VivaCam®) of the evaluated lesions. Case 1: 
a) Clinical image of the well-demarcated, lenticular, pinkish nodule with  telangiectasia, 
on the right nasolabial fold. b) Dermoscopic image revealing telangiectasia. Case 2: 
c) A skin-coloured nodule with telangiectasias in the left nasolabial fold. d) Small 
telangiectasia were seen with dermoscopy. Case 3: e) A periocular located erythematous, 
partly pigmented nodule with telangiectasia. f) Corresponding dermoscopic picture 
showing  telangiectasia and dark brown dots. Case 4: g) Clinical image of the perioral 
located lesion, showing a pearly erythematous nodular lesion with telangiectasia. 
h). Dermoscopic image exhibiting cobblestone globules. Case 5: i) A shiny, pearly nodule 
with telangiectasia located on the chest. j) Dermoscopy revealed telangiectasia. Case 6: 
k) A skin colored perioral located nodule. l) Dermoscopic image showing sparse 
telangiectasia.
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Case 3. A 47-year-old man without a history of non-melanoma skin cancer (NMSC), 
had an erythematous, partly pigmented, nodule with telangiectasias (Fig. 1e). The 
lesion was located in the periocular region for at least 20 years. However, the 
patient noticed some change in appearance during the last year, the lesion had 
grown slowly and bled sometimes. On dermoscopy this lesion showed brown dots 
and telangiectasia (Fig. 1f).  RCM imaging was performed in order to non-invasively 
evaluate the lesion. The epidermis was characterized by mild keratinocyte atypia and 
spongiosis. Further, the DEJ revealed a nonspecific pattern. Large and small nests 
of basaloid cells appeared as a bunch of grapes and were found in the upper and 
deeper dermis (Fig. 2e, Table 1). Peripheral palisading and branch-like structures were 
present within these nests, and the nests were surrounded by a cleft, fibrosis and 
blood vessels with an increased diameter (Fig. 2e). These RCM findings were in favor 
of a mixed type BCC with nodular and micronodular component. This diagnosis was 
confirmed by conventional histopathology (Fig. 2f). The lesion was surgically excised. 
Case 4. An 80-year-old woman visited our department after treatment of a previous 
nBCC. During this follow-up visit, a pearly erythematous nodular lesion with 
telangiectasia was seen in the right perioral region (Fig. 1g). Dermoscopy revealed 
cobblestone globules (Fig. 1h). RCM imaging of the epidermis showed a regular 
honeycomb pattern and at the upper papillary dermis several small dense (Fig. 2g) 
and sparse nests were found (Table 1). RCM revealed the dermal nests, some of them 
were surrounded by small blood vessels. These features were suggestive for a benign 
intradermal nevus. Histopathology showed dermal nests of non-atypical melanocytes 
(Fig. 2h), corresponding to the dermal nests seen with RCM and fitting to a diagnosis 
of intradermal nevus. As this lesion was benign, no further treatment was needed. 
  
Case 5. A 34-year-old woman, with severe sunburns during childhood, had a shiny, 
pearly nodule with telangiectasias on her chest, suspicious for either a nBCC or an 
intradermal nevus (Fig. 1i). Telangiectasias were seen with dermoscopy. Clinical and 
dermoscopic evaluation were not conclusive for differentiation between a nBCC 
or an intradermal nevus (Fig. 1j). RCM imaging of the epidermis showed a regular 
honeycomb pattern. In addition, at the level of the DEJ, a clod pattern with non-edged 
papillae was observed (Table 1). The clod pattern is characterized by dense packed 
aggregates, formed by melanocytes within the dermal papillae. Small and large, 
dense and sparse nests (Fig. 2i) were visible in both the upper and deeper dermis. 
These dermal nests were surrounded by blood vessels. Further, solar elastosis was 
present at the level of the dermis. These RCM features suggested a benign nevus. The 
diagnosis of an intradermal nevus was confirmed by histopathological examination 
demonstrating dermal nests of non-atypical melanocytes (Fig.2j). No further 
treatment was performed.
Case 6. A 47-year-old woman with a history of NMSC, was referred to our outpatient 
clinic, for the presence of a skin-coloured nodule (Fig. 1k), located in the perioral 
area. On dermoscopy sparse telangiectasias were visible (Fig. 1l). RCM examination 
showed mild keratinocyte atypia and spongiosis of the epidermis, but overall it 
showed a regular honeycomb pattern. At the basal layer a cobblestone pattern was 
visible (Table 1). The DEJ was characterized by a regular ringed pattern with edged 
papillae (Fig. 2k). Small, dense, round to oval dermal aggregates surrounded by small 
capillaries were seen in the papillary dermis. Based on these RCM features and the 
RCM learning curve, the lesion was diagnosed as an intradermal nevus. No biopsy 
was obtained and no further treatment was performed. 
Summary of cases
We observed several differences and similarities in RCM features for nBCCs and 
intradermal nevi. The imaged intradermal nevi showed a honeycomb pattern and 
minimal alterations in architecture of the epidermis. In contrast, the evaluated 
BCCs revealed disarray of the epidermis characterized by mild keratinocyte atypia 
and spongiosis. None of the BCCs showed a specific pattern of the DEJ. The DEJ of 
the intradermal nevi revealed a ringed or clod pattern with (non)edged papillae. 
The appearance of BCC nests compared to naevus nests, located at dermal level, 
was different. Dermal nests of nevus cells were characterized by dense or sparse 
aggregates. Nests of basaloid cells were visualized as tightly packed cells, with 
peripheral palisading, surrounded by a cleft and fibrosis. Further, BCCs showed a 
prominent vascularisation with enlarged blood vessels, surrounding or within the 
nests of basaloid cells. Although the imaged intradermal nevi revealed some blood 
flow, the peri-lesional blood vessels were less prominent compared to BCC. 
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Figure 2  Reflectance Confocal Microscopy (RCM) images (en face) of discriminating 
features and corresponding haematoxylin-eosin (HE) stained transversal tissue slides 
of nodular basal cell carcinomas (nBCCs) (a–f), and intradermal nevi (g–l). Case 1: a) 
RCM image demonstrates two small nests of basaloid cells (white asterisks). Within 
these nests, peripheral palisading and branch-like structures are present. The nests 
are surrounded by a cleft, fibrosis and blood vessels with enlarged diameter (white 
arrow). (b) Corresponding HE stained tissue section showing a large nodus of basaloid 
cells with peripheral palisading and surrounding cleft. The micronodular nests are 
depicted by the black arrows. Case 2: c) Confocal image of the dermis (100µm depth) 
demonstrating one large nest of basaloid cells (white asterisk). d) HE stained tissue 
section showing one large nodus of basaloid cells (black asterisk). Case 3: e) Bunch of 
grapes-like shaped nests of basaloid cells (white asterisk) visualized by RCM at dermal 
level (100µm). Highly reflective branches and peripheral palisading are recognizable 
within these nests. The nests are surrounded by a cleft and blood vessels with 
enlarged diameter (white arrow). f) Corresponding HE stained sections showing nests 
of basaloid cells (black asterisk) with peripheral palisading in the upper dermis. Case 4: 
g) RCM imaging shows small, round to oval, dermal nests representing dense clusters 
of nevus cells (white arrows). Dense nests are round to oval nests with dense clusters 
of monomorphic individual nevus cells which are hardly distinguishable. Some of the 
dense nests are more reflective than others.17,18 h) Histopathology shows dermal 
nests of non-atypical melanocytes (black arrows). The line indicates the level at which 
the en face oriented RCM image is obtained. Case 5: i) This round to oval structures 
visualized by RCM indicating sparse dermal nests (75 µm depth). The sparse clusters 
are nests composed of aggregates of well-demarcated round to oval nevus cells with 
dark nucleus and reflecting cytoplasm in which individual nevus cells (white arrow) 
are easily to discern.13, 14 j) Corresponding HE stained section showing dermal nests of 
non-atypical melanocytes and clusters of melanin (black arrow). Case 6: k) With RCM, 
bright round edged papillae (white arrows) are observed at the dermoepidermal 
junction. l) Representative transversal histopathology of an intradermal nevi reveals 
the dermal papillae (black arrows) which contain melanin in the basal layer of the 
epidermis, corresponding to the rings seen with RCM in k). The line indicates the level 
at which the en face oriented RCM image is obtained.
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Discussion 
 
Clinical differentiation between a nBCC and a benign intradermal nevus can be 
difficult.1 Even with additional dermoscopic evaluation, a correct diagnosis may be 
difficult. Currently, histopathological examination of a biopsy is the gold standard 
to diagnose a BCC. However, this technique has disadvantages, as it is an invasive 
procedure and selects only a small part of the lesion, which can cause sampling 
errors.15, 16 As excision margins differ between subtypes of BCC, this may lead to 
inadequate treatment.
 In our outpatient clinic, RCM appears to be of additional value in establishing 
the correct diagnosis of nBCCs and intradermal nevi. Most of the observed RCM 
features were in line with features described in literature and correlate well with 
the commonly known histopathological characteristics. Described RCM features 
of BCC are a honeycomb or cobblestone pattern, disarray of the epidermis, a 
cauliflower or nonspecific architecture of the DEJ, inflammatory infiltrates and 
prominent vascularity with enlarged vessels.17 Further, tumor nests of basaloid cells 
with peripheral palisading, bright filaments and a surrounding cleft are the most 
specific RCM features for BCC.17 Well known RCM features for intradermal nevi are 
a honeycomb or cobblestone pattern, ringed-, clod-, meshwork- or nonspecific 
architecture of the DEJ, with or without junctional nests or sheet-like structures, and 
dermal dense and –spars nests. 9, 10, 17
 In contrast to literature we did not observe a specific pattern of the DEJ in nBCCs. 
In literature, in many BCCs the DEJ has been described as a cauliflower architecture, 
corresponding to solid units of tumor cells, appearing as hypo-reflective aggregates 
surrounded by dark areas.4, 17 Vascularisation has been visualized by RCM in only 
20% of the nevi. However, in intradermal nevi it was a more common phenomenon 
(36%).18 In contrast, we observed vascularisation in all three evaluated intradermal 
nevi. 
 The learning curve of RCM is of importance for a correct diagnosis. In experienced 
hands, RCM provides a non-invasive diagnosis within 5 to 10 minutes, which is 
significantly shorter than the total processing time of a biopsy. In all 6 cases, the 
correct diagnosis was made by means of the helpful, non-invasive RCM. In one of 
the BCCs, a sampling error was avoided, because revision of a biopsy revealed also 
a micronodular component (besides the nodular aspect), as noticed with RCM. 
Detection of the micronodular component had therapeutic consequences, because 
a micronodular BCC is excised by a larger margin than a nBCC. In one intradermal 
nevus, RCM imaging avoided a biopsy of a bengin lesion in the face. Noteworthy, 
pigmented BCCs and nevoid melanoma might be pitfalls of differentiation between 
nBCCs and intradermal nevi by RCM. However, these diagnosis were not within the 
scope of this study. 
Table 1  Scored RCM features of the imaged lesions
Features nBCCs Intradermal nevi
Case I Case II Case III Case IV Case V Case VI
Epidermis
Regular honeycomb pattern -/+ -/+ -/+ + + +
Regular cobblestone pattern - - - - - +
Architectural disarray epidermis + + + -/+ - -/+
Mild spongiosis spinosum ++ + + - - -/+
Dermo-epidermal junction
Ringed pattern - - - - - +
Clod pattern - - - - + -
Nonspecific pattern + + + + - -
Edged papillae - - - - - +
Non-edged papillae - - - - + -
Dermis
Nests containing cellular structures + + + + + +
  Large (>300µm) + + + - + -
  Small (<300µm) + - + + + +
  Round - oval shaped + + + + + +
  Bunch of grape-like shaped - - + - - -
  Dense  - - - + + +
  Dense-sparse - - - + + -
  Branch-like structures + - + - - -
  Peripheral palisading + - + - - -
  Cleft + -/+ + - - -
Fibrosis surrounding nests + -/+ + - - -
Blood vessels close to nests + + + + + +
Diameter blood vessels +++ ++ +++ + ++ +
Solar elastosis - + + + + -/+
Inflammatory cells + - + - - -
- absent, -/+ mildly present, + present, ++ increased, +++ more increased
Chapter 3 Basal cell carcinoma
3
124 125
 Overall, this case-series study demonstrates that in routine patient care, RCM 
allows prospective in vivo differentiation between clinical equivocal nodular lesions 
e.g. nBCCs and intradermal nevi. Subsequently, biopsies of benign lesions in cosmetic 
areas could be avoided. Future studies have to explore the sensitivity and specificity 
of this clinical RCM application.
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Abstract
 
Background: In vivo Reflectance Confocal Microscopy (RCM) is a promising technique 
for the routine diagnostic workflow of melanoma. An overview of the subset of RCM 
features of melanoma and its clinical simulators based on systematic literature 
research is lacking.
Objective: We systematically reviewed literature concerning melanoma and its clinical 
simulators evaluated by RCM to provide an overview of the distinctive features, 
determined their accuracy and highlight niches in melanoma RCM research.
Methods: Pubmed, EMBASE, Cochrane Library and Web of science databases were 
searched. All RCM studies on melanoma and its simulators were reviewed and quality 
assessment was determined by the Strengthening the Reporting of Observational 
studies in Epidemiology checklist. 
Results: Literature search revealed 75 eligible studies for inclusion. An overview of 
the subset of distinctive RCM features for melanoma and its clinical simulators was 
provided. 
Limitations: A part of the studies was not primarily designed to differentiate melanoma 
from its clinical simulators. 
Conclusions: This systematic review provides an overview of the distinctive RCM 
features for melanoma and its clinical simulators. RCM deserves to be implemented 
in the diagnostic workflow of melanoma, which may reduce diagnostic and treatment 
delay, because RCM is the missing link between dermoscopy and histopathology.
Introduction
Although non-melanoma skin cancer (NMSC) is the most common skin cancer in 
humans1, melanoma has the highest mortality of all skin cancers.2, 3 Therefore, 
diagnostics of skin cancer has been a subject of interest for a long time. For many 
decades, solely clinical- and histopathological examination were available to determine 
the diagnosis.4 Since approximately two decades, dermoscopy was introduced as an 
additional step in the clinical approach of detecting melanoma. As with many new 
devices in medicine, it took a while before clinicians were comfortable with this 
technique and implementing this additional step in their diagnostic decision making. 
Currently, dermoscopy is well accepted and applied in dermatology5, because it 
improves diagnostic accuracy of melanoma and its simulators.6 Thereafter, in the late 
90’s the first in vivo Reflectance Confocal Microscope (RCM) was introduced in clinical 
practice7, mainly for detecting pigmented skin lesions, because of the strong contrast 
of melanin.8 Nowadays, RCM, which visualizes the skin in an en face plane with a 
depth of 200-300µm and a resolution comparable to light microscopy9, has become 
one of the promising non-invasive tools in a wide spectrum of dermatological entities. 
 Many studies have been published on diagnosing melanoma and other pigmented 
lesions with RCM.10-12 In 2013, Stevenson et al. explored the accuracy of detecting 
melanoma by RCM. 13 However, one of the main objectives in routine clinical practice, 
is the distinction between benign and malignant lesions.14 As melanocytic- and 
non-melanocytic lesions (ML and NML, respectively) may simulate melanoma, it is 
crucial to differentiate well between these lesions,  because prognosis and treatment 
choice differ.15 Since our confocal experience was mainly focused on NMSC and 
inflammatory skin diseases, we explored our experience by conducting a systematic 
review focused on the distinctive RCM features of melanoma and its clinical 
melanocytic and non-melanocytic simulators. The knowledge obtained from the 
systematic review was used to define a subset of RCM features of melanoma and its 
clinical simulators in order to explore their sensitivity and specificity. Furthermore, 
niches in melanoma research by in vivo RCM were highlighted. 
Methods
 
Pubmed, EMBASE, The Cochrane Library and Web of Science databases were used 
for the systematic literature search. The search was focused on confocal microscopy, 
melanoma and its (non)melanocytic clinical simulators adapted from the classification 
as described by Dermatology15 (Full details on the search strategy are available from 
corresponding author on request). We included studies with the in vivo Vivascope 
1000, 1500, 3000 systems. A language restriction was applied for other languages 
Chapter 4 Melanoma
4
132 133
than English, German or Dutch. Further inclusion criteria were melanoma and its 
clinical simulators, skin tissue, a minimum number of 15 patients and a diagnostic 
aim of the study. Studies about other entities than dermatology, other tissue than 
skin (e.g. nails, hairs, mucosa), in vitro and animal studies, unavailable texts, reviews 
and abstracts were excluded. Studies until 21th of October 2014 were included by a 
four-step method. All titles, and when necessary abstracts and/or method section, 
were screened by two independent reviewers (LH en VH).  Thereafter, all included 
titles and abstracts were screened by a checklist of in- and exclusion criteria. In the 
third step, full texts were screened for their eligibility. The final step included detailed 
assessment of the included full texts. Two independent reviewers (LH and VH) 
critically performed each step, differences were discussed with a third investigator 
(MG). Reference lists of all included studies were checked for additional studies not 
identified by the initial search. 
 Study characteristics such as diagnosis, study design, RCM features and accuracy 
were summarized by two independent reviewers (LH, VH). 
 The STrengthening the Reporting of OBservational studies in Epidemiology 
(STROBE) criteria were used for assessing the methodological quality of the included 
studies by two reviewers (LH, VH). In case of any dispute, a third reviewer (MG) was 
consulted. A minor modification of the criteria was applied, for using them in case 
series (Supplement 2 in chapter 2.1). Fulfilling more than 80% of the criteria was 
classified as A, 50-80% as B and when less than 50% of the criteria was achieved it 
was classified as C. 
Results
We identified 11,575 studies by the initial literature search, which included 4,182 
duplicates. Title screening resulted in inclusion of 629 studies. Most of the excluded 
articles did not meet the inclusion criteria: they used other RCM systems (an exception 
was made for two relevant studies which used the 1064nm Nd: YAG laser16, 17), were 
studies in other fields than dermatology or were abstracts. This selection step showed 
an overlap of 97% by the two reviewers. After title and abstract screening, 315 studies 
remained for further screening. Studies were excluded if they described other 
diagnoses than melanoma or its clinical simulators. Further, a large number of studies 
(n=49) was not available in full text and therefore excluded. The reviewers revealed 
an overlap of 92% in this selection. After full text screening, many studies were 
excluded because of the location of the lesions (nails, hairs, mucosa), the monitoring 
aim, the lack of a minimum number of 15 patients or the papers were reviews. The 
last selection step showed an overlap of 83.5% between the two reviewers. Finally, 
75 studies were included for this systematic review (Figure), n=41 studies included 
ML, n=18 NML and n=16 studies included both ML and NML. Italy (n=27) and Australia 
(n= 7) predominate the number of included studies about ML (Table 1).
 The majority of the included studies were cross-sectional (n=50). Other were 
case-control (n=13) and cohort studies (n=7) and a small number of case series (n=5). 
The methodological quality was moderate: 75% of the studies was classified as 
STROBE B (n=57) and 25% as C (n=18) (Table 1, 2). None of the studies met ≥80% of 
the criteria. The majority of the studies lacked detailed descriptions of the study 
setting, variables, power-analyses and any description of statistics. We classified the 
included studies into 12 subcategories: melanoma (n=43)10-12, 14, 16-54, lentigo maligna 
(LM, n=7)51, 55-60, lentigo solaris (LSo, n=5)18, 30, 57, 61, 62, nevi (n=41)10, 11, 14, 16, 17, 22-32, 35-46, 48, 
51-54, 58, 60, 63-68,  psoriasis (isolated plaque may simulate (amelanotic) melanoma)(n=6)30, 
69-73, seborrheic keratosis (SK, n=11)14, 30, 32, 36, 51, 58, 60, 65, 74-77, lichen planus-like keratosis 
(LPLK, n=2)19, 53, actinic keratosis (AK, n=9)19, 22, 30, 59, 78-82, squamous cell carcinoma (SCC, 
Figure  Flow chart: selection process of included studies. ML: melanocytic lesion, 
NML: non-melanocytic lesion.
Citations from databases
n=11,575
Title screening
n= 7,393
Titles and abstracts
n=629
Inclusion n= 75
n= 41 ML, n=18 NML, n=16 both ML+NML
Full text articles for full text screening
RCM + melanoma and its simulators n= 315
Web of Science: n=5,145Cochrane: n=86EMBASE: n=3,466Pubmed: n=2,878
Studies by references n= 0 Exclusion after full text screening n=240
No full text available n= 49
Exclusion n = 265
Exclusion n =6,595
Exclusion meeting abstracts n =169
Duplicates n =4,182
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n=7)19, 22, 32, 36, 49, 60, 80, basal cell carcinoma (BCC, n=14)14, 19, 22, 23, 28, 32, 36, 47, 51, 60, 83-86, 
dermatofibroma (DF, n=3)32, 36, 51, pyogenic granuloma (PG, n=1)36 (Table 1, 2). Further, one 
study described collisions tumors composed of some of the aforementioned 
diagnostic groups.60 Studies including multiple diagnoses were discussed in various 
subcategories. Thirty-three of the included studies had the aim to differentiate 
melanoma (including LM) from other diagnosis.10, 14, 16-19, 22-26, 28, 30-32, 34-48, 51, 52, 58 The most 
frequent described features are summarized by diagnosis (Table 3). 
Melanoma
Many included papers have extensively studied melanoma.10-12, 14, 16-54 As a result of 
the limited number of descriptions of the different melanoma subtypes, we focus on 
the general diagnosis melanoma. The most frequent described features in each skin 
layer for melanoma have been summarized in Table 3. Most studies characterized the 
epidermis of melanoma by an atypical honeycomb and –cobblestone pattern, with 
mild to marked cellular atypia and thereby poorly defined keratinocyte cell borders. 
Pagetoid cells (melanocytes), both round and dendritic, have been described 
predominantly widespread throughout the epidermis. The dermal epidermal junction 
(DEJ) was characterized by a ringed-, meshwork or non-specific pattern. Both edged 
and non-edged dermal papillae (DP) have been described. Irregular size and shape of 
the DP and the junctional nests with atypical melanocytes are characteristic for 
melanoma. Plump bright cells (melanophages) and pagetoid cells were located at the 
DEJ and dermis. The dermis was characterized by irregular dense, sparse or 
cerebriform dermal nests and sometimes sheet-like structures, represented by loose 
aggregates of atypical melanocytes. Thickened collagen fibers and more pronounced 
tortuous blood vessels were present. The studies showed a large variety in the 
sensitivity (37.8-100%) and specificity (23.6-100%) for the overall diagnosis of 
melanoma.14, 17, 18, 22, 24-26, 28, 31, 32, 37, 40, 44, 45, 49, 51 This can be explained by the different 
subsets of RCM criteria which were used to obtain the diagnosis of melanoma. The 
lowest specificity (23.6%) was measured by an automated system by a threshold to 
obtain a sensitivity of 100%.31 The positive predictive value varied between 
70.6-97.5%14, 17, 25, 26 and the negative predictive value was 93-99%.14, 25, 26 Most 
predictable feature for melanoma was  pagetoid infiltration of roundish cells (89.5%, 
80.0%, respectively).37 Most studies showed a reference test of both dermoscopy and 
histopathology, but not all studies correlated 100% of the imaged lesions.
Melanocytic simulators of melanoma 
In LM epidermal disarray and pagetoid cells were seen. The pagetoid cells were 
predominately located perifollicular in epidermis and DEJ. Junctional atypical melano- 
cytes were sometimes clustered in nests. DP were non-edged or less visible, especially 
located in the face. Atypical nucleated cells could be observed within the DP. 
Numerous plump bright cells, melanophages, were visible at dermal level (Table 3). 
LM was diagnosed with a sensitivity and specificity 85-93% and 61-76%, respectively.58 
Round large pagetoid cells were the most accurate RCM feature (sensitivity 100%, 
specificity 93.8%).56 
 Two included studies were primarily designed to characterize LSo. These studies 
showed a moderate methodological quality (STROBE B) without any statistical 
approach to determine the accuracy of the RCM features or for the diagnosis of LSo.61, 62 
LSo was often characterized by a regular honeycomb- and cobblestone pattern. The 
DP were edged with and increased pigmentation of the basal cells, without any 
atypical cells (Table 3).
 RCM features of nevi have been described from different perspectives; clinical, 
dermoscopic and/or histopathological. Here, we focused on the general diagnosis of 
benign nevi (BN) and its subcategories (junctional-, compound-, intradermal nevi), 
dysplastic (DN)- and Spitz nevi (SN). 
 Benign nevi were recognized by a regular honeycomb pattern, monomorphous 
melanocytes, well-defined keratinocyte borders, clearly defined junctional nests and 
regular DP. At the dermis clearly defined dermal nests, plump bright cells and coarse 
collagen fibers were observed. The epidermis showed the same features in junctional-, 
compound- and intradermal nevi except for pagetoid cells which were mostly seen in 
junctional- and compound nevi. Similar architectural patterns at the DEJ were seen in 
the different type of nevi. Junctional melanocytic nests were seen in junctional- and 
compound nevi, while dermal nests were seen in compound and intradermal nevi. 
The sensitivity and specificity of BN (including the sensitivity and specificity to 
differentiate benign from malignant lesions) varied between 78.1-100% and 
57.1-97.6%.14, 17, 22, 25, 26, 32, 40, 44, 51 Detection of monomorphic melanocytic cells in BN 
showed the highest sensitivity (98.2%) and specificity (98.9%).26
 DN and SN showed overlapping features with BN and melanoma (Table 3). DN 
showed more atypia at epidermal level than in BN, but less as compared to melanoma. 
Atypical cells were observed at the DEJ. Junctional nests at the junction were less 
regular and dermal nests were less defined. SN were characterized by disarray in the 
epidermis with some pagetoid cells. Characteristic at the junction were the 
non-edged DP, junctional nests and some atypical cells. Dermal nests, often dense at 
the periphery of the lesion, and plumb bright cells were seen. The sensitivity for the 
diagnosis of SN was 43.8%.40 
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Non-melanocytic simulators of melanoma
Numerous non-melanocytic lesions which clinically may simulate melanoma, and 
imaged by RCM, were included in this study: psoriasis30, 69-73, SK14, 30, 32, 36, 51, 58, 60, 65, 74-77, 
LPLK19, 53 , AK19, 22, 30, 59, 78-82, SCC19, 22, 32, 36, 49, 60, 80, BCC14, 19, 22, 23, 28, 32, 36, 47, 51, 60, 83-86, DF32, 36, 51 
and PG36 (Table 2, 3) The RCM features of the non-melanocytic simulators differed 
clearly at the various skin layers from melanoma features. Moreover, the diagnosis of 
BCC is less complex compared to melanocytic  lesions.28 Furthermore, 11 studies 
showed sensitivity and specificity for the RCM diagnosis and/or RCM features (Table 
2), mainly reported for BCC.  The highest sensitivity and specificity for BCC was the 
polarization of the nuclei in the epidermis (sensitivity 91.6%, specificity 97.1%).85 The 
most predictive feature for AK was pleomorphism at the SS (sensitivity and specificity 
100%).81 
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Discussion
 
This systematic review defined a subset of RCM features of melanoma and its (non)
melanocytic simulators. Differentiation between these lesions is essential as they 
have distinct therapeutic consequences.
 The degree of atypia and spread of pagetoid cells were more pronounced in 
melanoma comparing to LM, DN and SN. At the junctional level, more atypical nests 
were seen throughout melanoma. Dermal differences were found in the appearance 
of the atypical nests; cerebriform nests were a hallmark for melanoma, however 
dense and dense/sparse nests could also appear. In general, melanoma were more 
polymorphous compared to other differential diagnoses. 
 A confocal diagnosis should not be made by a single RCM feature, but according to a 
subset of different features at the level of the epidermis, DEJ and dermis. In addition, 
it should always be considered that melanoma may lack RCM characteristics and that 
typical RCM features may be missed by incomplete imaging.52 To prevent a sampling 
error and to include the most aggressive part of the lesion, the entire lesion has to 
be imaged. The final confocal diagnosis will strongly depend on the expertise of 
the confocalist. In any case, it is good to realize that RCM should be considered as an 
additional tool, complementing the initial clinical view of dermatologists. 
 According to the similarities and differences of the RCM features in melanoma 
and NML simulators, some of the included studies was not primarily designed to 
differentiate melanoma from ML or NML. This can be considered as a limitation.
 The methodological quality of the included studies was moderate as examined 
by the STROBE scores, however more well-designed statistical analyses have been 
performed in comparison to inflammatory skin diseases imaged by RCM.87 There has 
been a great RCM interest in melanoma. First melanoma has a high mortality rate and 
secondly, it is relatively easy to image melanocytic lesions by RCM because of the 
strong contrast of melanin. A meta-analysis showed a sensitivity of 93.3% and 
specificity of 75.9% for the RCM diagnosis of melanoma.13 Several differences within 
the data from Stevenson et al. were found. For example they reported a specificity of 
86%, in contrast to Curchin et al. as they described a specificity of 75%.22 In contrary 
to Stevenson et al.58, we showed separate results for melanoma and LM. LM may be 
considered as a separate type of melanoma in situ. Furthermore, Stevenson et al. 
displayed the sensitivity and specificity for the best threshold of RCM features, as we 
reported the range of the different thresholds.58 
 A niche in the field of RCM research  with respect to melanoma is the lack of 
studies with the focus on the Breslow thickness, because that is considered as the 
most important prognostic factor.34 The lack of these studies is related to the limited 
laser penetration depth of 200-300µm, which corresponds with reaching the papillary 
dermis. Technological development will hopefully overcome this limitation. For the 
near future, the progressive number of clinics using RCM in Europe and the USA, 
suggests an increasing role of the technique, particular in melanoma, in clinical 
setting. 
 In vivo RCM represents a relatively young research field in clinical dermato- 
oncology.88 However, we believe that RCM deserves to be implemented in the diagnostic 
workflow of melanoma, which may reduce diagnostic and treatment delay, because 
RCM is the missing link between dermoscopy and histopathology. In conclusion, RCM 
can have an additional value in complementing clinical expertise of dermatologists, 
if RCM is in experienced hands. RCM protocols developed by experts will facilitate 
further use of RCM in general dermatological practices. This systematic literature 
review, together with previously published protocols based on expertise of leading 
confocalists, may lead to more recognition for the value of RCM in clinical practice.
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Summary 
Since the last decades, medical technology has grown enormously and is inevitable in 
current medical practice. In vivo reflection confocal microscopy (RCM) allows non- 
invasive examination of the skin without skin damage. As such, RCM opens a new era 
of diagnosis and therapy monitoring possibilities in clinical dermatology. The studies 
presented in this thesis studied several aspects of RCM for inflammatory skin disease, 
basal cell carcinoma (BCC) and melanoma. The purpose of these studies is to make a 
significant contribution to implementation of RCM in clinical dermatology.
 
Inflammatory skin diseases
The aim of the study described in chapter 2.1 was to provide insight into the wide 
spectrum of inflammatory skin entities and infectious skin diseases imaged by RCM. 
An extensive literature search revealed 77 eligible studies of different diagnostic 
groups; papulosquamous and eczematous diagnoses (psoriasis, pityriasis rubra pilaris, 
lichen planus and lichen nitidus, radiation dermatitis, allergic contact dermatitis and 
irritant contact dermatitis), cutaneous T-cell lymphoma (mycosis fungoides, 
parapsoriasis en petite plaque, lymphomatoid papulosis, Sézary syndrome), bullous 
diseases (pemphigus foliaceus, pemphigus vulgaris, bullous pemphigoid, M. 
Hailey-Hailey, M. Darier-White), adnexal diseases (alopecia), autoimmune connective 
tissue diseases (lupus erythematosus, systemic sclerosis and lichen sclerosis) and 
various infectious skin diseases: parasitic (demodex folliculitis, larva migrans, 
leishmaniasis, scabies and pyemotes ventricosus), bacterial (secondary syphilis and 
bacterial secondary infection), fungal (tinea and onychomycosis) and viral (varicella, 
herpes, human papillomavirus, molluscum contagiosum). Each diagnosis showed 
distinctive RCM features, but revealed also similar features with different inflammatory 
skin diagnoses. 27 Case reports, 14 case series, 9 cohort studies, 20 case-control 
studies and 7 cross-sectional studies were included. The majority reached a moderate 
methodological quality (classified as STrengthening the Reporting of OBservational 
studies in Epidemiology (STROBE) B (56%) and STROBE C (44%). This was caused by 
the lack of descriptions of the study setting, lack of reporting the potential sources of 
bias, lack of explanations of the study size, lack of quantitative variables and absence 
of statistical analysis. In alignment with the moderate methodological quality, 6 out 
of 77 studies determined the accuracy of a RCM diagnosis and/or its features. The 
major limitation of the studies included in this systematic review was the limited 
number of well designed, high qualitative methodological  studies. The methodological 
quality was not assessed by the Quality Assessment of Diagnostic Accuracy Studies 
(QUADAS-2), because of the descriptive design of the included studies.  In addition, it 
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was not possible to conduct a meta-analysis because of the heterogeneity of the 
included studies, different diagnoses and limited statistical analyses. Future 
diagnostic RCM studies need to distinguish most common inflammatory skin diseases 
and their differential diagnoses. This may result in a ‘hands on’ decision tree for RCM 
diagnosis. 
 In chapter 2.2 we focused on the role of RCM in diagnosis of stable and unstable 
psoriatic plaques. Twelve stable plaques and fourteen unstable psoriatic plaques 
from thirteen patients with chronic plaque psoriasis were imaged by RCM. Unstable 
plaques showed a higher number of inflammatory cells within the (epi)dermis, 
including Munro and Kogoj microabscesses (all p <0.01). Furthermore, a larger 
diameter of dermal papillae (DP) (p=0.03) and a higher capillary flow (p<0.01) with 
more tortuous capillaries (p=0.04) were observed. No differences were seen between 
center and margin, except a higher number of edged DP at the margin in stable plaques 
(p=0.01). Numbers of epidermal inflammatory cells were predictive for unstable 
plaques (p=0.02). Therefore, areas with high number of epidermal inflammatory cells 
may be considered to be a RCM defined hot spot. Moreover, chapter 2.3 showed the 
diagnosis unstable psoriasis by epidermal inflammatory cell counts with a sensitivity 
and specificity of 91.7% and 98.3%, respectively and an accuracy of 0.92 (area under 
the curve). Overall, the study described in chapter 2.2 showed the ability of RCM to 
provide in vivo information of a psoriatic plaque. In future, this information might be 
used to adjust treatment strategies. The limited number of included subjects might 
be a drawback. Future case-control studies should include a higher number of 
psoriatic patients having stable and unstable plaques. Thereafter, validation of these 
results in therapeutic monitoring studies is desirable. 
 Literature describing the transition of RCM from research tool to clinical device 
is limited. In chapter 2.3 we aimed to conduct an implementation strategy, focused 
on psoriasis. Psoriasis was diagnosed and stable from unstable plaques were 
differentiated by means of a hands on RCM protocol. A four phase model was used: 
an exploring phase, a systematic literature search, a clinical approach and, finally, an 
integration phase to develop a clinical guideline for RCM in psoriasis. The ‘hands on’ 
protocol included several steps. First, the psoriatic lesion was selected and thereby 
well positioning of the patient. Then, the location within the lesion was selected and 
the metal ring was attached. The VivaCam was used to capture a dermoscopic 
picture. Finally, the RCM probe was attached to the metal ring for a standardized 
imaging procedure. The strategy may serve as a general RCM model for other 
dermatological entities. In addition, this may lead to more ‘hands on’ RCM protocols 
for clinical dermatological practice. However, the strategy was based on the RCM 
experience and approach from a single center, which can be considered as a 
limitation. Moreover, no differential diagnoses of psoriasis were examined within 
the model. 
Main conclusions for chapter 2:
- A large spectrum of inflammatory and infectious skin diseases has been imaged by 
in vivo RCM for diagnostic and monitoring purposes. The systematic review shows 
the need for well designed methodological studies in this field.
- Stable psoriatic plaques can be differentiated from unstable psoriatic plaques by 
using RCM. The numbers of epidermal inflammatory cells are predictive for 
unstable plaques. 
- A strategy for further implementation of RCM, focused on psoriasis, is established. 
This strategy may serve as a general RCM implementation model for other skin entities. 
Basal cell carcinoma 
Superficial basal cell carcinoma (sBCCs) can be treated adequately by, amongst 
others, non-invasive methyl-aminolevulinate photodynamic therapy (MAL-PDT). The 
PDT response rate depends on, amongst others, the correct diagnosed subtype BCC. 
Currently, histopathologic examination of a biopsy is the gold standard for the 
diagnosis of BCC and its subtype. Chapter 3.1 determined whether a treatment failure 
or recurrence was based on underdiagnosis of histological examination, so a more 
aggressive subtype than sBCC, that was missed on punch biopsy. The percentage of 
treatment failures that were underdiagnosed by the primary biopsy was 69.2%. The 
recurrences showed a mixed-type tumor in 48.6% comparing primary biopsy, 
repeated biopsy and excision specimen. 40.5% missed the most aggressive 
component of the tumor. The reliability of the initial biopsy is questionable concerning 
these mixed-type BCCs. Moreover,  the PDT response may be underestimated by the 
underdiagnosis of treated BCCs. The number of treatment failure and recurrences 
after PDT, and probably other non-invasive therapies, may be decreased by more 
extensive histopathological examination (e.g. deeper step-sections) or by prior 
non-invasive diagnostics such as RCM, that examines the entire lesion. 
 In chapter 3.2 we focused on distinguishment between nBCC and intradermal 
nevi by in vivo RCM. RCM was able to differentiate prospectively between these 
lesions. As a result, the number of excisions of benign intradermal nevi was reduced. 
Intradermal nevi revealed non-specific patterns at the dermo-epidermal junction 
(DEJ). In contrast, nBCCs revealed ringed, clod or meshwork patterns. Dermal 
melanocytic nests appeared as dense-sparse nests. Instead of melanocytic nests, 
nBCCs reveal tumor nests with basaloid cells and peripheral palisading. Further, 
nBCCs showed more prominent vascularization than intradermal nevi. The low 
number of included lesions is a limitation of the study. Future research should include 
higher number of patients. Further, histopathological confirmation of all lesions and 
the intervariability between observers needs to be addressed. 
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Main  conclusions for chapter 3:
- The number of mixed-type BCC in treatment failures and recurrences after 
MAL-PDT, and therefore underdiagnosed, may cause an underestimation of the 
PDT response. Non-invasive techniques, such as RCM, may be used prior to 
non-invasive therapy for an accurate tumor diagnosis.
- RCM is able to prospectively differentiate clinically difficult to distinguish nBCCs 
from intradermal nevi. This results in a reduced number of excision of benign 
lesions. 
Melanoma 
Many diagnostic RCM melanoma studies were performed by international research 
groups. However, an overview of the subset of distinctive RCM features for melanoma 
and its clinical simulators was lacking. We conducted a systematic review of most 
described RCM features for melanoma and its clinical simulators in chapter 4.1. The 
study showed an extensive systematic literature search. This search included 75 studies 
with twelve subcategories; melanoma, lentigo maligna, lentigo solaris, nevi, psoriasis, 
seborrheic keratosis, lichen planus-like keratosis, actinic keratosis, squamous cell 
carcinoma, basal cell carcinoma, dermatofibroma and pyogenic granuloma. Most 
described features for melanoma were an atypical honeycomb- and cobblestone 
pattern, cellular atypia and pagetoid cells widespread through epidermis and dermis. 
At the DEJ a ringed-, meshwork or non specific pattern was described. Both edged 
and non edged DP with irregular shape and size were seen. Further, junctional nests 
with atypical melanocytes, plump bright cells were reported. At dermal level dense, 
sparse or cerebriform dermal nests, thickened collagen and tortuous blood vessels 
were seen. The accuracy for the diagnosis varied with a sensitivity of 37.8-100% and 
specificity of 23.6-100%. A confocal diagnosis should not be made by a single RCM 
feature, but according to a subset of different features at the level of the epidermis, 
DEJ and dermis. In any case, it is good to realize that RCM should be considered as an 
additional tool, complementing the initial clinical view of dermatologists. The 
methodological quality of the included studies, assessed conform the STROBE scores, 
was moderate. A niche in the field of RCM research  with respect to melanoma is the 
lack of studies with the focus on the Breslow thickness. Future RCM studies for 
determination of the Breslow thickness with RCM in melanoma are needed, because 
this is an important prognostic factor. Technical improvement of the RCM technique 
may lead to a deeper laser penetration depth and therefore the ability to examine 
the total dermis. In future, RCM experience in melanocytic lesions is desired by our 
confocal group. Therefore, this systematic review should be considered as the 
foundation of a new RCM focus in our center.
Main conclusion for chapter 4:
- An accurate RCM diagnosis of melanoma can be made according to a subset of 
features from epidermis (atypical honeycomb- and cobblestone pattern, cellular 
atypia and pagetoid cells), DEJ (edged and non edged DP with irregular shape and 
size, junctional nests with atypical melanocytes, plump bright cells and pagetoid cells) 
and dermis (dense, sparse or cerebriform dermal nests, thickened collagen and 
tortuous blood vessels). In any case, it is good to realize that RCM should be considered 
as an additional tool, complementing the initial clinical view of dermatologists.
General discussion
Since the use of RCM its innovations and applications have been grown exponentially. 
International confocal research was primarily focused on melanocytic skin lesions 
because of the strong contrast of melanin.1 Morphology of nevi and melanoma have 
been described in detail and different algorithms for melanoma diagnosis have been 
proposed thereafter.2  Since then, an extensive spectrum of dermatological entities, 
including non-melanocytic lesions and inflammatory skin diseases have been imaged 
by RCM and the implementation of RCM in clinical practice is currently underway. 
 In this thesis we evaluated the application of RCM in inflammatory skin diseases3 
and mainly focused on psoriasis.4, 5 We also suggested that RCM could contribute to 
the accuracy of diagnosing BCC before non-invasive therapy such as PDT6  and 
showed the ability of RCM to differentiate between benign and malignant melanocytic 
and non-melanocytic proliferations.7, 8 
 The use of RCM in Dutch dermatological patient care is only approved for research 
and not registered in the Dutch dermatological guidelines yet. Radboud University 
Medical Center, Academic Medical Center Amsterdam and Antoni van Leeuwenhoek 
Hospital (Netherlands Cancer Institute) are currently using RCM for this purpose. 
Future collaboration of these centers (e.g. united in a Dutch confocal group) might 
lead to more insight into RCM applications and subsequent implementation of RCM 
in Dutch dermatological RCM guidelines. From an international point of view,  the 
RCM is now described as an additional technique for the diagnosis of actinic keratosis 
and basal cell carcinoma in an acknowledged text book for dermatologists.9 
 Implementation of RCM in clinical dermatological practice is impeded by several 
factors. These factors should be addressed in order to implement RCM in dermatological 
patient care. Laser penetration depth is limited to visualization of the upper dermis 
and a more powerful laser will be needed to image deeper layers of the skin. However, 
more laser power will increase the risk of tissue damage.10 If available, this technique 
could play a role in determination of Breslow thickness in melanoma11 or invasion 
dept in squamous cell carcinoma.12, 13 Another future perspective is automated RCM 
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imaging, which may overcome the low reproducibility of some confocal parameters 
and  ease the learning curve of beginning confocalists.14 In addition, portable devices 
(handheld-size) should be provided to ease its clinical use. Further, combining RCM 
with other optical techniques, such as optical coherence tomography (OCT) and 
multiphoton tomography (MPT), can optimize imaging.15 Definitions of RCM features 
have yet been described by several research groups 16-18 but there is still a need for 
higher consensus.14 Difficulties in precise and reproducible identification of cell types 
(such as differentiation between different types of inflammatory cells) contributes to 
this lack in consensus.14 
 The fact that most studies investigated the accuracy of RCM diagnoses retro-
spectively and methodological quality is often poor, are other limiting factors.19-21 
Prospective studies are needed to provide us with more accurate information about 
sensitivity and specificity. 
 Apart from technical innovations it has to be clearly stated by whom RCM 
measurement and subsequent interpretation of images should be done (e.g. 
dermatologists, pathologists or medical technicians), how these confocalists have 
been trained and if and whether they can use well-designed uniform guidelines. 
Intensive training is needed for adequate interpretation of RCM images and as in 
such reliable diagnosis.22 The setting in which RCM should be used is also matter of 
discussion. Whether it is ideal to use this diagnostic tool in specialized centers, such 
as the ‘Melanoma & Pigmented Lesion Clinic’ in Italy23, or in peripheral dermatology 
clinics is not entirely clear. 
 In addition to the confocal performer and setting in which RCM should be performed, 
the population eligible for RCM should be defined more properly. The incidence of 
non-melanoma skin cancer is still rising. Although it is just not feasible to diagnose all 
patients, there should be role for RCM in diagnosing high risk patients such as patients 
with basal cell naevus syndrome (also known as Gorlin-Goltz syndrome), transplant 
recipients and patients with a positive family history for melanoma.
 Once multiple prospective clinical studies demonstrate positive results, one 
should also take into account cost-effectiveness in order to be able to implement 
RCM in daily clinical practice. High device costs (device purchase €100,00023) do 
often limit their use to specialized dermatological (research) centers.24 Training and 
personnel costs need to be kept in mind as well.  On the other hand, systematic use 
of RCM dramatically decreased the number of benign lesions excised. This can be 
translated in a significant cost-benefit advantage.23  A cost-effectiveness study is 
inevitable for further implementation of RCM in the Netherlands. 
 Results described in this thesis contribute to further implementation of RCM in 
dermatology. In future, technical innovations may lead to a shift from a clinico-histo-
pathology diagnosis to a clinico-imaging diagnosis.25 A new era for dermatology by 
non-invasive imaging techniques has just begun and some critical steps still have to 
be undertaken to fully implement RCM in the Dutch dermatological patient care 
system. 
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Nederlandse Samenvatting
In de laatste decennia zijn geneeskunde en medische technologie onlosmakelijk 
verbonden. In vivo reflectie confocale microscopie (RCM), maakt het mogelijk de 
huid op een niet-invasieve manier te onderzoeken zonder huidschade te veroorzaken. 
Hiermee opent RCM een nieuw tijdperk van diagnostische en monitoring 
mogelijkheden binnen de klinische dermatologie. Het onderzoek gepresenteerd in 
dit proefschrift is gericht op de toepassing van RCM bij inflammatoire dermatosen, 
basaalcelcarcinomen (BCC) en melanomen. Met deze studies is beoogd een bijdrage 
te leveren aan de implementatie van RCM binnen de patiëntenzorg. 
Inflammatoire dermatosen
Het doel van de studie beschreven in hoofdstuk 2.1 was om inzicht te creëren in het 
brede spectrum van inflammatoire- en infectieuze huidziekten in beeld gebracht 
middels RCM. In een uitgebreide literatuurstudie werden 77 geschikte studies van 
verschillende diagnostische groepen geïncludeerd; papulosquameuze- en eczemateuze 
diagnoses (psoriasis, pityriasis rubra pilaris, lichen planus en lichen nitidus, bestralings-
dermatitis, contactallergische eczeem en orthoergisch eczeem), cutaan T-cel lymfoom 
(mycosis fungoides, parapsoriasis en petite plaque, lymphomatoïde papulose, Sézary 
syndroom), bulleuze ziekten (pemphigus foliaceus, pemphigus vulgaris, bulleus 
pemphigoid, M. Hailey-Hailey, M. Darier-White), adnexale ziekten (alopecia), auto- 
immuun bindweefselziekten (lupus erythematosus, systemische sclerodermie en 
lichen sclerose) en verscheidene infectieuze huidziekten: parasitair (demodex 
folliculitis, larva migrans, leishmaniasis, scabies en pyemotes ventricosus), bacterieel 
(secundaire syfilis en bacteriële secundaire infecties), fungaal (tinea en onychomycose) 
en viraal (varicella, herpes, humaan papillomavirus, molluscum contagiosum). Elke 
diagnose had onderscheidende RCM karakteristieken, maar liet ook gemeenschap-
pelijke kenmerken met andere inflammatoire huidziekten zien. In dit overzichtsar-
tikel werden 27 casuïstieken, 14 case series, 9 cohort studies, 20 case-control studies 
en 7 dwarsdoorsnede studies geïncludeerd. De meerderheid van de studies had een 
matige methodologische kwaliteit (geclassificeerd als categorie STrengthening the 
Reporting of OBservational studies in Epidemiology (STROBE) B (56%) en STROBE C 
(44%)). Deze matige kwaliteit was met name het gevolg van het gebrek aan omschrijving 
van de studie setting, gebrek aan omschrijving van potentiële bronnen van bias, 
gebrek aan uitleg over de studiegrootte, weinig kwantitatieve variabelen en de 
afwezigheid van statistische analyses. Slechts 6 van de 77 studies bepaalde de 
nauwkeurigheid van een RCM diagnose of van de afzonderlijke RCM kenmerken. De 
grootste beperking van de literatuur beschreven in dit systematische overzichts-
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artikel was het gebrek aan goed opgezette hoog kwalitatieve methodologische 
studies. Vanwege de descriptieve studieopzet werd de methodologische kwaliteit 
niet bepaald middels de Quality Assessment of Diagnostic Accuracy Studies 
(QUADAS-2). Daarnaast was het niet mogelijk een meta-analyse uit te voeren 
vanwege de heterogeniteit van de geïncludeerde studies, verschillende diagnoses en 
beperkte statistische analyses. In toekomstige diagnostische RCM studies zal de 
nadruk moeten liggen op het onderscheiden van differentiaaldiagnoses van de meest 
voorkomende inflammatoire dermatosen. Uiteindelijk zou dit kunnen resulteren in 
een praktische beslisboom voor RCM diagnoses. 
 In hoofdstuk 2.2 hebben wij ons met RCM gefocust op het diagnosticeren van 
stabiele en instabiele psoriasis plaques. Twaalf stabiele- en veertien instabiele 
psoriasis plaques van dertien patiënten met chronische plaque psoriasis werden in 
beeld gebracht met RCM. Instabiele plaques lieten een hoger aantal inflammatoire 
cellen in de (epi)dermis zien, inclusief Munro- en Kogoj microabcessen (alle 
p-waarde<0.01). Verder werd een grotere diameter van de dermale papillen (DP) 
(p=0.03) en een grotere capillaire flow (p<0.01) met meerdere kronkelige capillairen 
(p=0.04) geobserveerd. Er werd geen verschil gezien tussen centrum en rand, 
behalve een hoger aantal met rand begrensde DP in de rand van stabiele plaques 
(p=0.01). Het aantal epidermale inflammatoire cellen was voorspellend voor een 
instabiele plaque (p=0.02). Gebieden met hoge aantallen inflammatoire cellen 
kunnen worden beschouwd als een met RCM gedefinieerde hotspot. In hoofdstuk 
2.3 werden instabiele plaques gediagnosticeerd middels epidermale inflammatoire 
celtellingen met een sensitiviteit van 91.7% en specificiteit van 98.3%, met een 
nauwkeurigheid van 0.92 (oppervlakte onder de curve). Concluderend toont 
hoofdstuk 2.2 de mogelijkheid om middels RCM in vivo informatie te verkrijgen van 
een psoriasis plaque. In de toekomst kan deze informatie worden gebruikt voor het 
aanpassen van behandelstrategieën. Het beperkte geïncludeerde patiëntenaantal in 
deze studie is een mogelijke limitatie. In de toekomst zullen case-control studies 
hogere patiëntenaantallen met stabiele en instabiele plaques moeten worden 
uitgevoerd. Daarna is het wenselijk om deze resultaten te valideren in therapeutische 
monitoring studies. 
 Er is beperkte literatuur beschikbaar met betrekking tot de transitie van RCM 
van onderzoeksapparaat naar klinisch hulpmiddel. In hoofdstuk 2.3 werd een imple-
mentatiestrategie, gefocust op psoriasis, ontwikkeld. Middels een praktisch RCM 
protocol werd psoriasis gediagnosticeerd en stabiele en instabiele plaques gediffer-
entieerd. Het vier fase model dat werd gebruikt, bestond uit een exploratieve fase, 
een systematische literatuurstudie, een klinische benadering en uiteindelijk een 
integratiefase voor de ontwikkeling van een klinische richtlijn voor RCM toegepast bij 
psoriasis. Het praktische protocol was gebaseerd op verschillende stappen. Allereerst 
werd de psoriatische laesie geselecteerd met daarbij een goede positionering van 
patiënt. Daarna werd de locatie binnen de plaque bepaald en de metalen ring 
geplaatst. Vervolgens maakten we met de VivaCam een dermatoscopische foto. 
Uiteindelijk werd de RCM probe vastgemaakt aan de metalen ring voor een ge-
standaardiseerde beeldopname. Deze strategie zou als een algemeen RCM model 
voor andere dermatologische entiteiten kunnen fungeren. Daarnaast zou dit tot 
meerdere praktische RCM protocollen voor de klinische dermatologie kunnen leiden. 
Een nadeel is dat de strategie werd gebaseerd op de RCM ervaring en aanpak van één 
centrum en het ontbreken van differentiaal diagnoses. 
Hoofdconclusies hoofdstuk 2:
- Een groot spectrum van inflammatoire- en infectieuze huidziekten is voor 
diagnostische en monitoring doeleinden onderzocht middels in vivo RCM. Dit 
systematische overzichtsartikel laat de noodzaak voor hoogkwalitatieve method-
ologische studies in dit dermatologische veld zien.
- Stabiele psoriatische plaques kunnen middels RCM worden onderscheiden van 
instabiele psoriatische plaques. Het aantal epidermale inflammatoire cellen is het 
meest voorspellend voor instabiele plaques. 
- Een algemene strategie voor verdere implementatie van RCM, gefocust op 
psoriasis, is ontwikkeld. Deze strategie kan dienen als een algemeen RCM 
implementatie model voor andere huidziekten.  
Basaalcelcarcinomen
Superficiële basaalcelcarcinomen (sBCC) kunnen onder andere adequaat worden 
behandeld middels niet-invasieve methylaminolevulinaat-fotodynamische (MAL-PDT) 
therapie. De PDT behandelrespons hangt onder andere af van de nauwkeurigheid 
van het BCC subtype. Tot op heden wordt histopathologisch onderzoek van een biopt 
als de gouden standaard voor de diagnose van BCCs en subtypes beschouwd. De 
studie beschreven in hoofdstuk 3.1 bepaalde of het falen van behandeling (treatment 
failure) of het optreden van een recidief na behandeling was gebaseerd op een 
onderdiagnose van histologische onderzoek, dus of een agressiever subtype dan 
sBCC werd gemist door het biopt. Het percentage treatment failures ondergediag-
nosticeerd door het primaire biopt was 69.2%. Na vergelijken van het primaire biopt, 
het herhaalde biopt en het excisie preparaat lieten de recidieven in 48.6% een 
gemengd BCC zien. In de groep van recidieven miste 40.5% van de primaire biopten 
het meest agressieve gedeelte van de tumor. Bij de gemengde (mixed type) BCCs is 
de diagnose middels een biopt dus discutabel. Bovendien wordt de behandelrespons 
van PDT op deze manier onderschat. Het aantal treatment failures en recidieven na 
PDT, en waarschijnlijk ook bij andere non-invasieve behandelingen, kunnen worden 
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verminderd door intensiever histopathologisch onderzoek (zoals diepere door-
snijdingen) of voorafgaand aan behandeling door niet-invasieve diagnostiek waarbij 
de gehele tumor kan worden beoordeeld (zoals RCM).  
 Hoofdstuk 3.2 was gericht op het onderscheid maken tussen nodulaire BCCs 
(nBCCs) en intradermale naevi middels in vivo RCM. RCM is in staat om prospectief 
onderscheid te maken tussen deze laesies. Het aantal excisies van benigne 
intradermale naevi kon hierdoor worden verminderd. Intradermale naevi lieten een 
aspecifiek patroon op de dermo-epidermale overgang (DEJ) zien. In tegenstelling tot 
de dermale naevi, lieten nBCCs een ringvormig, geclusterd of netwerk patroon zien. 
Dermale melanocyten werden gezien in dichte- en in spaarzame nesten. nBCCs lieten 
tumornesten met basaloïde cellen en perifere palissadering zien. Verder toonde 
nBCCs meer prominente vascularisatie dan de intradermale naevi. Een beperking van 
de studie is het lage aantal geïncludeerde laesies. Toekomstige studies zouden 
grotere patiënten aantallen moeten includeren. Verder zouden alle laesies histopa-
thologisch bevestigd moeten worden en zal de interobserver variabiliteit onderzocht 
moeten worden. 
 
Hoofdconclusies hoofdstuk 3:
- Het aantal ondergediagnosticeerde treatment failures en recidieven na MAL-PDT 
kan leiden tot een onderschatting van het therapeutische effect van MAL-PDT. 
Niet-invasieve technieken zoals RCM kunnen voorafgaand aan niet-invasieve 
therapieën worden gebruikt om de diagnose van de tumor te verifiëren. 
- RCM is instaat prospectief te differentiëren tussen klinisch moeilijk te onderscheiden 
nBCC en intradermale naevi. Dit leidt tot minder excisies van benigne laesies. 
Melanomen 
 
Verschillende internationale onderzoeksgroepen voerden diagnostische RCM studies 
uit met betrekking tot melanomen. Een overzicht met een subset van RCM kenmerken 
voor melanoma en de klinische simulatoren ontbrak echter. Hoofdstuk 4.1 laat een 
systematisch overzichtsartikel met de meest beschreven RCM features voor melanomen 
en de klinische simulatoren zien. De studie toonde een uitgebreide systematische 
literatuurstudie. De zoekactie resulteerde in inclusie van 75 studies met twaalf sub- 
categorieën: melanomen, lentigo maligna, lentigo solaris, naevi, psoriasis, seborrhoische 
keratose, lichen planus-achtige keratose, actinische keratosen, plaveiselcelcarcinomen, 
BCCs, dermatofibromen en granuloma pyogenicum. De meest gerapporteerde kenmerken 
voor melanomen waren een atypisch honingraat- en cobblestone patroon, met 
cellulaire atypie en pagetoïde cellen wijdverspreid over epidermis en dermis. De DEJ 
toonde een ringvorming-, netwerk- of aspecifiek patroon met rand begrensde en/of 
zonder rand onbegrensde dermale papillen met irregulaire vorm en grootte. Verder 
werden junctionele nesten met atypische melanocyten en ‘plump bright cells’ 
gerapporteerd. In de dermis werden dichte-, spaarzame- en cerebriforme dermale 
nesten, verdikte collageen bundels en kronkelige bloedvaten gezien. De nauwkeurigheid 
van de diagnose varieerde met een sensitiviteit van 37.8-100% en specificiteit van 
23.6-100%. Een confocale diagnose dient niet gemaakt te worden op basis van één 
RCM kenmerk, maar dient gebaseerd te zijn op een samenstelling van verschillende 
kenmerken van de epidermis, DEJ en dermis. RCM dient altijd te worden beschouwd 
als een additioneel hulpmiddel complementair aan de initiële dermatologische 
klinische blik. De methodologische kwaliteit van de geïncludeerde studies was matig 
volgens STROBE scores. Er is een gebrek aan RCM studies met de focus op het bepalen 
van de Breslow-dikte bij melanomen. Toekomstige studies over dit onderwerp zijn 
nodig aangezien dit een belangrijke prognostische factor is. Dit kan worden bereikt 
met technische verbetering, waardoor een diepere laser penetratie kan worden 
bereikt. Daardoor is de gehele dermis te onderzoeken met RCM.
 Het beoogde doel van onze confocale groep is RCM ervaring opdoen met 
betrekking tot melanocytaire laesies. Dit systematische overzichtsartikel dient als 
een basis voor een nieuwe RCM focus binnen ons centrum. 
Hoofdconclusie hoofdstuk 4:
- Om een melanoom nauwkeurig te kunnen diagnosticeren met RCM, moet er 
gebruik worden gemaakt van een combinatie van kenmerken in de epidermis 
(atypisch honingraat- en cobblestone patroon met cellulaire atypie, pagetoïde 
cellen), DEJ (ringvorming-, netwerk- of aspecifiek patroon op DEJ, met of zonder 
rand begrensde dermale papillen met irregulaire vorm en grootte, junctionele 
nesten met atypische melanocyten, ‘plump bright cells’, pagetoïde cellen) en 
dermis (dichte en spaarzame en cerebriforme dermale nesten, verdikte collageen 
bundels en kronkelige bloedvaten). RCM dient altijd te worden beschouwd als een 
additioneel hulpmiddel complementair aan de initiële dermatologische klinische 
blik.
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“It always seems impossible until it’s done” (Nelson Mandela). 
Het is zover: mijn proefschrift is af! Veel mensen hebben op hun eigen manier bijgedragen 
aan dit proefschrift. Graag wil ik jullie hiervoor in het bijzonder bedanken.
Dr. van Erp en dr. Gerritsen, beste Piet en Rianne, jullie zijn een goed op elkaar ingespeeld 
duo. Tijdens mijn promotietraject heb ik vaak ervaren hoe jullie elkaar kunnen aanvullen. 
Door jullie manier van begeleiden heb ik mijzelf kunnen ontwikkelen tot de onderzoeker 
die ik nu ben, maar heb ik ook de ruimte gekregen te groeien als persoon. 
 Beste Piet, al snel werd mij duidelijk dat onze Brabantse ‘roots’ goed bij elkaar 
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geweest voor het onderzoek. Bovenal vond ik dit ook erg gezellige momenten om de 
week met je door te nemen. 
 Beste Rianne, jouw vertrouwen in mij en de mogelijkheid om altijd even binnen 
te lopen voor overleg en advies (ondanks je drukke klinische agenda) heb ik als zeer 
prettig ervaren. Bedankt voor de ruimte voor eigen inbreng in dit promotietraject.
Professor dr. dr. P.C. M. van de Kerkhof, beste professor, bedankt voor de mogelijkheid 
om dit promotietraject op uw afdeling te hebben mogen doorlopen. Uw positieve 
instelling en betrokkenheid zijn mede van belang geweest voor de totstandkoming 
van dit boekje.
RCM-team, beste Esther, Malou en Kim, wij hebben met z’n allen, ieder met een eigen 
visie, een mooie basis gelegd voor het RCM-onderzoek en verdere toepassingen 
binnen de dermatologie. Ik wens jullie allemaal veel succes bij toekomstig onderzoek 
en verdere (klinische) carrières. 
Dr. Hendriks, beste Jan, hartelijk dank voor uw inzichten en ondersteuning bij de 
statistische analyses. Ik heb onze samenwerking als zeer prettig ervaren en wens u 
veel geluk en plezier tijdens uw pensioen.
Dr. Blokx, beste Willeke, bedankt voor de samenwerking en beoordeling/revisie van 
verschillende histopathologische coupes tijdens het RCM-onderzoek.
Jimmy, bedankt voor de revisies van de coupes voor de PDT studie.
Biebgenootjes: Renée, Inge, Juul, Maartje, Jorre en Jeffrey, om met zó een fijne club 
mensen te mogen werken is een voorrecht. Van serieuze interesses in elkaars onder-
zoeksprojecten tot aan hilarische momenten op de vrijdagmiddag. Bedankt voor 
alles!
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Lieve Renée en Inge, bedankt dat jullie mijn paranimfen zijn.
Klinisch onderzoekers: Denise, Marisol, Sabine en Selma, samen met jullie is de 
klinische onderzoeksgroep compleet. Ik wens jullie allemaal veel succes met het 
afronden van jullie projecten. 
Voormalig biebgenootjes: Anne, Anke, Annet, Romy, Karlijn en Margit: ook jullie bedankt 
voor de gezellige momenten in de bieb. De door jullie in het leven geroepen Boeddha- 
offers worden nog steeds in ere gehouden… en met succes! 
Lab collega’s: bedankt voor de kritische vragen en opmerkingen tijdens de LOTTO, 
Journal Club en congressen. Bovenal bedankt voor de gezellige momenten in de 
koffiekamer en tijdens de paas-, sinterklaas- en kerstborrels! 
Stafleden en AIOS:  bedankt voor de interesse en verwijzing van patiënten voor het 
RCM-onderzoek. 
Inge en Lieke: bedankt voor de gezellige koffiemomenten tussendoor.
Medisch Fotografen: beste Anja, Annie en Jan, hartelijk dank voor de hoog kwalitatieve 
fotodocumentatie van de (onderzoeks)patiënten. Anja, bedankt voor de mooie RCM 
reportage.  
Beste Wilbert, bedankt voor je enthousiasme, luisterende oor en gezelligheid.
Bibliothecaressen, beste Elmie en Tina, bedankt voor de tips voor de uitgebreide 
zoekacties voor de systematische reviews. 
Beste Veroniek, bedankt voor je hulp met het systematische review over melanocytaire 
laesies. Wat hebben wij veel artikelen gelezen! Ik wens je veel succes in de toekomst.
Dr. Panduru, dear Mihaela, thank you for your clinical view on the RCM project and 
implementation process. Good luck with RCM imaging at your dermatological 
department in Romania. 
Verpleging en administratie: bedankt voor de prettige samen werking. Rita, Annelies 
en Masha, bedankt voor jullie inzet tijdens de verschillende PDT onderzoeken en 
klinische trials.
Secretariaat, beste Diny, Wendy,Manon en Eelke, bedankt voor jullie gezelligheid en 
hulp als ik deze nodig had.
Lieve Anouk, Helen, Iris, Judith, Lieke, Marloes, Rieke en Stephanie. Al sinds de brugklas 
vriendinnen en nog steeds niet uit elkaar gegroeid;-). Ik wil jullie heel erg bedanken 
voor alle mooie momenten die we samen hebben gedeeld en nog gaan delen. Met als 
hoogte punt ieder jaar weer: Carnaval in Oeteldonk! 
Anouk, jouw prachtige ontwerp van de kaft maakt het boekje helemaal af, super 
bedankt!
Lieve Véronique en Lili: sinds onze geboortes zijn jullie mijn vriendinnen uit Vught. 
Willemijn, met jou erbij zijn onze dates met z’n vieren altijd gezellig. Het was voor 
jullie misschien niet altijd even duidelijk waar ik mee bezig was, maar jullie zijn er op 
jullie manier voor mij geweest. 
Lieve Marja en Maroeska, soms uit het oog, maar niet uit het hart. Bedankt voor jullie 
interesse in mij en in mijn onderzoek. We zien elkaar snel weer in Maastricht!
 
Lieve Angelique, vaak denk ik nog terug aan onze mooie tijd tijdens ons co-schap 
psychiatrie in Syracuse, USA. Bedankt voor  je interesse in mijn promotietraject en 
gezelligheid in Maastricht, Den Bosch of Nijmegen. Ik wens jou veel succes met jouw 
promotietraject.
Lieve Opa en Oma, jullie zijn er altijd voor me. Ik vind het heerlijk als ik even langs kan 
komen voor een kop koffie (met iets lekkers), gezelligheid en af en toe wat medisch 
advies (hè opa). 
Lieve Romée, lieve sis, stiekem ben je niet meer klein, maar je blijft altijd mijn kleine 
zusje. Bedankt dat je er altijd voor me bent. Ik hou van je.
Lieve pap en mam, door jullie oneindige liefde en vertrouwen in mij ben ik geworden 
wie ik nu ben. Bedankt dat jullie er altijd voor mij zijn. Ik hou van jullie.
 
Lieve Harry en Nelleke, wat voel ik me al jaren thuis bij jullie. Jullie betrokkenheid en 
interesse in mijn onderzoek en in mijzelf waardeer ik enorm. Wat is het fijn om deel 
uit te maken van de familie Hover.
Lieve Marjolein, Mark en Joselien, de afgelopen jaren zijn we met elkaar volwassen 
geworden. Bedankt voor alle fijne en gezellige momenten die we samen gedeeld 
hebben en nog zullen gaan beleven. Lieve Loïs en Levi, wat kan ik genieten van jullie 
knuffels en tekeningen. 
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Lieve Robbert, wat jij voor mij betekent valt nauwelijks te beschrijven. Met jouw lach, 
onuitputtelijke energie en liefde maak je mij compleet. Ik hou van jou en heb zin in de 
rest van ons leven samen!
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